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This section provides a medium through which
Canadian surgeons can declare themselves,
briefly and informally, on the day-to-day affairs of surgery.

QUILL ON SCALPEL

T reatment of Advanced Cancer of
Prostate
W.L. Orovan, MD, FRCSC, FACS
Associate Professor o f Surgery (Urology), McMaster University. Chief, Department o f Surgery,
St. Joseph's Hospital, Hamilton, Ont.

fter the pioneering work of
Charles Huggins and Clarence
Hodges in 1941,1 who demonstrat
ed the efficacy of androgen depriva
tion in palliative treatment of ad
vanced prostatic cancer, there were
few new developments in this field.
Large studies carried out in the
United States by the Veterans Ad
ministration Cooperative Urological
Research Group (VACURG)2 in the
1970s did confirm improvement in
symptom-free intervals, but no
study has demonstrated conclusive
ly a survival benefit for patients
treated with androgen manipula
tion.3 The two major modalities of

A

hormone manipulation used during
this time were bilateral orchiecto
my and the administration of exoge
nous estrogens in doses ranging
from 1 to 5 m g/d. The latter,
especially at higher dosage, was
associated with an increased risk of
cardiovascular complications and
death. Benefits of treatment were
not universal; only about 75% of
patients responded and the median
duration of response was about 3
years.4
In the late 1970s and early
1980s, partly in response to the
cardiovascular risk factors identified
with exogenous estrogen and the
Tel.: <613) 731-9331
Telex: 053-3152
Fax: (613) 523-0937

The Canadian Journal of Surgery
1867 Alta Vista Dr.
Ottawa, Ont. K1G 3Y6

reluctance of some patients to un
dergo surgical orchiectomy, alterna
tive means of hormone manipula
tion became available. These agents
fit broadly into three categories:
luteinizing hormone-releasing hor
mone (LHRH) analogues, antiandro
gens and the synthetic imidazoles.
The LHRH agonists act primarily
on the central feedback control of
luteinizing hormone release. An ini
tial surge of luteinizing hormone
can precipitate a transient increase
of the patient’s symptoms (flare
reaction), but subsequently a reduc
tion in circulating androgens to
castrate level occurs. The LHRH
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agents are administered by subcuta
neous injection, either daily or,
more recently, monthly in timedrelease form. Side-effects have been
less severe than those noted with
exogenous estrogens and an equiva
lent treatment benefit has been doc
umented.5
The antiandrogens, cyproterone
acetate (Adrocur) and flutamide
(Euflex), can be administered orally.
They have proven equivalent in effi
cacy to exogenous estrogens or
surgical castration and in addition
provide benefit by reducing the inci
dence of treatment complications.6
The duration of response to hor
mone manipulation is limited and
virtually all patients will eventually
relapse and the disease will prog
ress. Treatment options available
for this apparently androgenindependent or “hormonally es
caped” treatment group are limited.
Cytotoxic chemotherapy using
cyclophosphamide, 5-fluorouracil,
Adriamycin and others, either in
dividually or in combination regi
mens, have given mixed results.
Administration of these toxic
agents in generally aged and debili
tated patients, many of whom mani
fest other cardiovascular or pulmo
nary diseases, has severely limited
their effectiveness.
In this issue of the Journal
(pages 349 to 352), Eichenberger
and Trachtenberg present their
early findings with the use of syn
thetic imidazoles to treat patients
with androgen-independent prostat
ic cancer. They note that the imid
azole ketoconazole, primarily an an
tifungal agent, when used frequent
ly at a high dose has been demon
strated to inhibit the production of
both adrenal and testicular andro
gens. Studies in patients with previ
ously untreated advanced prostatic
cancer have demonstrated that this
compound can produce castrate lev
els of circulating androgens;7 thus,
it represents an alternative in the
316

first-line treatment of advanced
prostatic cancer. Moreover, the au
thors suggest that these com
pounds may also have a role in the
treatment of androgen-independent
or “hormonally escaped” patients.
The data from this uncontrolled
study suggest subjective improve
ment in symptoms as reflected by
the patients’ reduced need for anal
gesics and a trend toward halting
the progression of disease in some
patients. The latter finding must be
treated with some skepticism in
view of the variable rate at which
the disease progresses.
Of interest is the authors’ asser
tion that no significant difference in
duration of response could be dem
onstrated between the patients who
had been treated with conventional
forms of androgen ablation and the
14 patients who failed total andro
gen ablation. The concept of total
androgen ablation was introduced
by Labrie and associates,8 who con
tended that simple ablation of tes
ticular androgens is insufficient
for adequate hormonal treatment
and that total androgen deprivation,
including adrenal sources, must be
effected before an adequate re
sponse of hormone-dependent pros
tatic cancer can be achieved. This
controversial theory is at present
being evaluated by a randomized
prospective trial in the United
States. The finding of Eichenberger
and Trachtenberg that ketocona
zole seems to affect both groups
equally suggests that ketoconazole
may, in fact, have a non-androgenbased effect on prostatic cancer.
The authors quote one in-vitro
study9 to support this contention
and speculate about the site of
action of direct cytotoxic effects of
ketoconazole on androgen-independ
ent human prostatic cancer cells.
With the rapid evolution of alter
native hormonal treatment options
for advanced prostatic cancer, the
most difficult clinical problem re
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mains that of androgen-independent
late-stage disease. The usefulness of
ketoconazole in this context re
mains to be defined but the early
results quoted by Eichenberger and
Trachtenberg give some reason for
optimism.
If the authors’ contentions are
borne out through further in-vitro
and prospective randomized con
trolled clinical trials, this will repre
sent an important advance in the
treatment of this difficult and com
mon malignant condition.
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Monoclonal Antibodies — Gazing Into
the Submicroscopic
Nis Schmidt, MD, MSc, FRCSC
Member. Editorial Board. Canadian Journal o f Surgery. Clinical Professor, Department o f
Surgery. University o f British Columbia, St. P a u l’s Hospital, Vancouver, BC

have always been dis
Humans
satisfied with their limitations.
Climbing onto horseback extended
their ability to travel; harnessing
steam increased muscle power out
of all proportion; computerization
expanded the capacity to store and
sort data beyond expectation. Rais
ing antibodies to protein antigenic
material is going beyond the micro
scope when appropriate labelling
and manipulation of these complex
biologic substances are carried out.
Monoclonal antibodies, developed in
1975 by Kohler and Milstein,1
opened a new era in immunobiology
which continues to expand in expo
nential shock waves, touching all
aspects of medicine and surgery in
areas of diagnosis, prophylaxis,
treatment and research.
The July issue of the Canadian
Journal o f Surgery (pages 279 to
282) contained an article entitled
“ Immunohistologic diagnosis of
multiple carcinomas. The role of
monoclonal antibodies against carcinoembryonic antigen” by Guiot
and associates, in which they pres
ent a whole new world of diagnostic
possibilities by using anti-carcinoembryonic antigen (CEA) monoclon
al antibodies to differentiate and
clarify the relationship between
multiple adenocarcinomas in indi
vidual patients. Five cases were pre
sented in which the monoclonal
antibodies helped to differentiate
the multiple carcinomas and to ar

rive at an appropriate plan of man
agement. In each case, the diagnos
tic problem was ascertaining the
nature of a second tumour in pa
tients with a history of colonic
cancer. The question concerned the
treatment of a second tumour as a
separate entity or as a metastasis
from the colonic cancer.
The application of this new bio
logic science to diagnosis is far
from simple. Initially, the antibodies
developed were mouse and rodent
xenoantibodies, and they were asso
ciated with the expectant problems
of foreign proteins. For diagnostic
and therapeutic application, human
antibodies are obviously more desir
able. The antibody used by Guiot
and colleagues was a mouse antiCEA antibody (D14), which has
been shown to be quite specific and
sensitive to CEA, hence the success
in their investigation. Human mo
noclonal antibodies for routine use
in diagnosis and investigation are
yet to come.
Monoclonal antibodies were the
result, initially, of sensitizing labo
ratory animals with viable lymphoid
and myeloma cell lines, resulting in
antibodies with detectable sensitivi
ty but poor specificity. The evolu
tion of clones of cells has allowed
greater sensitivity and specificity of
the antibodies, and research is now
at the point where the established
names and catalogued antibodies
are available for diagnostic, thera

peutic and research activities the
world over. Refinements of the
process now identify not only cell
lines but cell surface receptor anti
gens, even protein molecules and
genetically manipulated material, all
of which have become feasible as
specific antigenic material to raise
antibodies of high sensitivity and
specificity. In addition to raising
and purifying the antibodies, label
ling procedures add immunofluorescent, immunoenzymatic and immunonucleotide tags, greatly add
ing to the scope and use in practical
and research procedures. For exam
ple, immunofluorescence has facili
tated the development of practical
cell sorters and cell counters for
laboratory use in hematology.
Besides the use of monoclonal
antibodies for imaging and investi
gational purposes, monoclonal anti
body toxin conjugates open up pos
sibilities of aiming ‘‘magic bullets” .
Antibody toxin conjugates will find
extensive application in im
munosuppression. Antibody phar
maceutical conjugates conceivably
will find use in specific antigen
selectivity for tumour therapy, anti
microbial therapy and the suppres
sion and treatment of diseases for
which cellular secretion can be sup
pressed or ablated.
Much of this is still conjectural,
since the cloning of cell lines, isola
tion of antigens, purification and
accumulation of the antibody, re-
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■CIPRO®
Ciprofloxacin Hydrochloride
THERAPEUTIC CLASSIFICATION
Antibacterial Agent
PRESCRIBING INFORMATION
ACTIONS
ju g H
Ciprofloxacirt, a synthetic fluoroquinolone, has a bactericidal mode o f action. This action is
the nicks on the DNA strands induced by this ajpha subunit, leading to the degradation ofthe
ONA by exonucleases. This bactericidal activity persists not only during the multiplication
phase, but also during the resting phase of the bacterium.
Ciprofloxacin retained some of its bactericidal activity after inhibition of RNA and protein
synthesis by rifamycin and chloramphenicol, respectively. These observations suggest
ciprofloxacin may possess two bactericidal mechanisms, one mechanism resulting from
the inhibition of DNA gyrase and a second mechanism which may be independent on RNA
and protein synthesis.
S AND CLINICAL USES
CIPRO*' (Ciprofloxacin Hydrochloride Monohydrate) may be indicated for the treatment of patients
with the follow ing infections caused by susceptible strains of the indicated microorganisms:
RESPIRATORY TRACT INFECTIONS:
Acute bronchitis and acute pneumonia caused by:

Enterobacter cloacae
Escherichia coli
Haemophilus influenzae
Klebsiella pneumoniae

Proteus mirabilis
Pseudomonas aeruginosa
Staphylococcus aureus
Streptococcus pneumoniae

Due to the nature of the underlying conditions which usually predispose patients to
Pseudomonas infections of the respiratory tract, bacte r ia i e radical i ons may not be achieved
it) patients who display clinical improvement despite evidence of in vitro sensitivity. !n
patients requiring subsequent courses of therapy, CiPRO® should be used alternately with
other anti-pseudomonal agents. Some strains of Pseudomonas aeruginosa may develop
resistance during treatment. Therefore, susceptibility testing should be performed periodi
cally during therapy to detect the emergence of bacterial resistance,
URINARY TRACT INFECTIONS:
Upper and lower urinary tract infections, such as complicated and uncomplicated cystitis,
pyelonephritis, and pyelitis, caused by:

Citrobacter diversus
Cilrobacler Ireundii
Enterobacter cloacae
Escherichia coli
Klebsiella pneumoniae
Klebsiella oxytoca
Morganella morganii

Proteus mirabilis
Pseudomonas aeruginosa
Serratia marcescens
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus taecalls

i

SKIN AND SOFT TISSUE INFECTIONS:
caused by

Enterobacter cloacae
Escherichia coli
Klebsiella pneumoniae
Proteus vulgaris
Proteus mirabilis

Pseudomonas aeruginosa
Streptococcus pyogenes
Staphylococcus aureus
Staphylococcus epidermidis

BONE AND JOINT INFECTIONS:
caused by:

Enterobacter cloacae
Pseudomonas aeruginosa

Serratia marcescens
Staphylococcus aureus

INFECTIOUS DIARRHEA: (When antibacterial therapy is indicated)
caused by:

Escherichia coli (enterotoxigenic strains)
Campylobacter Jejuni

Shigella flexneri
Shigella sonnei

Appropriate culture and susceptibility tests should be performed prior to initiating treatment
in order to isolate and identify organisms causing the infection and to determine their
susceptibilities to ciprofloxacin. Therapy with CIPRO® may be initiated before results of
these tests are known. However, modification of this treatment may be required once results
become available or it there is no clinical improvement. Culture and susceptibility testing
performed periodically during therapy will provide information on the possible emergence of
bacterial resistance.
CONTRAINDICATIONS
CIPRO*' (Ciprofloxacin Hydrochloride Monohydrate) is contraindicated in patients who have
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.

318

CJS, VOL. 32, NO. 5, SEPTEMBER 1989

WARNINGS
Children
The safety of CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) in children has not yet
been established. Damage to juvenile weight-bearing joints and lameness were observed
both in rat and dog studies but not in weaned piglets (see Product Monograph TOXI
COLOGY). Histopatnological examination of the weight-bearing joints of immature dogs
revealed permanent lesions of the cartilage. Consequently, CIPRO* should not be used in
prepubertal patients.
Pregnancy
The safety of CIPRO* in the treatment of infections in pregnant women has not yet been
established (see PRECAUTIONS).
PRECAUTIONS
General
Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients
receiving therapy with CIPRO* (Ciprofloxacin Hydrochloride Monohydrate). These reactions
have occurred within the first 30 minutes following the first dose and may require epineph
rine and other emergency measures.
CIPRO'" may cause central nervous system (CNS) stimulation which may lead to tremor,
restlessness, light-headedness, confusion, and very rarely to hallucinations or convulsive
seizures. Therefore, CIPRO® should be used with caution in patients with CNS disorders,
such as severe cerebral arteriosclerosis or epilepsy. Patients with known convulsive seizure
disorders should only be treated with CIPRO® if anticonvulsive therapy has been initiated.
Crystallufia related to ciprofloxacin has been reported only rarely in man because human
urine is usually acidic. Patients receiving ciprofloxacin should be well hydrated and alkalinity
of the urine should be avoided. The recommended daily dose should not be exceeded.
Crystals of ciprofloxacin have been observed rarely in the urine of human subjects but more
frequently in the urine ot laboratory animals.
Prolonged use of CIPRO® may result in the overgrowth of nonsusceptible organisms Careful
observation of the patient is therefore essential, and if superinfection should occur during
therapy, appropriate measures should be taken.
Pregnancy
The safety of CIPRO ’ in pregnancy has not yet been established. CIPRO® should not be used
by pregnant women unless the likely benefits outweigh the possible risk to the fetus CIPRO"
has been shown to be non-embryotoxic and non-teratogemc in animal studies.
Nursing Mothers
It is not known whether ciprofloxacin is excreted in human milk. However, it is known that
ciprofloxacin is excreted in the m ilk o f lactating rats and that other drugs of this class are
excreted in human milk, A decision should be made to discontinue nursing or to discontinue
the administration of CIPRO'®, taking into account the importance of the drug to the mother
and the possible risk to the infant.
Drug Interactions
Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma
concentration and prolongation of elimination half-life of theophylline. This may result in
increased risk of theophylline-related adverse reactions. If concomitant use cannot be
avoided, plasma concentrations of theophylline should be monitored and dosage adjust
ments made as appropriate.
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of
caffeine. Excessive caffeine intake should be avoided.
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an
increase in the level of ciprofloxacin in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug with ciprofloxacin has
been reported to increase the risk of CNS stimulation and convulsive seizures.

■mmmmt

...............

...

Since ciprofloxacin is eliminated primarily by the kidney, CIPRO* should be used with
caution and at a reduced dosage in patients with impaired renal function (see DOSAGE AND

ADVERSE REACTIONS
CIPRO* (Ciprofloxacin Hydrochloride Monohydrate) is generally weii tolerated. During worldwide
clinical investigation, 8,861 courses of ciprofloxacin treatment were evaluated for drag
safety. (Included in this evaluation were data from 283 patients who received ciprofloxacin
oftly intravenously and 169 patients who received sequential i«ravenous7orai ciprofloxacin
therapy.)
Adverse events, whether drag-related or not. occurred in 10.2% of patients. These adverse
events occurred in the following frequencies: Gastrointestinal System (5.0%), Central
Nervous System (1(6%), Skin/Hypersensitivity (1 4%). and Adverse Laboratory Changes
(5.6%)
The most frequently repotted events, drug-related or not were nausea tt. 6%) and diarrhea
(

1. 2% ) .

Additional events that occurred in less than 1% ot ciprofloxacin courses are listed below
Gastrointestinal: vomiting, dyspepsia abdominal pain anorexia
Central Nervous System: dizziness, light-headedness, headache, nervousness anxiety.
agitation, restlessness, tremor, lethargy, drowsiness, somnolence
Skin/Hypersensitivity: rash, pruritus, local edema, urticaria, increased perspiration,
photosensitivity
Most of the adverse events were described as only mild or moderate in severity.
There have been 9 reports of arthropathy associated with CIPRO' Three of these reports
involved children. Arthralgia was usually the first symptom which led to rapid assessment
and withdrawal of the drug. No irreversible arthropathies have been observed
Adverse Laboratory Changes
Changes in laboratory parameters listed asadverse events without regard todrug relationship (5.6%):
Hepatic:
Elevations of: SGPT (1.3%), SGOT (1 4%),
Alkaline Phosphatase (0.4%), y-giutamyl transpeptidase (0.3%)
LDH (0.3%), Serum bilirubin (511%)
Hematologic: Eosinophilia (0.6%), leukopenia (0.2%)
Renal:
Elevations of: Serum creatinine (0.3%), BUN (0.3%)
Other changes occurring in less than 0.1% of courses were: elevated uric acid elevated
cholesterol, increase in blood platelets, monocytes, and leukocytes
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® (Ciprofloxacin Hydrochloride Mono
hydrate). In the event of acute overdosage, the stomach should be emptied by inducing
vomiting or by gastric lavage. The patient should be carefully observed and qiven sup
portive treatment.
DOSAGE AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the
severity and nature of the infection, the susceptibility of the causative organism and the
status of renal function.
CIPRO® (Ciprofloxacin Hydrochloride Monohydrate) may be taken before ot after meals.
Absorption is faster on an empty stomach. Patients should be advised to drink fluids liberally
and not take antacids containing magnesium or aluminum.
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finement of sensitivity and specifici
ty, understanding of the interaction
of in-vitro and in-vivo responses still
depend on untold hours of laborato
ry time and thought, not to mention
all the dollars required to finance
the research.
Practical application is, however,
well advanced. Testing for carcinoembryonic antigen in gastrointesti
nal carcinoma and breast cancer
estrogen receptor binding is com
monplace. Endocrine function
studies, including parathormone
and adrenocorticotropic hormone
levels, are in daily use. “OKT3”
antibody, which appears to exact
direct immunosuppressive activity
and inactivate lymphoid T cells
from circulation, is currently being
used in the treatment of acute rejec
tion in histocompatible renal grafts

and for in-vitro prevention of graft
versus host disease in recipients of
bone marrow transplants. Mono
clonal antibody BB5-M2 causes
stimulation of parathyroid hormone
release in human parathyroid cell
cultures, indicating that a possible
specific cell-surface macromolecule
may be operative in the regulation
of calcium and parathormone, and
this promises control in calcium
disorders. Enzyme immunoassay
has allowed accurate pregnancy
testing in a simple, across-the-counter kit.
The scope of the subject of mo
noclonal antibodies is overwhelming
and beyond a simple editorial re
view. Suffice it to say that this
subject, which only 15 years ago
occupied the thought of scientists
observing mice in cloistered labora

tories, has now evolved sufficiently
to influence the everyday clinical
practice of surgeons, as described in
the article by Guiot and colleagues
in their stimulating and imaginative
report. It is obvious that if we keep
our eyes open, we will be in store
for more surprises from the submicroscopic in the area of monoclonal
antibodies.
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Adult
The recommended dosages of CIPRO * are:
Location of
Infection

Type/Severity

Unit
Dose

Fre
quency

Daily
Dose

Urinary Tract

M ild/Moderate
Severe/Complicated

250 mg
500 mg

q 12h
q 12h

500 mg
1000 mg

Lower Respiratory
Tract
Bone & Joint
Skin S Soft Tissue

Mild/M oderate
Severe/Complicated*

500 mg
750 mg

q 12h
q 12h

1000 mg
1500 mg

Infectious Diarrhea

Mild/Moderate/Severe

DOSAGE FORMS
Availability
CIPRO’ 250-each tablet contains ciprofloxacin hydrochloride monohydrate
equivalent to 250 mg ciprofloxacin,
CIPRO* 500-each tablet contains ciprofloxacin hydrochloride monohydrate
equivalent to 500 mg ciprofloxacin.
CIPRO® 750-each tablet contains ciprofloxacin hydrochloride monohydrate
equivalent to 750 mg ciprofloxacin.
STORE BELOW 30° C (86° F).

Strength
500 mg

q 12h

1000 mg

* e.g. hospital-acquired pneumonia, osteomyelitis.
Depending on the severity of the infections, as well as the clinical and bacteriological
responses, the average treatment period should be approximately 7 to 14 days. Generally,
treatment should last 3 days beyond the disappearance of clinical symptoms or until
cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6
to 8 weeks and up to 3 months. With acute cystitis, a five-day treatment may be sufficient.
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabo
lized and partially cleared through fhe biliary system of the liver and through the intestine
(see Product Monograph: HUMAN PHARMACOLOGY). This alternate pathway of drug
elimination appears To compensate for the reduced renal excretion of patients with renal
impairment. Nonetheless, some modification of dosage is recommended, particularly for
patients with severe renal dysfunction. The following fable provides dosage guidelines for
use in patients with renal impairment. However, monitoring of serum drug levels provides
the most reliable basis for dosage adjustment. Only a small amount of ciprofloxacin (< 1 0%)
is removed from the body after hemodialysis or peritoneal dialysis.
Creatinine Clearance
mL/min (m L/s)

Dose

> 3 0 (0 .5 )
< 3 0 (0 .5 )
and patients on hemodialysis
or peritoneal dialysis

No dosage adjustment
Use recommended dose
once daily or half
the dose twice daily

When only the serum creatinine concentration is available, the following formula (based on
sex, weight and age of the patient) may be used to convert this value into creatinine
clearance. The serum creatinine should represent a steady state of renal function:
Males:
Weight (kg) x (140 - age)
72 x serum creatinine(mg/1 OOmL)
Females:
0.85 x the above value
To convert to international units, multiply result by 0.01667
CHILDREN
The safety and efficacy of CIPRO® in children have not been established. CIPRO® should not
be used in prepubertal patients (see WARNINGS).
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ecent federal legislation on
drug patents has given phar
maceutical manufacturers in Cana
da prolonged terms of patent pro
tection. In return for this protec
tion, these companies have commit
ted a substantial portion of their
income into drug research. As a
result, a great deal of “research”
money has become available to in
vestigators willing to be involved
with clinical trials, and drug testing
and reporting.
This research effort has become a
major source of funding in many
areas, providing space, personnel
and equipment. In effect, the drug
being evaluated supports the ongo
ing function of the laboratory and
the investigation. In some in
stances, the result of the study
becomes the property of the phar
maceutical company and may not be
presented without the company’s
approval. This type of financial sup

R

port is also being used to fund
conferences and seminars, the sub
jects of which are related to the
pharmaceutical products. Often the
entire seminar, including invited
speakers and expenses of the orga
nization or university division hold
ing the seminar, is financed by the
drug company involved.
The ethical problems involved in
this type of “investigation” and
reporting are obvious, and just a
generation ago would not be con
doned in our universities. There is,
however, a substantial shortfall of
available research funding from
granting agencies, particularly for
part-time and new researchers and
agencies. More and more investiga
tors are turning to industry for
support and, indeed, universities at
higher levels are fostering joint in
dustry-university projects. Our med
ical professional organizations at
local, national and international lev

els depend on industry’s financial
support through commercial exhib
its and direct grants to preserve the
calibre of meetings and maintain a
reasonable registration fee. These
companies are providing essential
and otherwise unavailable support.
In this respect they need to be
encouraged.
What is lacking are guidelines
regarding this type of investigation
and financial support, particularly
concerning ethical reporting of this
work to physicians and the public.
The current, apparently compro
mised position of the investigator
and indeed the profession needs
immediate and close scrutiny. The
financial need, no matter how wor
thy, must not compromise the prin
ciples of academic investigation and
reporting in our institutions. If we,
the profession, do not address this
subject, other regulating agencies
representing the public will. ■

SESAP VI Question
Item 245
The statistical five-year survival rates for cancer may be artificially improved by all of the following EXCEPT
(A) detection of disease with a screening test before symptoms develop
(B) a change in the staging of patients due to earlier detection of metastases
(C) treatment prolonging the disease-free interval
(D) loss of patients to follow-up
(E) an improved method of treatment of disease
For the incomplete statement above, select the one completion that is best of the five given.
For the critique of Item 245 see page 339.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6.
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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CORRESPONDENCE

Rupture of the Diaphragm
To the editors. I have just finished
reading the article “Spontaneous
rupture of the diaphragm in labour:
a case report” (Can J Surg 1989;
32: 212-213). I read it with interest
because I am a general surgeon
doing obstetrics and gynecology al
most exclusively.
Looking at the sequence of
events, I wonder if the authors
considered that the diaphragm
might have been ruptured by the
efforts at cardiopulmonary resusci
tation made when the patient suf
fered a cardiac arrest on the way to
the radiology department.
The possibility of a pulmonary
embolus or some other catastrophe
resulting in cardiac arrest would be
more likely than a ruptured dia
phragm occurring as a result of
labour. Since the patient did not die
for 3 weeks, an autopsy to deter
mine possible pulmonary embolism
or other causes of her initial pain
may not have been helpful.
I would be interested in the au
thors’ comments.
G.E. Rosenquist, MD, FRCSC
St. Lawrence Medical Clinic,
Morrisburg, Ont.
K O C 1X0

To the editors. Dr. Rosenquist’s
comments are well taken and obvi
ously it is impossible to exclude
completely an alternative explana
tion for the patient’s clinical course.

Contributions to the Correspondence section
are welcome. They should be typewritten
and double spaced.

However, several facts argue
against a pulmonary embolus or
other, presumably cardiac, cause.
The patient’s initial complaints were
epigastric and left shoulder pain,
and vomiting. Vomiting and epigas
tric pain are unusual with pulmo
nary embolism, yet expected with a
ruptured diaphragm with stomach
herniated into the chest. The pa
tient then gradually deteriorated
over the next 21 hours before cardi
ac arrest, a finding compatible with
cardiorespiratory embarrassment
from abdominal contents gradually
herniating into the chest but un
usual for pulmonary embolism
where one would expect either reso
lution or complete cardiovascular
collapse.
The patient was extremely unsta
ble until the herniated viscera were
reduced and the diaphragm was
repaired, after which she had no
further problems. This implies that
it was the presence of the herniated
viscera that was the underlying
problem.
Finally, the patient was bedridden
postoperatively for the 3 weeks
until life support was terminated
due to her encephalopathy. During
this time no further difficulties with
cardiac rhythm, cardiac output or
oxygenation were encountered. If
an underlying venous thrombosis
was present, we would have expect
ed further problems.

Doctor or Mister?
To the editors. 1 am indebted to
Doctors (or is it “Misters”?) Cairns,
de Gara, Rees-Davies, Fraser and
Thomas for their interest in my
article on the correct appellation of
British surgeons, and why it differs
from the virtually universal designa
tion of Doctor.
As I believe I tried to indicate, the
title Mister has a great deal to do
with early English history when
surgery and barbery appear to have
developed synchronously, often at
loggerheads with each other as to
their proper domain.
It was King Henry VIII who
finally separated the two divisions
of the cutting process, honouring
each with the epithet “Master” . In
time, as the Oxford English and
Skeat’s dictionaries show, “Master”
was corrupted into “Mister” .
I doubt that there will ever be a
change. English surgeons will con
tinue to shudder to the end of
foreseeable time at the mere
thought of giving up the venerable
title. American surgeons will adhere
to their incorrect designation, by
English standards, according to
some of your correspondents.
Both, however, have much to be
proud of. English “Misters” pro
duced a Lister and American “ Doc
tors” a Halsted.
P. Eibel, MD, FRCSC

David B. Ross, MD
405 Poplar Dr.,
Dartmouth, NS
B2W 4K8

Ste. 370,
5845 Cote des Neiges,
Montreal, PQ
H3S 1Z4
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CANADIAN SOCIETY OF CARDIOVASCULAR AND
THORACIC SURGEONS

D oes the Surgical Trauma of
“ Exploratory Thoracotomy” Affect
Survival of Patients With Bronchogenic
Carcinoma?
A. Paul, MD; D. Marelli, MD; J.A.S. Wilson, MD, FRCS(Edin), FRCSC;
R.C-J. Chiu, MD, PhD; D.S. Mulder, MD, MSc, FACS, FRCSC
A retrospective review was carried out to assess the possible adverse
immunosuppressive effect of exploratory thoracotomy on the survival of patients
with non-small cell carcinoma of the lung with N2 nodal metastases.
Between 1960 and 1982, 48 patients with non-small cell bronchogenic carcinoma
underwent exploratory thoracotomy; lung resection was not done because
mediastinal lymph nodes were involved. The survival of these patients was compared
with that of 64 patients in whom N2 disease was established by mediastinoscopy
alone and who did not undergo thoracotomy.
There were no significant differences with respect to age, sex, tumour type and
adjunctive radiotherapy. There were slightly more T4 tumours in the thoracotomy
group (50% versus 30%). The hospital stay was longer in the thoracotomy group
(2.3 ± 1.1 versus 1.5 ± 0.9 months [mean ± SD]). However, follow-up studies
showed that, although these patients had a more traumatic procedure, the actuarial
survival curves for the two groups were virtually identical, and the 12-month
survival rates were less than 20% for both groups. The median survival was 6.0
months for the thoracotomy group and 7.0 months for the mediastinoscopy group.
These findings failed to demonstrate an adverse immunosuppressive effect of
thoracotomy on lung cancer patients.

Cette etude retrospective a ete faite a evaluer la reaction immunosuppressive
possible de la thoracotomie exploratrice sur la survie des patients souffrant de
cancers pulmonaires autres que le cancer a petites cellules, avec metastases
ganglionnaires au stade N2.
Entre 1960 et 1982, 48 patients souffrant de cancers bronchopulmonaires autres
que le cancer a petites cellules, ont subi une thoracotomie exploratrice; du a
l’atteinte des ganglions lymphatiques mediastinaux, il n’y eut pas de resection
pulmonaire. La survie de ces malades a ete comparee a celle de 64 patients dont le
stade evolutif N2 fut etabli par mediastinoscopie seule, sans thoracotomie.
II n’y avait aucune difference pour ce qui etait de l’age, du sexe, du type de
tumeur ou de la radiotherapie adjuvante. II y avait un peu plus de tumeurs au stade
T4 dans le groupe soumis a la thoracotomie (50% par rapport a 30%). L’hospitalisation a ete plus longue dans le groupe de thoracotomie (2.3 ± 1 .1 mois par rapport a
1.5 ± 0.9 mois [moyenne ± ecart type]). Toutefois, la surveillance des suites
therapeutiques a revele que, meme si ce groupe avait subi une intervention plus
traumatique, les courbes de survie actuarielles etaient virtuellement identiques; la
survie a 12 mois etait inferieure a 20% pour les deux groupes. La survie mediane fut
de 6.0 mois pour le groupe de thoracotomie et de 7.0 mois pour le groupe de
mediastinoscopie. Ces resultats n'ont pas fait la preuve que la thoracotomie produit
un effet immunosuppressive chez les patients souffrant de cancers pulmonaires.
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t is widely believed that major
surgical procedures decrease
host resistance to cancer.1-5 Several
experimental reports have shown
that lymphocyte function is de
pressed after surgery and accelerat
ed tumour growth has been demon
strated in such models.1-5 Survival
has been shorter for two-stage re
section o f obstructing colonic can
cer than for primary resection. En
hanced tumour growth secondary
to immunosuppression caused by
surgery itself has been proposed as
an explanation for this difference.6
To our knowledge there are no data
concerning the influence o f surgical
trauma on the clinical outcome in
lung cancer patients.
To test the hypothesis that major
surgical trauma may adversely af
fect the survival of patients with
unresectable lung cancer, we took
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THORACOTOMY AND BRONCHOGENIC CARCINOMA

the time of diagnosis. Only patients
with squamous cell carcinoma or
adenocarcinoma were included. Fol
low-up consisted of periodic clinical
and radiologic evaluation.
If patients had no evidence of
ongoing infection and were in good
overall physical condition, they
were offered radiotherapy (5000 to
6000 rad). An additional 12 pa
tients who underwent exploratory
thoracotomy were not included in
the study because they received
nonstandardized chemotherapy.
The x2 test was used to compare
the patients in each group for age,
sex, preoperative weight loss and
primary tumour classification at the
time of diagnosis. Actuarial survival
was calculated for both groups of
patients as well as for those who
received adjunctive radiotherapy.10
When autopsy was not available,
cause of death was established on
clinical, radiologic and laboratory
bases.

Patients and Methods

advantage of the fact that, in the
past, N2 nodal involvement was
established only after exploratory
thoracotomy (a major surgical inter
vention) and that, recently, cervical
mediastinoscopy has replaced thora
cotomy for this purpose. Currently,
because of the high sensitivity and
specificity of mediastinoscopy in de
tecting N2 disease,7 exploratory
thoracotomy for lung cancer is car
ried out only when preoperative
staging fails to detect unresectable
stage III disease. It was reasoned
that if major surgical trauma is
detrimental to the survival of pa
tients with terminal cancer, those
who undergo exploratory thoracot
omy may have a shorter survival
than those who do not, provided
the tumour staging and other risk
factors are comparable. We, there
fore, undertook a retrospective re
view of patients with bronchogenic
carcinoma determined to be inoper
able after thoracotomy revealed me
diastinal lymph-node involvement.
This historical cohort, consisting
mainly of patients treated before
mediastinoscopy was used, was
compared to a control group who
had the same nodal involvement
diagnosed by mediastinoscopy
alone. The purpose of this study
was to assess the effect of explor
atory thoracotomy on survival of
these patients.

All patients admitted to the Mon
treal Chest Hospital for investiga
tion of bronchogenic carcinoma are
clinically staged by history-taking,
physical examination, chest x-ray,
tomography, liver function studies
and bronchoscopy. Liver and bone
scanning are performed if indicated.
Since 1965, mediastinoscopy has
been used with increasing frequency
so that, now, virtually all patients
who are candidates for tumour re
section undergo this procedure.
Between 1960 and 1982, sam
pling of mediastinal lymph nodes,
with frozen-section histologic ex
amination during exploratory thora
cotomy revealed preoperatively un
diagnosed N2 disease in 48 patients
with non-small cell carcinoma
(group 1). Tumour resection in
these patients was contraindicated
because of the nodal involvement.
As a control group, we selected 64
consecutive patients evaluated for
bronchogenic carcinoma between
1978 and 1982 (group 2). These
patients had non-small cell carcino
ma and N2 nodal metastases histo
logically proven by mediastinoscopy
alone; they did not undergo explor
atory thoracotomy. Patients were
re-staged according to the present
TNM classification.89 In all cases,
disease was limited to stage III at

Results
In group 1 patients, N2 disease
was discovered and histologically
proven. Preoperative mediastinos
copy was equivocal or negative in
20 of these patients. The other 28
did not undergo mediastinoscopy.
Postoperative complications were

Table I. Distribution of Age, Sex, Radiotherapy and Weight Loss
Sex

Age, yr
Group
1: thoracotomy
(1 9 6 0 - 1982)
2: mediastinoscopy
alone (1 9 7 8 - 1982)

Weight loss

Radiotherapy

No.

Mean

Range

M

F

Yes

No

<10%

>10%

48

62

4 2 -7 7

38

10

26

22

42

6

64

61

3 6 -7 5

48

16

36

28

56

7

Table II. Primary Tumour Classification and Distribution of Cell Type
Primary tumour class

Cell type

Group

T2

T3

T4

Squamous

Adenocarcinoma

1: thoracotomy
2: mediastinoscopy
alone

12

12

24

30

18

21

24

19

43

21
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limited to pneumonia and atelecta
sis in seven patients and did not
prevent hospital discharge in any
case. One patient had a fatal pulmo
nary embolism on postoperative day
7. In group 2 patients the N2
disease was histologically proven by
mediastinoscopy alone. There were
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no serious complications in this
group. The use of blood transfu
sions for replacing intraoperative
blood loss was comparable in the
two groups.
Patients in both groups were
comparable for age and sex (Table
I). Differences in weight loss and

CJS, VOL. 32. NO. 5, SEPTEMBER 1989

frequency of adjunctive radiothera
py were not significant. The TNM
classification of primary tumours in
both groups ranged from T2 to T4.
Although T4 tumours were more
common in the thoracotomy group,
differences in overall primary tu
mour distribution were not statisti
cally significant (Table II). Similar
ly, tumour cell types were compara
ble for both groups.
Eleven patients from group 1
were lost to follow-up between 1
and 11 months postoperatively, and
12 patients in group 2 were lost to
follow-up between 1 and 8 months
after the diagnosis was established.
Thus, follow-up rates were 77% and
81% respectively.
The median hospital stay was 2.0
months (range from 0 to 4 months)
for patients in group 1, compared
with 1.0 months (range from 0 to 6
months) for group 2. This was
found to be statistically significant
(Student’s t-test, p < 0.05). Figure
1 shows that actuarial survival
curves were virtually identical for
both groups. Median survival for
group 1 patients was 6.0 months
(range from 0 to 15 months) and
for group 2, 7.0 months (range
from 0 to 50 months). Overall sur
vival after 1 year was less than 20%
for both groups. The power of
these data in detecting a 15% differ
ence in the 12-month actuarial sur
vival rate is 0.80. In all cases, death
was secondary to disease progres
sion. The cell type and the primary
tumour classification did not affect
survival.
All patients who received adjunc
tive radiotherapy had increased me
dian survival regardless of whether
they underwent thoracotomy (9.0
months versus 5.0 months, p <
0.005). However, actuarial survival
curves comparing these patients
with those not receiving adjunctive
treatment revealed that radiothera
py did not change the 1-year surviv
al rate significantly (Fig. 2).

THORACOTOMY AND BRONCHOGENIC CARCINOMA

Discussion
Surgery has been suspected to
have an immunosuppressive effect,
which may promote tumour
growth. Experimentally, there is a
correlation between accelerated tu
mour growth and multiple operative
procedures.8 Other models have re
vealed increased pulmonary metastases and impaired immunity after
surgical trauma.2 Eggermont and
colleagues3 have made similar ob
servations in animals subjected to
major surgical trauma, but not in
those subjected to minor proce
dures. In this model, immune func
tion was only transiently impaired.
This would suggest a time-limited
immunosuppressive effect.
Clinical results have not been as
conclusive. Perioperative blood
transfusions have been found to
exert a negative effect on survival
in patients with rectal cancer.11 An
immunosuppressive effect is sus
pected. Surgery and anesthesia
have produced a measurable depres
sion in immune response in normal
patients.4 The clinical implications
of this observation are not known.
Fielding and Wells6 retrospectively
noted shortened survival in patients
who underwent two-staged resec
tion of obstructing colonic cancer
compared with those who under
went primary resection. These re
sults have been used to support the
hypothesis that surgery itself facili
tates tumour growth. Alternatively,
these findings may be explained by
the decision of the surgeon to select
more complicated cases for staged
resection.
This study is concerned exclu
sively with stage III non-small cell
lung cancer. The poor prognosis
associated with this tumour stage is
widely recognized.12"14 Thus, sur
vival as an end point to study
possible accelerated tumour growth
seems to be appropriate in these
patients. Patients who underwent

exploratory thoracotomy were re
trospectively compared with a
group who had the same disease
classification but had not been sub
jected to a major surgical proce
dure. Both groups of patients were
comparable with respect to age,
sex, preoperative weight loss, in
traoperative use of blood products,
cell type and use of adjunctive
radiotherapy.
It should be stressed that al
though this is a retrospective study,
there is no selection bias, because
patients were assigned to the
groups, not by surgeon’s judge
ment but by the historical fact that
mediastinoscopy was not routinely
practised when the earlier patients
underwent thoracotomy. These pa
tients were then compared with
those who had similar lesions but
did not require thoracotomy simply
because they were seen after me
diastinoscopy became available.
Since the group 1 patients pre
date group 2, it is possible that
improvements in postoperative care
could affect the comparison. How
ever, if this were the case, it should
increase rather than reduce the dif
ference in the survival data. The
fact that we could not find such a
difference indicates that even with
improved postoperative manage
ment, avoiding exploratory thora
cotomy did improve prognosis.
Thus, the use of historical controls
in this case strengthens rather than
weakens our conclusions.
Patients who underwent thora
cotomy were found to have signifi
cantly increased hospital stay. This
may be in part related to normal
postoperative care and to deteriora
tion of physical condition and quali
ty of life secondary to exploratory
thoracotomy.15 The fact that all
patients but one were eventually
discharged implies that this effect
was a transient one attributable to
operative trauma. Nevertheless, to
spend 1 month of their limited

expected survival in hospital rather
than at home with their families, is
a human cost that cannot be mea
sured in dollars or in days. There
fore, the use of mediastinoscopy in
N2 disease patients, although it
does not improve survival, has
benefits beyond avoiding the less
desirable exploratory thoracotomy,
which is often more painful in the
postoperative period.
When patients who received ad
junctive radiotherapy were com
pared with all others, regardless of
thoracotomy, they were found to
have significantly increased surviv
al. However, this result was subject
to a selection bias because only
patients with good performance
were offered radiotherapy. From
these data, we cannot conclude,
therefore, that radiotherapy has a
beneficial effect on survival in pa
tients with stage III non-small cell
disease. This emphasizes the need
for a randomized trial of radiothera
py in these patients so that results
may be compared to an untreated
control group.16"19
In conclusion, our data failed to
demonstrate any adverse effect of
surgical trauma on the survival of
patients with bronchogenic carcino
ma. Any immunosuppressive effect
an “ exploratory thoracotomy’’ may
cause was not reflected in patient
survival.
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Clinical experience gained over the past
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Om ental Pedicle Grafting in the
Treatment of Poststernotomy Mediastinitis
J. Pierre Bedard, MD, FRCSC; Farid Shamji, MD, FRCSC; Wilbert J. Keon, MD, FRCSC
Mediastinitis after median sternotomy may be life-threatening. It should be managed
by providing adequate mediastinal drainage, removing all foreign material
(including infected and dead tissues) and obliterating any dead space.
Obliterating dead space may be difficult using the usual method of creating a
vacuum with large-bore tubes. Alternative methods consist of muscle or omental
transpositions. The authors describe the cases of two men who had mediastinitis, 1
week and 3 months respectively, after coronary artery bypass grafting. In both
cases, the mediastinitis was treated successfully by omental pedicle grafting.
From their experience, the authors recommend omental grafting as a method of
obliterating a large mediastinal dead space when the sternal edges can be
approximated but the space cannot be closed by conventional methods.

La mediastinite consecutive a une sternotomie mediane peut mettre en danger la vie
du malade. Elle doit etre traitee par un drainage mediastinal adequat, le retrait de
toute substance etrangere (y compris les tissus infectes ou morts) et Termination de
Tespace mort.
II peut etre difficile d’eliminer Tespace mort lorsqu’on utilise la methode
habituelle qui consiste a faire le vide a l’aide d’un tube de gros calibre. Les
transpositions du muscle ou de Tepiploon constituent des alternatives. Les auteurs
decrivent les cas de deux hommes qui ont souffert d’une mediastinite, respectivement 1 semaine et 3 mois apres pontage aortocoronarien. Dans les deux cas, la
mediastinite a ete traitee avec succes par greffe d’un pedicule d’epiploon.
D’apres leur experience, les auteurs recommandent la greffe d’epiploon comme
methode d’eliminer les espaces morts mediastinaux importants, quand les bords du
sternum peuvent etre rapproches mais que Tespace ne peut etre referme par les
methodes conventionnelles.

edian sternotomy is the most
common incision used in car
diac surgery. Although wound in
fection is rarely associated with this
incision, its occurrence may lead to
mediastinitis, which carries signifi
cant mortality and morbidity.
As for any wound infection, the
treatment should consist of exten
sive debridement, adequate irriga-

M

tion and drainage and the adminis
tration of appropriate antibiotics.
Sometimes the wound is difficult to
close and alternative methods, such
as omental pedicle graft or muscle
transposition, must be considered.
We present two cases of postster
notomy mediastinitis treated suc
cessfully with debridement and
omental pedicle grafting.
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Case Reports
Case 1

A 55-year-old man underwent
four-vessel aortocoronary bypass
grafting in October 1986. Three
months later, chest pain, fever and
hemoptysis developed. A chest film
revealed an anterior mediastinal
mass, and an echocardiogram con
firmed the presence of a large false
aneurysm of the ascending aorta.
Cardiopulmonary bypass was estab
lished with femorofemoral bypass.
Using profound hypothermia (at
18°C) and circulatory arrest, the
median sternotomy incision was
opened, and the false aneurysm was
entered, blood clots were evacuated
and the hole on the ascending aorta
was identified. The false aneurysm
was related to an infection and
dehiscence of a proximal coronary
artery graft anastomosis. The defect
on the aorta was controlled with
interrupted Prolene suture, cardio
pulmonary bypass was resumed and
the patient warmed.
After the false aneurysm was re
paired, we were left with a large
defect in the mediastinum and ex
tensive raw surface on the medial
aspect of the upper lobe of the left
lung. While the patient was being
warmed, the sternotomy incision
was extended down to the umbili
cus so that a well-vascularized
omental pedicle could be obtained.
Once mobilized, the omentum was
brought up to the anterior mediasti
num so that it would cover both the
mediastinal defect and the raw area
of the lung. The chest wall was
closed in layers and two rubber
catheters were left in the mediasti-

OMENTAL PEDICLE GRAFTING

num for irrigation using 0.5% Proviodine solution. The patient was
discharged home 4 weeks after the
operation. He was free of infection
2 years later.
Case 2

A 62-year-old man had under
gone three coronary artery bypass
grafting operations. Six days after
the last one, he suffered sternal
dehiscence, which required debride
ment and reapproximation. Then, 6
days after that, the sternal dehis
cence recurred with severe mediastinitis. Further management included
radical debridement of the sternum,
anterior mediastinal tissue and sub
cutaneous fat, followed by irriga
tion with antiseptic solution and
packing of the mediastinum for 1

FIG. 1. Anatomy and blood supply of
greater omentum.

FIG. 2. Mobilization of vascularized
omental pedicle graft.

week. Because there was a large
dead space in the anterior mediasti
num due to marked fibrosis from
previous operations, a laparotomy
was carried out and an omental
pedicle graft obtained and moved up
into the anterior mediastinum to
close the dead space. The sternum
was reapproximated as usual. The
patient was discharged home 3
weeks later and was free of infec
tion after 1 year.

through its epiploic branches.
Hence, the omental pedicle graft
usually does not need to be de
tached from the greater curvature
of the stomach (Fig. 2). The omen
tal pedicle is then delivered into the
anterior mediastinum through a re
trosternal tunnel, making sure that
gastric outlet obstruction from vol
vulus is avoided. The omental pedi
cle graft is anchored in place in the
anterior mediastinum with absorb
able sutures.

Technique for Mobilizing an
Omental Pedicle Graft

Discussion

The median sternotomy incision
is extended interiorly and the peri
toneal cavity entered through the
linea alba. A well-vascularized
omental pedicle graft is then pre
pared as follows.
The greater omentum hangs
down from the lower convexity of
transverse colon in front of the coils
of small intestine. It is a continua
tion downwards of the gastrocolic
omentum from the greater curva
ture of stomach and it receives its
blood supply from the epiploic
branches of the gastroepiploic ar
cade (Fig. 1). This arcade runs
along the greater curvature of the
stomach. The attachment of greater
omentum to the lower convexity of
the transverse colon along the avas
cular plane is exposed by gently
lifting the greater omentum up
wards over the costal margin. This
avascular plane is divided to sepa
rate a segment of greater omentum
8 to 10 cm wide from the transverse
colon. The preparation of this seg
ment of greater omentum by ligat
ing and dividing lymphatics and
blood vessels in the gastrocolic
omentum is continued as far as 5 to
6 cm from the greater curvature of
the stomach. This allows the gas
troepiploic arterial arcade to be pre
served and maintains the blood sup
ply to the omental pedicle graft

The principles of treatment of
wound infections apply to postster
notomy mediastinitis. First, all for
eign material (including necrotic tis
sue and dead bone) must be ade
quately debrided. This is followed
by irrigation with an antiseptic solu
tion and immediate direct closure of
the sternum if possible. Cultures of
the wound are obtained and cover
age with broad-spectrum and then
specific antibiotics is provided.
An important factor contributing
to failure of treatment for postster
notomy mediastinitis is the presence
of a dead space posterior to the
sternum.1 It may be present in the
mediastinum because of the rigidity
of the retrosternal compartment.
The use of an omental flap is
helpful in those cases as it will not
only fill up the dead space, but also
provide healthy tissue with a pro
pensity for new blood supply and
granulation.2
The omentum has a number of
properties that offer protection
from infection: it has a rich vascular
and lymphatic supply which favours
neovascularization;3 it possesses a
rich source of macrophages which
will resist infection and seal areas of
inflammation;4 because of its double
layer of peritoneum it offers a large
absorptive surface which will favour
absorption of fluids;5 finally, its
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bulkiness will seal areas of inflam
mation, fill up dead space and cover
tissue defects.2-3-6 Because of its
advantages, the omentum is becom
ing more widely used by the cardiothoracic surgeon.
In our first patient, the omentum
was used not only to fill up the
large dead space left behind by the
false aneurysm but also to seal
communications with the bronchial
tree and cover the stitches used to
close the aorta. In our second pa
tient, the omentum was used to fill
up the large dead space provided by
the rigid wall of the mediastinum

due to the three previous coronary
artery bypass graft operations.
It is worth re-emphasizing that
the basic treatment of poststernoto
my mediastinitis remains adequate
debridement and drainage. The use
of an omental flap is not necessary
in all cases, but is useful under
certain circumstances.
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BOOK REVIEW S

CARDIOTHORACIC TRAUMA. Panagiotis N. Symbas. 404 pp. Illust. W.B.
Saunders Company Canada Limited,
Toronto, 1989. $128.25. ISBN
0-7216-2817-3.
This textbook on chest trauma is writ
ten by a surgeon with more than two
decades of experience in a major US
trauma centre. In addition to his exten
sive clinical experience, he is also the
director of an active surgical research
laboratory where problems associated
with cardiothoracic trauma have been
studied. Many of the strengths of this
book are the result of the author’s
experience.
The book is well organized, concise
and clearly written, and the quality of
the illustrations, particularly the roent
genograms, is superb. The extensive
references following each chapter will
be especially useful for readers who
wish to obtain source material or de
tailed information on specific subjects.
In the preface it is stated, “The
material described in this text is de
signed to be of benefit to any provider
of health care to patients with thoracic
injury either in the early or late postin
jury period”. The systematic and au
thoritative essays certainly fulfil this
objective. For nonthoracic surgeons,
330

such as emergency room physicians and
paramedic staff, and for surgical resi
dents and medical students, the detailed
description of basic concepts of care for
chest trauma, including early resuscita
tion and chest-tube drainage, is particu
larly useful. However, it is important for
these readers to keep in mind that this
text should not be read and used in
isolation. Many patients who suffer car
diothoracic trauma also have injury to
other organs. For example, patients
with blunt trauma requiring intubation
and respiratory support may also have
suffered cervical spine injury, and inap
propriate manipulation may cause per
manent paraplegia. Setting priority in
the management of multiorgan damage
is not within the scope of this book;
these aspects are emphasized in the
ATLS (Advanced Trauma Life Support
course of the American College of Sur
geons, Committee on Trauma).
For the cardiothoracic surgeon who
provides definitive operative care, this
book can also serve as a useful refer
ence. Again, its strength is the authori
tative statements based on the author’s
experience. Consequently, in the discus
sion of each subject, particularly the
controversial areas, one notices person
al biases. For example, the potentially
lethal complications of systemic air em
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bolism associated with penetrating inju
ry of the lung are dealt with in a single
sentence. Neither its pathophysiology
nor the diagnosis and management are
discussed. On the issue of shunting for
the repair of vascular injuries involving
the innominate or carotid artery, the
author relies largely on information
obtained from carotid endarterectomies.
There is considerable difference in the
available collateral circulation for endar
terectomy if the carotid artery is occlud
ed at its bifurcation or if the common
carotid or innominate artery is occluded
unilaterally. In the former, only intra
cranial collaterals can perfuse the terri
tory of the occluded internal carotid
artery. In the latter, however, extra
cranial collaterals via the branches of
the external carotid arteries provide
much more important and reliable col
laterals. Likewise, repair of ruptured
descending thoracic aortas using cen
trifugal pumps without heparinization
has given good results in recent years,
but this approach is not elaborated on
in the present text.
There are other minor inconsisten
cies. The references are generally ar
ranged in the order of their appearance
in the text, but of the 28 references in
continued on page 372
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Catheter Drainage of the Pericardium: Its
Safety and Efficacy
C.D. Morgan. MD, FRCPC; S.A. Marshall, MD, FRCPC; J.R. Ross, MD, FRCPC
A retrospective chart review identified 46 consecutive patients who underwent
catheter drainage of the pericardium over 3 years. Cardiac tamponade was present in
the majority of patients, and the underlying cause was tumour metastasis in 72%.
Pericardial catheterization was accomplished by the Seldinger technique using the
subxiphoid approach. Catheter insertion was successful in 42 of the 46 patients, and
in only 1 was there a serious complication. The mean duration of catheter drainage
was 3 days. The pericardial space was successfully drained in all but one patient,
who subsequently required surgery. Intrapericardial chemotherapy was administered
in 27 patients. There was no instance of catheter-associated sepsis. Supraventricular
arrhythmias occurred in 19% of patients, but all were managed medically. There
were no late complications attributable to the period of drainage. The authors
conclude that catheter drainage of the pericardium is a safe and effective means of
providing definitive drainage of the pericardial space.

Une etude retrospective des dossiers medicaux a permis d’identifier 46 patients qui,
au cours d’une periode de 3 ans, ont subi un drainage par catheter du pericarde.
Dans la majorite des cas, une tamponade etait presente et la cause sous-jacente, dans
72% des cas, etait des metastases tumorales. Le catheterisme pericardique fut realise
grace a la technique de Seldinger en utilisant un abord sous-xiphoi'de. L’insertion
du catheter fut reussi chez 42 des 46 patients et on n’a rencontre qu’une seule
complication serieuse. La duree moyenne du drainage fut de 3 jours. L’espace
pericardique fut draine avec succes dans tous les cas, sauf un qui necessita une
intervention chirurgicale subsequente. Une chimiotherapie intrapericardique fut
administree a 27 patients. On n’a enregistre aucun cas de sepsie due au catheter.
Des arythmies supraventriculaires sont apparues chez 19% des patients, mais elles
purent etre traitees medicalement dans tous les cas. II n’y eut aucune complication
retardee attribuable a la periode de drainage. Les auteurs concluent que le drainage
pericardique par catheter est un moyen sur et efficace d’offrir un drainage definitif
de l’espace pericardique.

he approach to drainage of
hemodynamically im portant
pericardial effusions remains con-

T

troversial. Although there is no
question about the role of a defini
tive surgical procedure in cases of
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traumatic cardiac tamponade, pa
tients with nontraumatic cardiac
tamponade have traditionally been
managed by needle pericardiocente
sis. Unfortunately, this procedure is
associated with serious complica
tions, and frequently a single peri
cardial tap is unsuccessful in prov
iding long-term relief.1-3 Although
there are some4-1’ who advocate
open surgical drainage in this set
ting, these patients may tolerate
surgery poorly due to advanced
systemic disease. Our institution is
allied to a major regional cancer
institute and we have, of necessity,
been required to manage a large
number of patients with cardiac
tamponade due to malignant dis
ease. Concerns over the safety and
efficacy of traditional medical and
surgical management led us to ex
plore the role of pericardial cathe
terization in this clinical setting.

Methods
A retrospective chart review iden
tified 46 consecutive patients who
underwent catheter drainage of the
pericardium between May 1982 and
May 1985. There were 36 women
and 10 men (mean age 55 years).
The procedure was performed for
clinically suspected cardiac tam pon
ade in all but three patients in
whom the procedure was performed
for diagnostic purposes. All patients
had a moderate to large pericardial
effusion (Table I) documented by
preceding two-dimensional echocar-
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diography. All procedures were per
formed in the intensive care unit by
a staff cardiologist or by a cardiolo
gy subspecialty trainee under the
direct supervision of an attending
cardiologist. Pericardial catheteriza
tion was performed by the Seldinger
technique using the subxiphoid ap
proach.7-8 The patients were awake
and supine. When necessary for
patient comfort the head of the bed
was elevated to 30°. After infiltra
tion of the skin and subcutaneous
tissues with 1% lidocaine without
epinephrine, a small incision was
made to the left of the xiphisternum
to ease subsequent passage of the
catheter. A 17-gauge 20-cm spinal
needle with trocar was then inserted
beneath the costal margin at ap
proximately 30° to the horizontal
plane and directed towards the mid
point of the left clavicle. The needle
was advanced under continuous
electrocardiographic guidance with
the trocar frequently withdrawn
until the pericardial sac was en
tered, as documented by free aspira
tion of pericardial fluid without STsegment elevation or dysrhythmias.
A J-tipped guide wire measuring
0.025 inches (0.064 cm) in diame
ter was inserted through the nee
dle into the pericardial space under
fluoroscopic guidance. No special
effort was made to direct the guide
wire posteriorly within the pericar
dial sac. That the wire had indeed
entered the pericardial space and
not a cardiac chamber was con
firmed by (a) the observation that
the guide wire could be advanced
well into the known pericardial re
flections off the great vessels, and

(b) the absence of dysrhythmias
with guide wire manipulation. The
subcutaneous tissues were then
carefully dilated using a no. 7F
standard vein dilator. Under fluoro
scopic guidance, a 25-cm long 6.5F
polyethylene catheter (Vas Cath of
Canada, Ltd., Mississauga, Ont.)
with six 0.035-inch (0.089-cm) di
ameter side-holes, spirally arranged
between 1 and 3 cm from the tip,
was advanced into pericardial space
so that its tip was no more superior
than the centre of the cardiac sil
houette (Fig. 1). The catheter was
sutured to the skin and covered by
a sterile occlusive dressing.
The pericardial effusion was
drained continuously by gravity
using a closed system. A stopcock
was included to permit sampling of
the pericardial fluid and instillation
of chemotherapeutic agents. Open
ing of the system was kept to a
minimum and strict aseptic tech
nique was emphasized. Heparin was

not used to maintain catheter pat
ency. Fluid was sent for cytologic
examination, cell counts and
Gram's staining and, in addition,
was cultured daily. A chest x-ray
film was obtained after the proce
dure to document catheter location.
All patients underwent continuous
electrocardiographic monitoring
while the catheter was in situ.

R esults

Percutaneous catheter insertion
was successful in 42 of the 46
patients. In two of these, the cathe
ter entered the right atrium, result
ing in a nonfatal cardiac arrest in
one and no sequelae in the other. In
both instances, immediate repeat
catheterization was successful.
Both these cases occurred early in
our experience when a straight
guide wire was being used. Since
switching to a J-tipped guide wire,

T a b le 1. C a u se s o f P e ric a rd ia l E ffu s io n s in
46 P a tie n ts
C ause

No.

%

M a lig n a n t d is e a s e
U re m ia
C o n n e c tiv e tis s u e d ise ase
V iru s
H y p o th y ro id is m

33
6
3
3
1

72
13
6 .5
6 .5
2
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FIG. 1. Diagram showing technique of catheter insertion.
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we have not seen this complica
tion. In two patients, no fluid was
obtained through the needle despite
adequate fluid demonstrated by
echocardiography. In two other pa
tients, the catheter could not be
passed over the guide wire despite
apparently adequate subcutaneous
dilatation. In 41 of the 42 patients
successfully cannulated, the effu
sion was adequately drained. One
patient suffered recurrent tampon
ade, despite initial successful drain
age and a patent catheter. In this
patient, the catheter tip travelled
anterior to the right ventricle and
was likely too far superior for ade
quate drainage. The catheter was
repositioned and tamponade was re
lieved. The patient ultimately re
quired a pericardial window. Of the
entire group, this was the only
patient who required surgical inter
vention.
The mean duration of catheter
drainage was 3 days (ranging from
1 to 5 days) and during this time 27
patients received intrapericardial
tetracycline and 3 intrapericardial
steroids. When indicated, tetracy
cline poudrage was performed as
described previously.9 Briefly, this
involved the daily intrapericardial
instillation of 500 mg of tetracy
cline to a maximum total of 2.0 g.
Daily cultures from all pericardial
effusions were sterile. Eleven (26%)
of 42 patients had a fever with a
temperature greater than 38.5°C.
Two (5%) of 42 catheter tips cul
tured positive for Staphylococcus
epidermidis upon removal. This was
most likely due to skin contamina
tion; no subsequent local infections
developed. In the majority of febrile
patients, a potential alternative
cause of fever could be identified.
There were no sustained dysr
hythmias during the insertion pro
cedure. Subsequently, a new su
praventricular tachycardia devel
oped in 8 (19%) of 42 patients
during the period of drainage. All of

these patients had also received
intrapericardial tetracycline. No pa
tient suffered hemodynamic com
promise and the dysrhythmias were
successfully treated medically. One
(2%) of 42 patients required cathe
ter removal due to refractory peri
cardial pain. Even though we did
not use heparin or vacuum-assisted
drainage, there were no instances in
which, because of clotting, the
catheter had to be removed before
the drainage or planned course of
treatment was completed. There
were no late complications attribut
able to catheter drainage.

Discussion
Malignant disease and uremia are
common causes of hemodynamically important nontraumatic pericar
dial effusion. Primary malignant tu
mours of the pericardium are ex
ceedingly rare. Secondary involve
ment is most frequently encoun
tered with carcinomas of the lung
and breast. Large pericardial effu
sions are reported to occur in up to
7% of patients on long-term dialy
sis,10 and when cardiac tamponade
occurs, it cannot be managed by
dialysis alone. Needle pericardi
ocentesis will relieve nontraumatic
tamponade in 60% to 90% of
cases.1-2 Although useful in the
acutely deteriorating patient with
tamponade, it is less effective for
long-term management. Krikorian
and Hancock1 reported that 76% of
patients required multiple taps,
placement of indwelling catheters
or definitive surgical drainage. Guberman and associates2 noted that
20% of patients with nontraumatic
tamponade ultimately required peri
cardial resection for recurrent accu
mulation of fluid.
Our results indicate that when an
indwelling catheter is used routinely
as part of the initial drainage proce
dure, the need for subsequent sur

gical te rv e n tio n or repeat drain
age pbcedures falls to less th an
10%. !his m ay , in part, be because
the indwelling catheter permits r e 
peated adm inistration of intraperi
cardia chemotherapy. The compli
cation ra te in this series is lower
than that reported with needle peri
cardiocentesis.1 10 Only one of o u r
patients h a d a life-threatening com 
plication. In comparison with previ
ous studies, all had a t least a mod
erate pericardial effusion as demon
strated by two-dimensional echocar
diography. Failure to obtain peri
cardial fluid in two - patients may
have been due to the presence of
intrapericardial clot, loculations, fi
brous tissue or tumour masses.11
The fact th at previous studies in
cluded patients who had not under
gone echocardiography may have
contributed to the higher complica
tion rates in some earlier reports.3
The incidence of supraventricular
dysrhythmias (19%) in this series is
higher than that reported previous
ly. This may be the result of either
the continued dysrhythmogenic po
tential of a foreign body in the
pericardial space over a prolonged
period or the intense inflammatory
reaction seen after intrapericardial
instillation of tetracycline. The lat
ter mechanism is supported by the
observation that all patients who
had supraventricular dysrhythmias
also received intrapericardial tetra
cycline.
There has been concern that the
presence of an indwelling catheter
could lead to septic pericarditis. In
our series, 26% of patients had a
temperature greater than 38.5°C
recorded while the catheter was in
situ. Many patients had clinically
apparent foci of infection elsewhere,
and pericardial fluid cultures were
uniformly negative. The occurrence
of fever did not bear any relation to
the concurrent intrapericardial use
of tetracycline. These results con
firm that the risk of infection is
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negligible when appropriate aseptic
technique is used both at the time
of catheter insertion and during
subsequent manipulations of the
system such as fluid aspiration for
culture and instillation of chemo
therapeutic agents.
In this series, catheter blockage,
when it occurred, could always be
managed by manual flushing of the
catheter with a small volume of
physiologic saline solution. Elabo
rate precautions against catheter
clotting do not appear necessary.12
The size and arrangement of the
side-holes near the catheter tip may
be important in preventing catheter
blockage,13 but with the data from
this series we cannot directly ad
dress this issue.

Conclusions
We recommend that catheter
drainage of the pericardium be un
dertaken in the cardiac care unit,
intensive care unit or cardiac cathe
terization laboratory, where appro
priate resuscitation equipment is
immediately available. In our experi
ence. the keys to safe and success
ful pericardial catheterization in
clude the following: (a) the use of a
J-tipped guide wire, (b) continuous
electrocardiographic and fluoro
scopic monitoring and (c) adequate
dilatation of all tissues from skin to
pericardium before the catheter is
introduced. Percutaneous catheter
drainage of hemodynamically sig
nificant nontraumatic pericardial ef
fusions is a safe and effective alter
native to conventional surgical in
tervention. The technique may be of
particular value in critically ill pa
tients who may be poor candidates
for surgery. The ability to adminis
ter intrapericardial chemotherapy
through the catheter is an impor
tant adjunctive measure in the con
trol of malignant pericardial tam
ponade .9
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CANADIAN SOCIETY OF CARDIOVASCULAR AND THORACIC SURGEONS

Current Operative Morbidity Associated
With Elective Surgical Resection for Lung
Cancer
Jean Deslauriers, MD, FRCSC;* Robert J. Ginsberg, MD, FRCSC;t Pierre Dubois, MD, FRCSC;t
Maurice Beaulieu, MD, FRCSC;§ Melvyn Goldberg, MD, FRCSC;|| Michel Piraux, MD, FRCSC§
To determine the current operative morbidity for elective surgery of lung cancer,
the authors reviewed the charts of 1076 consecutive patients who underwent
pulmonary resection between 1978 and 1984 at two major Canadian teaching
hospitals.
Of these patients, 731 (68%) had a normal course. Minor complications occurred
in 206 patients (19%); the majority were supraventricular arrhythmias (100 events)
and atelectasis (41 events). Nonfatal major complications occurred in 105 patients
(9.8%). The overall operative death rate was 3.2%. If supraventricular arrhythmias
are excluded, nearly 80% of patients had a smooth postoperative course.
In order to correlate the occurrence of complications with pre- and perioperative
data, several possible risk factors were analysed. For major complications and death,
the age, the forced expiratory volume, weight loss, coexisting disease, stage of
cancer and extent of resection were significant risk factors (p < 0.05).
The data show that elective pulmonary surgery can be done safely and
complications prevented. The necessary requirements are: proper selection of
patients, a well-performed operation and prompt treatment of potential problems.

Pour determiner la morbidite associee a la chirurgie elective d’un cancer du
poumon, les auteurs ont revu les dossiers de 1076 malades ayant subi une resection
pulmonaire entre 1978 et 1984 dans deux hopitaux universitaires canadiens.
Sept cent trente et un malades (68%) ont eu des suites postoperatoires
entierement normales. Deux cent six malades (19%) ont present des complications
d’ordre mineur, ces dernieres etant surtout des arrythmies supra-ventriculaires (100
malades) ou des atelectasies (41 malades). Des complications majeures mais non
fatales sont survenues chez 105 malades (9.8%) et la mortality operatoire a ete de
3.2%. En excluant les arrythmies supra-ventriculaires, quelques 80% des malades
ont eu des suites operatoires normales.
Dans le but d’etablir une correlation entre morbidite et donnees pre- ou
perioperatoires, plusieurs variables ont ete etudiees. Pour les complications
majeures et deces operatoires, l’age, la fonction respiratoire, la perte de poids, les
maladies co-existantes, le stade de la tumeur et l’etendue de la resection ont ete
identifies comme facteurs de risque statistiquement significatifs (p < 0.05).
Ces resultats demontrent que la chirurgie pulmonaire peut etre pratiquee de fa?on
securitaire, la plupart des complications pouvant etre prevenues. Un effort doit
cependant etre fait pour bien selectionner les malades, bien faire la chirurgie et
traiter sans delai les problemes potentiels.

lthough pulmonary resection is
recognized as the best treat
ment for lung cancer, there is little
published inform ation on the
30-day morbidity associated with
such operations. Nagasaki and col
leagues1 from the Memoral SloanKettering Cancer Center reported a
19% operative morbidity, but their
series included 202 patients with
either biopsy only or with intersti
tial implantation of radioisotopes.
Keagy and associates2 analysed
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morbidity and mortality in 369 con
secutive pulmonary lobectomies
performed between 1970 and 1983
and found that 41% of patients had
postoperative management prob
lems. Much of the remaining litera
ture is limited to the reporting of
specific postoperative problems or
to collective reviews of potential
complications after elective resec
tions.3
This analysis of 1076 consecutive
resections done during the years
1978 and 1984 at two major Cana
dian hospitals was undertaken to
determine the current complication
rate for operative treatment of lung
cancer. In addition, possible risk
factors were analysed in the hope of
correlating the occurrence of com
plications to pre- and perioperative
data.

Study Population
We reviewed the records of 1076
consecutive patients (907 men, 169
women) who underwent elective re
section for lung cancer between
1978 and 1984. The patients
ranged in age from 29 to 86 years.
For all cases, preoperative work
up included posteroanterior and lat
eral chest roentgenography, bron
choscopy, electrocardiography,
basic biochemical tests, and liver
function studies; 62% (672 patients)
had pulmonary function studies.
These tests were usually limited to
measurement of forced expiratory
volume (FEV,), forced vital capacity
(FVC) and diffusing capacity of the
lung for carbon monoxide (DLCO).
Arterial blood-gas determinations,
exercise tolerance tests and isotopic
regional function studies were also
performed in selected patients with
compromised function. Mediastinos
copy was done in 92% of cases,
with random node sampling at three
different levels. Very few patients
were subjected to thoracotomy
336

when nodal metastases were identi
fied by mediastinoscopy.
All tumours were staged accord
ing to the TNM classification.4
Staging was based on complete clin
ical and pathological assessment of
the primary tumour (T status) and
surgical sampling of at least the
bronchopulmonary, hilar and medi
astinal nodes (N status).
The types of procedures per
formed at thoracotomy are listed in
Table I. Limited resections (segmental/wedge) were carried out only
when the patient’s pulmonary re
serve was thought to be compro
mised; these were done infrequent
ly. Lobectomies included all simple
lobectomies, bilobectomies, sleeve
lobectomies or extended lobecto
mies. Similarly, standard, intrapericardial or extended pneumonecto
mies were all included in the pneu
monectomy group. A complete re
section was defined as removal of
all gross carcinoma, disease-free re
section margins and the highest
mediastinal node free of tumour.
According to these criteria, 89% of
procedures were considered com
plete.
Operative death was defined as
death occurring within 30 days of
the surgery or directly related to
the operation if it occurred after 30
days. For example, a patient who
died on the 40th postoperative day
of a bronchopleural fistula would
fall into the operative death group.
Nonfatal postoperative complica
tions were classified as minor or
major. Minor complications were
defined as events that had no im
portant impact on the patient’s
postoperative course; in contrast,
major complications were events
considered to be life-threatening.
When a given patient had both
minor and major postoperative com
plications, he was coded as having
major complications only, although
the nature of the minor complica
tion was also recorded.
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The influence of each selected
pre- or perioperative risk factor on
the development of postoperative
complications was examined by x2
analysis. For this purpose, patients
T a b le

1. Type of Procedure in Patients Who
Underwent Thoracotomy
N o . of
p a tie n ts

P ro c e d u re

Limited resection (wedge or
segmental)
Lobectomy
Pneumonectomy
T a b le II.

(%)
58 (5)
616(57)
402 (38)

Minor Complications After Elective
Pulmonary Surgery
N o . of

C o m p lic a tio n

e v e n ts

Respiratory
Atelectasis requiring no or
only one bronchoscopy
Air leak for > 14 d
Cardiovascular
Atrial or ventricular
arrhythmias responding to
drug treatment
Pleural
Pneumothorax requiring tube
drainage
Pleural effusion requiring
thoracentesis or tube
drainage
Miscellaneous

100

Total

239

41
25

25
9
39

Major Complications After
Elective Pulmonary Surgery

T a b le III .

N o . of
C o m p lic a tio n

Respiratory
Atelectasis requiring two or
more bronchoscopies
Pneumonia/lung abscess
Respiratory failure
Cardiovascular
Myocardial infarction
Pulmonary embolism
Congestive heart failure
Cerebral thrombosis
Pleural
Empyema and/or
bronchopleural fistula
Miscellaneous
Hemorrhage requiring
reoperation
Wound dehiscence
Chylothorax
Cardiac herniation
Other
Total

e v e n ts

21
20
15
2
2
4
6
29
9
2
2
1
20
133
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were included in one of two catego
ries for each factor as follows: (a)
older or younger than 60 years, (b)
Table IV. Deaths After Elective Pulmonary
Resection
Primary cause of death
Respiratory
Respiratory failure
Cardiovascular
Cerebral thrombosis
Pulmonary embolism
Pleural
Empyema and/or
bronchopleural fistula
Miscellaneous
Hemorrhage
Esophagopleural fistula
Tumour embolism
Other
Total

No.

FEVi greater or smaller than 2.0 L,
(c) weight loss greater or smaller
than 10% of ideal body weight, (d)
presence or absence of coexisting
diseases, (e) carcinoma stage I or
stages II and III, and (f) limited
resection and lobectomy or extend
ed resection and pneumonectomy.

13
4
2
8
1
2
2
2
34

FIG. 1. (Top) Preoperative chest x-ray
film of 68-year-old man who underwent
left pneumonectomy for large necrotic
tumour of upper lobe. (Bottom) Angio
gram done 24 hours postoperatively,
showing occlusion of both femoral ar
teries by tumour embolism.

Results
Of the 1076 patients, 731 (68%)
had a normal course, whereas 206
patients (19%) had 239 minor com
plications (Table II). These included
atelectasis (41 patients), prolonged
bronchoalveolar air leaks (25), su
praventricular arrhythmias (100)
and simple pneumothorax requiring
tube drainage (25 patients). If su
praventricular arrhythmias are ex
cluded, nearly 80% of patients had
an uncomplicated postoperative
course.
One hundred and thirty-three
nonfatal major complications oc
curred in 105 patients (9.8%), most
of these being pleural or respiratory
in nature (Table III). Major atelecta
sis requiring two or more broncho
scopies was noted in 21 patients,
pneumonia in 20 and respiratory
failure requiring mechanical assis
tance in 15 patients. Only two pa
tients had a myocardial infarction,

FIG. 2. Barium swallow showing ex
travasation at site of esophagopleural
fistula following right pneumonecto
my.

which in both cases was not fatal.
Wound complications were also un
common since only two individuals
had a wound dehiscence and none a
wound infection. Unusual complica
tions included chylothorax (two pa
tients) and postpneumonectomy
cardiac herniation (one).
Thirty-four (3.2%) of the 1076
patients died postoperatively (Table
IV). The commonest primary causes
of death were respiratory failure (13
patients), bronchopleural fistula (8)
and cerebral thrombosis (4). Fatal
esophagopleural fistulas occurred in
two patients (Fig. 1) and tumour
embolism in two others (Fig. 2).
Comparison by x2 analysis of the
group with major complications or
death and those without, or with
only minor complications, showed
that all six variables were signifi
cant risk factors. Complications
were more common in patients
older than 60 years of age, in
patients with an FEVj smaller than
2 L, in patients with weight loss
greater than 10% of normal body
weight, in patients with coexisting
diseases, in patients with lung can
cer stages II and III, and in patients
who had an extended resection or
pneumonectomy.

Discussion
In general, the reported morbidi
ty after operative treatment of lung
cancer is high because the majority
of patients are elderly and most
have chronic obstructive lung dis
ease. Breyer and associates5 have
shown, however, that advanced age
is not necessarily associated with
high morbidity. They reported an
overall death rate of 3% among 218
thoracotomies performed in patients
older than 70 years and concluded
that no patient should be denied
thoracotomy because of age. Simi
larly, the Lung Cancer Study
Group6 retrospectively looked at the
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operative death rate among patients
in the various participating institu
tions during the years 1979 to
1981. There were 81 deaths among
2220 resections, an incidence of
3.7%. Although the death rate was
significantly higher for pneumonec
tomy patients (6.2%) and for pa
tients 70 years or older (7.1%), it
was concluded that major resec
tions could be done with acceptable
mortality even in elderly patients.
Preoperative pulmonary function
is regarded by many as the most
important predictor of operative
morbidity. Keagy and colleagues7
have shown, however, that the re
sults of three spirometric tests
(FEV1; FVC and FEVi/FVC) did
not correlate with postoperative
morbidity or mortality in patients
who underwent pneumonectomy for
carcinoma of the lung. In a similar
study on lobectomy patients, Keagy
and colleagues2 showed an in
creased number of complications
among male patients and those
older than 60 years. Stepwise dis
criminant analysis included FEVi as
a significant predictor of postopera
tive complications.
In this series, the variables con
sidered to be significant for the
development of major complications
or death were old age, compromised
pulmonary function, coexisting dis
eases, weight loss, extent of resec
tion and stage of disease.
The analysis of age as a risk
factor (Table V) shows a substantial
increase in the number of complica
tions after the fifth decade. This
difference is greater in the seventh
decade being 13% in the 60 to 69

years age group and 24.5% in the
70 to 79 years age group. The
lower morbidity seen in older pa
tients (80 years or older) reflects
more rigorous preoperative selec
tion.
Morbidity was also found to be
significantly higher in patients with
compromised pulmonary function
(Table VI), this being most signifi
cant (p < 0.005) in patients with an
FEVj smaller than 1.2 L. Prolonged
air leaks, atelectasis and respiratory
failure were the commonest man
agement problems seen in this
group.
Among all variables analysed, one
of the most important was the ex
tent of weight loss suffered preoperatively (Table VII). Major complica
tions occurred about twice as often

Table VI. Pulmonary Function: Adjusted Morbidity According to Forced Expiratory Volume/s
(FEV,) (672 Patients)
FEV,, L

No. of resections

Major complications
and death, %

< 1.2
1 .2 -2 .0
> 2.0

100
297
275

22—
14
— p < 0.005
14—

Table VII. Weight Loss: Adjusted Morbidity According to Percentage Weight Loss (1015 Patients)
Weight loss, %

No. of resections

Major complications
and death, %

None
< 10
> 10

681
208
126

9—
12
— p < 0.001
20—

Table VIII. Extent of Resection: Adjusted Morbidity According to Type of Operation (1076
Patients)
Type of operation

Major complications
and death, %

< 50
50 - 59
60 - 69
70 - 79
> 80

3.0—
10.7-—
13.0—
24.5
20.0—

338

No. of
resections

Lesser resection
Simple lobectomy
Simple pneumonectomy
Extended lobectomy
Extended pneumonectomy

Table V. Age-adjusted Morbidity According
to Decade (1076 Patients)
Age, yr

in patients with a weight loss great
er than 10%.
The stage of disease and, most
importantly, the extent of operation
(Table VIII) were important predic
tors of morbidity. With simple re
sections, the incidence of complica
tions was around 10%, no matter
how much lung was removed. In
contrast, there was a significant
increase in the number of complica
tions among patients who needed
more extended procedures such as
the removal of the chest wall, peri
cardium or trachea.
There are several reasons why
the morbidity observed in this series
is relatively low and in keeping with
recently published information (Ta
ble IX). Medical operability requires
consideration of age, weight loss,

58
495
121
231
171

Major complications
and death, %
10.4—
11.2—
10.0—
20.0— i
17.0—

Table IX. Literature on Operative Morbidity and Mortality for Pulmonary Resection
Series

Years
analysed

No. of
cases

Nagasaki and colleagues, 19821
Ginsberg and colleagues, 1983®
Keagy and colleagues, 19852

1973-1980
1979-1981
1970-1983

961*
2200
369t

‘ Includes 202 nonresected patients.
tLobectomies only.
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Complications, Operative
%
mortality, %
21
41

2
3.7
2.2
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coexisting diseases and cardiopul
monary function. Similarly, the as
sessment of technical resectability
requires consideration of the clinical
stage of disease and possible extent
of resection. Patients in their sev
enth or eight decade, those with
compromised pulmonary function
or with locally advanced disease
may be operated on with reasonably
low levels of morbidity and mortali
ty, but they must be carefully se
lected.89 Golebiowski10 has empha
sized the hazards of coexisting dis
eases in elderly patients.
Patients should be optimally pre
pared preoperatively by learning the
methods for coughing, deep breath
ing, incentive spirometry and chest
physiotherapy. In addition, all pa
tients should receive proper expla
nations about the nature of the
surgery and its possible hazards.
The procedure itself should be well
and rapidly performed; the anesthe
tist must know about all modern
techniques of intubation, one-lung
anesthesia and perioperative moni
toring. Postoperatively, new meth
ods of analgesia such as epidural or

cryoanalgesia should be routinely
used and finally, but most impor
tant, potential problems must be
recognized and treated at the earli
est stage possible.

Conclusions
The morbidity rates for elective
surgery of lung cancer, collected
from consecutive cases at two
major teaching units for thoracic
surgery, show that pulmonary sur
gery can be done safely and compli
cations prevented if an effort is
made to select patients properly,
perform the operation well and treat
any potential problem promptly.
During the presurgical work-up,
special consideration must be given
to age, pulmonary function and
extent of resection that may be
required.
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Cardiovasc S urg 1971; 61: 2 6 5 -2 7 0

SESAP VI Critique
Item 245
Physicians must regularly read and interpret data regarding improved methods of treatment of disease. Recently,
several questions have been raised as to the actual or artifactual improvement of survival rates. If new detection
methods pick up disease earlier, the survival may seem longer simply because the patient has had the disease
longer, rather than because the cure rate is better. For example, liver-spleen or bone scans can now reveal
previously undetectable metastases, thus shifting a tumor, formerly diagnosed as “favorable,” to a higher stage.
This shift artifactually improves the survival of both groups. Such considerations mandate caution in
recommending different treatment without careful consideration whether the method of treatment is truly better
than the previous method.

¥
Reference
245/1. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: stage migration and new diagnostic
techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608, 1985
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SPRIMAXIN®
(imipenem and cilastatin sodium
for injection)
Antibiotic

•
•
•
•
•
•

Morganella morganii
Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN® especially when
recommended dosages based on renal function
and body weight were exceeded. These expe
riences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known
factors that predispose to seizures.

•
•
•

Clostridium (excluding C. difficile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

ACTION

WARNINGS

Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.

PRIMAXIN® (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN® OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EAC TIO N S MAY REQUIRE
E P IN E P H R IN E AND OTHER EMERGENCY
MEASURES.

PRIMAXIN® c o n s is ts o f tw o c o m p o n e n ts :
(1) imipenem, a derivative of thienam ycin, a
carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzyme w h ic h m e tabolizes and in a ctiva te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in the
urine.
Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
E s c h e ric h ia c o li and s e le c te d s tra in s o f
Pseudomonas aeruginosa, imipenem has been
shown to have highest affinity for PBP-2, PBP-1a
and PBP-1 b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
death without filament formation. When imipenem
is removed prio r to com plete killing of gram
negative species, the remaining viable cells show a
measurable lag, termed a “ post-antibiotic effect’’
(PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for
injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
of bacteria. Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient's clinical condition.
Imipenem is active in vitro against a wide range of
gram -positive and gram -negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactam ase producin g. Patients have
responded while under treatment with PRIMAXIN®
for single or mixed infections of the following body
systems, when they were associated with a number
of pathogenic species and strains of the genera
listed:
1.
2.
3.
4.
5.
6.
7.
8.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
E ndocarditis caused by Staphylococcus
aureus
Bone and Joint Infections
Skin Structure Infections

Gram-positive Aerobes

•
•
•
•

Listeria monocytogenes
Nocardia asteroides
Staphylococcus (excluding many strains
which are methicillin resistant)
Streptococcus (excluding S. faecium)

Gram-negative Aerobes

•
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella

emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
these or other species. Inother studies, PRIMAXIN®
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
under TOXICOLOGY in the complete monograph).
Nursing Mothers

It is not known whether PRIMAXIN® is excreted in
milk. If the use of PRIMAXIN® is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN® is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

Concomitant administration of PRIMAXIN® and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically
added to other antibiotics. PRIMAXIN® has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN® with any other beta-lactam antibiotics
has any therapeutic advantage.

Pseudomembranous colitis

ADVERSE REACTIONS

Pseudomembranous colitis has been reported with
the use of PRIMAXIN®. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.

PRIMAXIN® (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it difficult to
determ ine causal relationship of adverse ex
periences to therapy with PRIMAXIN®.

Mild cases o f pseudomembranous colitis may
respond to drug discontinuance alone. In more
s e v e re c a s e s , m a n a g e m e n t m ay in c lu d e
sig m o id o s c o p y, ap p ro p ria te b a c te rio lo g ic a l
studies, fluid, electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN® were:

PRECAUTIONS
General

Prolonged use of PRIMAXIN® (imipenem and
cilastatin sodium for injection) may result in
overgrowth o f resistant organisms. Repeated
evaluation of the patient's condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusional states, or seizures have been
reported with PRIMAXIN® especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
and/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherence to recommended dosage
schedules is urged especially in patients with
known factors that predispose to seizures (see
DOSAGE A N D A D M IN IS T R A T IO N ). A n ti
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated n e u rolo gically and placed on anti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN®
should be decreased or discontinued.
Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im p a irm e n t (see DOSAGE AND A D M IN IS 
TRATION - Dosage in P atients w ith Renal
Insufficiency).
Use In Pregnancy

The use of PRIMAXIN® in pregnant women has not
been studied, therefore, PRIMAXIN® should be
used during pregnancy only if clearly needed. Use
of this drug in women of childbearing potential
requires that the anticipated benefits be weighed
against possible hazards.
Reproduction studies with bolus I V. doses suggest
an apparent intolerance to PRIMAXIN® (including

Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
p o ssib ly, pro b a b ly, o r d e fin ite ly related to
PRIMAXIN® were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

Special Senses

transient hearing loss in
patients with impaired hearing
tinnitus

<0.1
<0.1

Respiratory

dyspnea
hyperventilation
thoracic spine pain

0.1
<0.1
<0.1

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less

Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Dosage in Elderly Patients

<0.1
<0.1

The recommended dosage of PRIMAXIN® in elderly
patients with normal renal function is the same as
given for adults above. Renal status of elderly
patients may not be accurately portrayed by
measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.

Renal
oliguria/anuria
polyuria
Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Body as a whole
polyarthralgia
asthenia/weakness

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, increased
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN®
(imipenem and cilastatin sodium for injection)
represent the quantity of imipenem to be ad
ministered by I.V. infusion only. An equivalent
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined
by the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN®
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.
Dosage in Adults

P a tie n ts w ith c r e a tin in e c le a r a n c e s o f
< 5 m L/m in/1.73m 2 « 0 .0 8 mL/s/1.73m2) should
not receive PRIMAXIN® unless hemodialysis is
instituted w ithin 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . The p a tie n t sh o u ld re ce ive
PRIMAXIN® after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be carefully
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN® is recommended only when the benefit
outw eighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN® in
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION

RENAL
F U N C T IO N

M ild
i m p a ir m e n t

M o d e r a te
i m p a ir m e n t

DOSE

DOSAGE
IN T E R V A L

M A X IM U M
TO TAL
D A IL Y
DOSAGE

(g)

(h )

(g)

3 1 -7 0
(0 .5 2 -1 .1 7 )

0 .5

6 -8

1 .5 -2

2 1 -3 0
(0 .3 5 - 0 .5 0 )

0 .5

8 -1 2

1 -1 .5

0 .2 5 - 0 .5

12

0 .5 -1 .0 **

C R E A T IN IN E
C LE AR AN C E
m L /m in /1 .7 3 m *
( m L /s /1 .7 3 m2)

TABLE 1

S e v e re *
i m p a ir m e n t

0 -2 0
( 0 - 0 .3 3 )

P a tie n ts w ith c re a tin in e clearance o f 6 to
20 mL/min/1.73 m* (0.1 - 0.3 mL/s/1.73 rrp) should
be treated with 250 mg (or 3.5 mg/kg whichever is
lower) every 12 hours for most pathogens. When
the 500 mg dose is used in these patients, there may
be an increased risk of seizures.
xx The hig h e st dose is only recommended fo r
in fe ctio n s due to less susceptible organism s
primarily some strains of Ps. aeruginosa.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.
Males:

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

0.85 x above value.

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:
(lean body weight, kg) x (140 -age, years) x 1.4736

I.V . Adm inistration
Dosage
Interval

Daily
Dose

250 mg

6h

1.0 g

Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

D o se
(m g o f im ip e n e m )

and in females the estimated creatinine clearance
(mL/s) is:
(lean body weight, kg) x (140 - age, years) x 1.2526
(72) x (serum creatinine concentration, /zmol/L)

ADULT DOSAGE OF PRIMAXIN®

PRIMAXIN® is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.
Dosage in Infants and Children

Mild

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

x Primarily some strains of Ps. aeruginosa.

RECONSTITUTION
Contents of the vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.
A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the
remaining 90 mL of the infusion solution.
Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the vial
to the infusion solution.
CAUTION; CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Injection w ith 0.02% sodium
bicarbonate solution
5% Dextrose and 0.9% S odium C h lo rid e
Injection
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOL-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
Reconstituted solutions

(72) x (serum creatinine concentration, /zmol/L)

The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

Severity
o f in fectio n

Dosage in Patients with Renal Insufficiency

Each reconstituted 250 mg or 500 mg dose should
be given by intravenous infusion over twenty to
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who
develop nausea during the infusion, the rate of
infusion may be slowed.

T h e re com m e nde d to ta l d a ily d o sage o f
PRIMAXIN® in children and infants 3 months of age
and older is 60 to 100 mg/kg of body weight divided
into 4 equal doses given at six hour intervals. The
higher dosages should be used for infants and
young children. The total daily dosage should not
exceed 2 grams. Clinical data are insufficient to
recommend an optimum dose for infants and
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

Solutions of PRIMAXIN® range from colourless to
yellow. Variations of colour within this range do not
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted
as above maintains satisfactory potency fo r fou r
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN® has been found to
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.

DOSAGE FORMS
AVAILABILITY
PRIMAXIN® is supplied as a sterile powder m ixture
in vials containing imipenem a n hydro us and
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature
below 30° C.
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CANADIAN SOCIETY OF CARDIOVASCULAR AND THORACIC SURGEONS

Prolonged Ventricular Support Using a
Centrifugal Pump
Fredrick B.Y. Hoy, MD; Carol Stables, RN; Robert C. Gomez, MD;
James R. Munns, MD; Dale M. Geiss, MD; Dennis Flack, CCP;
David Filko, CCP; James Zischler, CCP, Dean Schmidt, RN
The Biomedicus centrifugal pump was required to provide prolonged ventricular
support to 13 patients with hemodynamic instability: 11 after cardiovascular
surgical procedures, 1 after myocardial infarction and 1 after failure of a heart
transplant.
The duration of support ranged from 3.5 hours to 9 days (mean 72 hours).
Complications included bleeding in six patients, renal insufficiency in three and
central nervous system deficit in three. Six patients (46%) were successfully weaned
from the pump. The patient with graft failure had hyperacute rejection of a second
heart. Five patients were discharged from the hospital. There was one death 8
months postoperatively.
Prolonged ventricular support with the centrifugal pump may allow recovery of
potentially reversible ventricular dysfunction in selected patients after cardiac
surgical procedures.

L’usage de la pompe centrifuge Biomedicus fut necessaire pour assurer un soutien
ventriculaire de longue duree chez 13 patients souffrant d’instabilite hemodynamique: 11 apres chirurgie cardiovasculaire, 1 apres infarctus du myocarde et 1 apres
echec d’une greffe cardiaque.
La duree de l’intervention de soutien a varie de 3.5 heures a 9 jours (moyenne de
72 heures). Les complications rencontrees comprennent: saignement chez six
patients, insuffisance renale chez trois et deficit neurologique chez trois. Six
patients ont pu etre sevre de la pompe avec succes (46%). Le patient greffe a subi le
rejet aigu d’un second coeur. Cinq patients ont pu recevoir leur conge de l’hopital. II
y eut une mortalite, 8 mois apres l’intervention.
Chez des patients choisis qui ont subi diverses chirurgies cardiaques, un soutien
ventriculaire prolonge peut permettre la guerison de dysfonctionnements potentiellement reversibles.

espite advances in surgical
technique, myocardial preser
vation, anesthesia and pharmacolo
gy, some patients cannot be weaned

D

from cardiopulmonary bypass after
cardiovascular surgical procedures.
Several devices are currently avail
able for temporary support of the
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heart until it recovers sufficiently to
sustain adequate cardiac output.
This article outlines our experience
with the use of the centrifugal
pump for prolonged ventricular
support.

Patients and Methods
Between July 1986 and July
1988, 13 patients, who ranged in
age from 6 weeks to 69 years,
required prolonged ventricular sup
port with a centrifugal pump (Bi
omedicus Pump, Biomedicus, Min
neapolis, Minn.). Use of the device
was indicated in 11 patients who
could not be weaned from cardi
opulmonary bypass after open-heart
surgical procedures, in 1 patient
because of graft failure after or
thotopic cardiac transplantation and
in 1 patient because of cardiogenic
shock after acute myocardial infarc
tion.
All patients had refractory cardio
genic shock before mechanical as
sistance was instituted. This was
defined as a cardiac index of less
than 2.0 L/min-m~2 with a left or
right atrial pressure, or both, great
er than 20 mm Hg, a mean arterial
pressure less than 60 mm Hg and
urine output less than 20 m l/h
despite maximal inotropic support,
intra-aortic balloon counterpulsa
tion, optimal pre-load and after-load
and correction of metabolic abnor
malities. In the pediatric population,
refractory cardiogenic shock was
characterized by persistent hypoten-

CENTRIFUGAL PUMP VENTRICULAR SUPPORT

sion, anuria or oliguria, poor pe
ripheral perfusion and metabolic ac
idosis despite elevated filling pres
sures and maximal inotropic and
vasodilator support.
In 10 patients, left ventricular
support was used, with venous out
flow from the left atrium and arteri
al inflow into the aorta. In one
patient, right ventricular support
was used, with right atrial venous
outflow and pulmonary arterial in
flow. Two patients were essentially
on cardiopulmonary bypass with ve
nous outflow from the right atrium
and arterial inflow into the aorta
and with the use of a Biomedicus
pump and membrane oxygenator.
The duration of support ranged
from 3.5 hours to 9 days (mean 72
hours). Flow rates were maintained
at the highest rate afforded by the
venous return. This ranged from
1.0 to 5.0 L/min in adults (mean 3
L/min) and 0.35 to 0.8 L/min for
the two children. When hemostasis
was secure after the surgical proce
dure, activated coagulation times
were maintained in the range of
150 to 200 seconds using heparin.
In eight patients, intra-aortic bal
loon counterpulsation had been in
stituted before the Biomedicus
pump was inserted.
Attempts to wean the patient
from ventricular support were
begun when the patient’s cardiac
index was greater than 2
L/min*m~2 during temporary with
drawal of the support.

Results
Six (46%) of the 13 patients
could be weaned from ventricular
assistance. All of them had left
ventricular support — after coro
nary artery bypass grafting in five
and after extensive myocardial in
farction in one. Five of the six
patients also had an intra-aortic
balloon pump in place.

Of the seven patients who could
not be weaned from the ventricular
support, one patient required right
ventricular assistance after a repeat
aortic valve replacement and coro
nary artery bypass grafting; this
patient died of right ventricular fail
ure. One patient on cardiopulmo
nary bypass after repair of the truncus arteriosus died of a cerebrovas
cular accident. One patient was on
cardiopulmonary bypass after or
thotopic transplantation and had
acute rejection of a second heart.
One patient, who was on left ven
tricular support after coronary ar
tery bypass grafting, died of right
ventricular failure. Another, on left
ventricular support after repair of a
double outlet right ventricle, also
died of right ventricular failure. Of
two others on left ventricular sup
port after mitral valve replacement,
one died of a cerebrovascular acci
dent and the other of biventricular
failure.
Complications were frequent.
Bleeding occurred in six patients
(46%). Renal failure occurred in
three (23%); none survived. A docu
mented cerebrovascular accident oc
curred in three patients (23%); only
one survived.
Five patients were discharged
from the hospital. One patient, al
though weaned from the device,
died of low cardiac output 3 weeks
later. This was the patient who
suffered a large myocardial infarc
tion and was considered too old for
a heart transplant. One other pa
tient died 8 months postoperatively
of unknown cause.

Discussion
Much progress has been made in
the field of mechanical ventricular
assistance, ranging from intra-aort
ic balloon pumping, prolonged car
diopulmonary bypass and centrifu
gal pumping to pneumatically driv

en ventricles and use of artificial
hearts.
The Biomedicus centrifugal
pump uses the rotating motion of
cones to accelerate the blood during
its course between inlet and outlet
ports of the pump, where rotational
energy is recovered in the form of
pressure-flow work. The pressure
head created by the pump generates
movement of blood. While operat
ing at a given constant speed, the
pump generates a nearly constant
pressure over a wide range of flow
rates. Power for the pumping action
is transmitted via magnetic cou
pling to the mated drive magnet
which is fixed to the motor drive.1
The Biomedicus pump can be used
with little or no heparinization; it
will not pump or suck air and will
not pump against increased resist
ance. The Biomedicus pump is also
readily available, the cost is low and
it is user friendly.
To be effective, a ventricular as
sist device must aid the ventricle in
maintaining a reasonable perfusion
pressure and cardiac output for
vital organ perfusion. It must in
crease the myocardial oxygen sup
ply or decrease myocardial oxygen
consumption to make oxygen avail
able to injured cells and reduce
magnitude of myocardial injury. It
must reduce pre-load to allow time
to restore high-energy substrates,
decrease edema and restore ade
quate function.
Cardiogenic shock refractory to
medical management carries an
85% to 100% mortality.2 Intra-aort
ic balloon pumping produces im
provement in up to 75% of patients
but can only be used if there is a
reasonable amount of ventricular
function remaining. Improvements
in anesthesia, intraoperative myo
cardial protection, pharmacology
and surgical techniques have left
only a small number of patients
who cannot be weaned from cardi
opulmonary bypass. In these pa-
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tients, optimal results may be ob
tained if ventricular assistance is
instituted when the period of isch
emia is short. The recognition of
cardiogenic shock, as previously de
fined, should lead to the consider
ation of ventricular assistance in
patients considered to have revers
ible ventricular dysfunction.
Problems associated with the use
of ventricular assist devices include
bleeding, inflow obstruction, renal
insufficiency, infection and biven
tricular failure.
Heparin may be reversed postoperatively until hemostasis is se
cured. Activated coagulation times
may then be maintained in the
range of 150 to 200 seconds with
out thrombus forming in the cen
trifugal pump. The role of antiplate
let agents is still undetermined. In
flow obstruction may be minimized
by using a large cannula in the left
atrium or left ventricle via the mi
tral valve. A patent foramen ovale
must be ruled out. The early use of
arteriovenous ultrafiltration is im
portant because of the frequency of
renal insufficiency. Infection is also
a potential problem because the
cannulas must traverse the skin to
the outside power supply. Right
ventricular failure may not be rec
ognized until left ventricular assis
tance has been instituted. Biven
tricular assistance should be consid
ered if volume loading and adminis
tration of Isuprel do not maintain
adequate cardiac output.
Our results are similar to those
reported in other series. Zumbro
and colleagues3 reported a series of
33 patients, in which 25 were sup
ported by the Biomedicus pump and
8 by the Pierce Donahey pump. Ten
patients (30%) were discharged
from the hospital. Complications
were frequent; they included bleed
ing in 36%, central nervous system
deficits in 18%, sepsis in 30%, renal
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failure in 61% and respiratory fail
ure in 61%. There was a 30%
incidence of biventricular failure.
Park and associates4 reported on
41 patients supported by the Bi
omedicus pump for periods ranging
from 2 to 186 hours. Twenty-one
patients (51%) were weaned from
the pump and 13 (32%) were dis
charged from the hospital. Death in
most cases was the result of pro
gressively decreasing cardiac func
tion and multiorgan failure. Right
ventricular support was used if the
left ventricular assist device was
incapable of producing a cardiac
output greater than 1.8 L/min.
Park and associates believed that
nonpulsatile flow provided adequate
support to preserve vital organ
function.4 Schoen and associates5
reported on 41 patients supported
with a pulsatile pump. Eleven pa
tients (27%) were weaned and 6
patients (15%) were discharged
from the hospital. The mean dura
tion of ventricular assistance was
62 hours. Most patients who died
survived less than 30 hours on
ventricular assistance. The presence
of established myocardial necrosis
itself did not preclude a favourable
hemodynamic response or survival.
Pae and colleagues6 reported that
12 (48%) of 25 patients were
weaned from the Penn State device
and 9 (36%) were discharged from
the hospital. Long-term survivors
had an excellent quality of life with
minimal cardiac disability. Kanter
and colleagues7 reported 14 survi
vors (23%) of 62 patients supported
by the Pierce Donahey or Bi
omedicus pump. There was a 67%
rate of major complications in the
survivors. Crippling cardiac disabili
ty in survivors was unusual.
In summary, a number of pa
tients who have undergone techni
cally satisfactory open-heart proce
dures experience cardiogenic shock.
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Those with potentially reversible
ventricular dysfunction may benefit
from the use of temporary ventricu
lar support with a mechanical de
vice. The most effective and costefficient device and the indications
and contraindications to the use of
these devices have yet to be defined
and require further study.

References
1. P ennington DG, M cBride LR: The use of
mechanical support devices in heart
transplant recipients. In Myerowitz PD
(ed): Heart Transplantation, Futura Pub.
Mount Kisco, NY, 1987: 357-387
2. P ae WE. P ierce WS: Mechanical left
ventricular assistance: current devices,
future prospects. In M oran JM. Michaeu s LL (eds): Surgery for the Complica
tions of Mvocardiai Infarction, Grune,
New York, 1980: 411-425
3. Zumbro GL. K itchens WR. S hearer G. et

al: Mechanical assistance for cardiogenic
shock following cardiac surgery, myocar
dial infarction, and cardiac transplanta
tion. Ann Thorac Surg 1987; 44: 11-13
4. P ark SB. Liebler GA. Burkholder JA. et
al: Mechanical support of the failing
heart. Ann Thorac Surg 1986; 42: 627631

5. Schoen FJ. P almer DC. B ernhard WF. et
al: Clinical temporary ventricular assist.
Pathologic findings and their implications
in a multi-institutional study of 41 pa
tients. J Thorac Cardiovasc Surg 1986;
92: 1071-1081
6. P ae WE jr . P ierce WS, P ennock JL, et
al: Long-term results of ventricular assist
pumping in postcardiotomy cardiogenic
shock. J Thorac Cardiovasc Surg 1987;
93: 434-441
7. Kanter KR, R uzevich SA, P ennington
DG, et al: Follow-up of survivors of
mechanical circulatory support. J Thorac

Cardiovasc Surg 1988; 96: 72-80

Change in Publication Dates
Readers and subscribers please note
that starting in 1990 the publication
dates for the Canadian Journal o f
Surgery will be February, April,
June, August, October and Decem
ber.

►

cost effective
prophylactic
alternative

in contaminated
or potentially
contaminated
gastro-intestinal
surgery
Claforan

.. was superior

in preventing infectious
morbidity and side effects
and reduced hospital
drug costs compared
directly with multidose
regimens of cefazolin
or cefoxitin (p value not
statistically significant)
Dr. R.N. Jones

ROUSSEL
ROUSSEL CANADA INC.
MONTREAL, QUEBEC
©Registered Trademark of Roussel Uclaf, Paris

For prescribing information see reverse

I C l |V

P r e s c r ib ^ C l ^

Information

cefotaxime
sodium

f O

IYTi
C lI

I I

IIM
^

■■■■■■■MlHH

Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium)
a semi synthetic cephalosporin antibiotic, results from inhibition of cell wall
synthesis.
Indications and Clinical Uses
Treatment: CLAFORAN (cefotaxime sodium) may be indicated for the treatment
of infections caused by susceptible strains of the designated micro organisms
in the diseases listed below.
Lower respiratory tract in fe c tio n s: pneumonia and lung abscess caused by
Streptococcus pneumoniae (formerly Diplococcus pneumoniae), other streptococci
(excluding enterocci, e.g. S. taecalis), Straphylococcus aureus (penicillinase and
non penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract infe c tio n s: caused by Escherichia coli, unspecified Klebsiella
species (including K. pneumoniae), Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor
rhea caused by N. gonorrhoeae including penicillin resistant strains
B acterem ia/S e pticem ia: caused by Escherichia coli, unspecified Klebsiella
strains and Serratia marcescens.
Skin in fe c tio n s: caused by Staphylococcus aureus (penicillinase and non
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli,
Proteus mirabilis and indole positive Proteus.
Intra-abdominal infections: caused by Escherichia coli, and unspecified Kleb
siella species.
Gynecological infections: including pelvic inflammatory disease, endometritis
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although
clinical cures were achieved, bacteriological follow-up was not available.
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN
has been used with some success in wound and intra-abdominal infections against
some strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulo
cytopenic patients, results of therapy with CLAFORAN have not been impressive.
CLAFORAN should not be considered in the treatment of enterococcal infections,
i.e. Streptococcus taecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order
to isolate and identify the causative organisms and to determine their suscep
tibilities to CLAFORAN. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re-evaluated once these results
become available.
Prophylactic U se : The administration of CLAFORAN perioperativety (preoperative
ly, intraoperatively and postoperatively) may reduce the incidence of certain infec
tions in patients undergoing elective surgical procedures (eg. abdominal or vaginal
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative
use of CLAFORAN may also reduce the incidence of certain postoperative infections
Effective use for elective surgery depends on the time of administration (see Dosage
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin)
is recommended.
If there are signs of infection, specimens for culture should be obtained for iden
tification of the causative organism so that appropriate therapy may be instituted.
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics.
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether
the patient has had previous hypersensitivity reactions to cefotaxime,
cephalosporins, penicillins or other drugs CLAFORAN should be given with caution
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including
CLAFORAN should be administered with caution to any patient who has
demonstrated some form of allergy, particularly to drugs. If an allergic reaction
to CLAFORAN occurs, the drug should be discontinued and the patient treated
with the usual agents (e.g. epinephrine, antihistamine, pressor-amines or
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins
(and other broad spectrum antibiotics); therefore, it is important to consider its
diagnosis in patients who develop diarrhea during the administration of CLAFORAN.
This colitis can range from mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor
mal flora of the colon and may permit overgrowth of Clostridium difficile or other
Clostridia. It has been established that a toxin produced by Clostridium difficile
is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of CLAFORAN and replace
ment with a suitable specific antibiotic. Moderate to severe cases should be manag
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis
is not relieved by discontinuance of CLAFORAN administration or when it is severe,
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis
(eg. vancomycin) or other suitable therapy may be indicated. Other possible causes
of colitis should also be considered (see Averse Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals
with a history of lower gastrointestinal disease, particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently,
use of the drug in pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child-bearing potential requires that the anticipated
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible
organisms. Constant evaluation of the patient's condition is essential. If super

infection occurs, therapy should be discontinued and appropriate measures taken.
Although CLAFORAN rarely produces alterations in kidney function, evaluation
of renal status is recommended, especially in severely ill patients receiving high
doses.
Patients with markedly impaired renal function should be placed on the special
dosage schedule recommended under Dosage and Administration, because nor
mal dosage in these individuals is likely to produce excessive and prolonged serum
antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment
with the cephalosporin group of antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing
substances but not with the use of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
Hypersensitivity (1.8%); Rash, pruritus, fever. Local (5%): Injection site inflam
mation with intravenous administration. Pain, induration and tenderness after in
tramuscular injection. Gastrointestinal (1.7%): Colitis, diarrhea, nausea and
vomiting. Symptoms of pseudomembranous colitis can appear during or after
CLAFORAN treatment. Hem ic and Lym phatic System ( < 1%). Mild, reversi
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some
patients developed positive direct Coomb's test during treatment with CLAFORAN.
Genitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient
elevations in SGOT, SGFT, serum LDH and serum alkaline phosphatase levels
have been reported. Kidney ( < 1%): Increased serum creatinine and BUN have
occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with CLAFORAN, no
specific information on symptoms or treatment is available. Treatment of over
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium) may be administered intramuscularly or in
travenously after reconstitution (see Table with recommended mode of reconstitution
according to route of administration).

large muscle such as the upper outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia,
bacterial septicemia, or other severe or life-threatening infections, or for patients
who may be poor risks because of lowered resistance resulting from such
debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure,
or malignancy, particularly if shock is present or impending.
For bolus administration a solution containing 1 or 2 g of CLAFORAN can be
injected over a period of 3 to 5 minutes. Using an infusion system, it may also
be given over a longer period of time through the tubing system by which the
patient may be receiving other intravenous solutions. Butterfly* or scalp vein type
needles are preferred for this type of infusion. However, during infusion of the
solution containing CLAFORAN, it is advisable to discontinue temporarily the ad
ministration of other solutions at the same site.
Reg’d TM of Abbott Laboratories.
Reconstitution
For Intramuscular U se : CLAFORAN should be reconstituted with Sterile Water
for Injection or Bacteriostatic Water for Injection in accordance with the volumes
recommended in the following table.
Reconstitution Table

Intramuscular

Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Daily Dose
Type of Infection
Uncomplicated
Gonorrhea
Uncomplicated
infections
Moderately
severe to severe
infections
Very severe
infections (e.g.
septicemia)
Life-threatening
infections

(g)

Frequency and Route

1

1 g IM (single dose)

2

1 g every 12 hours
IM or IV
1-2 g every
8 hours IM or IV

3-6

6-8

up to 12

2 g every
6-8 hours IV
2 g every
4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated
surgery, recommended doses are as follows.
(a) 1g IM or IV administered 1/2 to IV 2 hours prior to the initial surgical incision
to ensure that adequate antibiotic levels are present in the serum and tissues
at the start of surgery
(b) 1g IM or IV administered 1V2 to 2 hours following the first dose; for lengthy
operative procedures, additional intraoperative doses may be administered, if
necessary, at appropriate intervals (IV 2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1g is administered IV as soon as the umbilical cord is clamped.
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 m g/kg IV q 12 h
1-4 weeks of age
50 m g/kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg,
the recommended daily dose is 50 to 100 mg / kg IM or IV of body weight divid
ed into 4 to 6 equal doses, or up to 180 m g /k g / day for severe infections.
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a minimum of 48 to 72
hours after the patient defervesces or after evidence of bacterial eradication has
been obtained; a minimum of 10 days of treatment is recommended for infec
tions caused by Group A beta-hemolytic streptococci in order to guard against
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical
appraisal is necessary during therapy of chronic urinary tract infections and may
be required for several months after therapy has been completed; persistent in
fections may require prolonged treatment. Doses less than those recommended
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on
sex, weight, and age of the patient) may be used to convert these values into
creatinine clearance.
Males: Weight (kg) x (140 - age) Females: 0.85 x above value
72 x serum creatinine
Administration
Intram uscular: CLAFORAN should be injected well within the body of a relatively

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

2
3
5

2.2
3.4
6.0

230
300
330

500 mg vial
1 g vial
2 g vial

’ shake to dissolve.
For direct intravenous injection (bolus) a n d /o r continuous intravenous
in fu s io n : 500 mg, 1 and 2 g vials should be reconstituted with at least 10 mL
of Sterile Water for Injection, Reconstituted solution may be further diluted with
50 to 1000 mL of the fluids recommended for IV infusion.
Reconstitution Table

Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative
organisms, severity of the infection and condition of the patient.

Volume to be
Added to
Vial (mL)*

Intravenous
500 mg vial 10
1 g vial
2 g vial

Volume to be
Added to
Vial (mL)*

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

10.2
10
10

50
10.4
11.0

95
180

’ shake to dissolve.
Solutions for IV In fu s io n : CLAFORAN is compatible with the following infu
sion fluids:
- Sterile Water for Injection
- 0.9% NaCI injection
- 5% dextrose injection
- 0.9% NaCI and 5% dextrose injection
- 0.45% NaCI and 5% dextrose injection
- 0.2% NaCI and 5% dextrose injection
- Sodium Lactate injection
- 5% dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5% dextrose injection
- Ringer's injection
- Lactated Ringer's solution
- Lactated Ringer’s with 5% dextrose injection
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 mL of Sterile Water for Injection is isotonic.
Stability of Solution
S tora ge: Solutions of CLAFORAN range from light yellow to amber, depending
on concentration and the diluent used. The solutions tend to darken depending
on storage conditions and should be protected from elevated temperatures and
excessive light.
’ ’ Reg’d TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution
maintains satisfactory potency for 24 hours at room temperature (25°C) and for
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted solu
tions may be further diluted with 50 to 1000 mL of the recommended infusion
fluids in Viaflex” intravenous bags. Such solutions maintain satisfactory poten
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine maintains satisfactory potency for
up to 24 hours at room temperature and 48 hours under refrigeration (reference
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit maximum stability in the pH 5-7 range.
Special Instru ctions; Parenteral drug products should be inspected visually
for particulate matter and discoloration prior to administration. Solutions of
CLAFORAN range from light yellow to amber, depending on concentration and
diluent used. The dry powder as well as solutions tend to darken, depending
on storage conditions.
Incom patibilities; Solutions of CLAFORAN must not be admixed with
aminoglycoside solutions. If CLAFORAN and aminoglycosides are to be ad
ministered to the same patient, they must be administered separately and not
as a mixed injection.
Solutions of CLAFORAN should not be prepared with diluents having a pH above
7.5 such as Sodium Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder,
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as
acid on a dry basis).
S tora ge: CLAFORAN in the dry state should be stored at room temperature,
protected from light and heat.
Product monograph available on request
Reference
Jones R.N. et a l.: Antibiotic Prophylaxis of 1036 Patients Undergoing Elective
Surgical Procedures. The American Journal of Surgery, 1987; 153 . 341-346.
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Lithotripsie des calculs biliaires:
evaluation de l’ultrasonographie comme
moyen de diriger le traitement par ondes
de choc extracorporelles
Yves-Marie Dion, MD, FRCSC;* Jacques Morin, MD, FRCSC;* Bruno Laroche, MD, FRCSC;t
Gilles Robert, MD, FRCSC;t Michel Thabet, MD, FRCSCt
La lithotripsie des calculs biliaires par ondes de choc extracorporelles est une
procedure recemment developpee qui serait une alternative au traitement chirurgical
de la cholelithiase symptomatique. Selon la litterature, 15% a 25% des personnes
symptomatiques seraient candidates a cette procedure si elle est prouvee efficace.
Presentement, l’echographie semble un des meilleurs moyens devaluation et de
suivi durant la procedure de lithotripsie. Les auteurs ont mis au point un modele in
vitro qui permet de comparer les evenements qui surviennent dans le modele
experimental et ce qui est en meme temps note a l’echographie. Les caracteristiques
echographiques des differentes phases de la lithotripsie des calculs biliaires sont
presentees.

Extracorporeal shock-wave lithotripsy is a procedure recently introduced to treat
gallstone disease. According to the literature, 15% to 25% of symptomatic persons
will be candidates for this procedure if it proves effective. Currently, sonography is
one of the best methods for monitoring the performance of lithotripsy. The authors
have confirmed this. They have designed an in-vitro model which allows comparison
between what is actually happening during gallstone lithotripsy and what is being
seen by real-time sonography. The sonographic characteristics of the different
phases of gallstone lithotripsy are presented.

’idee de la lithotripsie par ondes
de choc extracorporelles a evolue a partir des observations faites
par un groupe de physiciens qui
travaillaient sur les effets produits
par des nuages de pluie a travers
lesquels passaient des avions supersoniques et sur les effets de petits
meteorites qui frappaient des satel-

L

lites.1 Ils ont note que les gouttes
d’eau et autres petites particules
generaient des ondes de choc qui
causaient des dommages, non seulement a la surface, mais aussi a
l’interieur de ces vehicules.1 C’est
ainsi qu’en 1974, le premier projet
de recherche a visee medicale voyait
le jour en Allemagne, avec comme

Du *Service de chirurgie et du fService d'uroiogie. Hopital St-Franpois d Assise, I Universite
Laval. Quebec, PQ

hypothese que les calculs renaux
pouvaient etre detruits par des
ondes de choc extracorporelles.1
Depuis, plus de 60 000 patients ont
ete traite avec succes, cette tech
nique etant applicable a 80% de
tous les patients porteurs de calculs
renaux.1 En 1983, Brendel et Enders1 etudierent les effets de la
lithotripsie par ondes de ch oc ex
tracorporelles sur les calculs bi
liaires humains implantes dans les
vesicules biliaires de chiens. En
fevrier 1988, les resultats d’une
etude clinique etaient publies.2 Les
auteurs rapportent un taux de
succes de 91%, 18 mois apres la
lithotripsie qui est combinee a un
traitement aux acides chenodesoxycholiques et ursodesoxycholiques.
Recemment, un article faisait le
point sur les resultats obtenus a ce
jour et sur les questions sur le
sujet, qui demeurent sans reponse
actuellement.3 Cependant,
apres
avoir consulte la litterature, nous
n’avons note aucun article decrivant
la procedure de lithotripsie. Nous
rapportons notre experience suite a
la fragmentation in vitro de 15
calculs biliaires.

Materiel et methode
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Le lithotripteur utilise est l’appareil de seconde generation EDAP
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LT-01. Les ondes de choc sont
emises par des ceramiques qui tapissent le fond d’une coupelle. Cette
coupelle est recouverte d’une mem
brane qui est mise en contact avec
le modele experimental grace a un
gel conducteur (fig. 1). Le modele
experimental consiste en une cuvet
te dont la base est recouverte d’une
membrane de meme type que la
coupelle. Deux litres et demi d’eau
sont places dans cette cuvette. Par
la suite, un sac de fine polythene,
dans lequel ont ete precedemment
places 75 ml d’eau et le calcul, est

FIG. 1. Coupelle (longues fleches) de
l’appareil EDAP LT-01, recouverte
d’une membrane (courtes fleches) sur
laquelle se trouve le modele experi
mental.

insere dans la cuvette (fig. 2). La
cadence des ondes de choc a ete
etablie a 20 coups/s. Ensuite, le
calcul est repere echographiquement et les ondes de choc sont
mises au foyer au niveau du calcul
grace a un curseur qui apparait sur
l’appareil echographique (fig. 3).
Quinze calculs biliaires de taille, de
forme et de composition differentes
ont ete soumis a la lithotripsie. Les
caracteristiques echographiques qui
seront mentionnees sont le fruit de
ces experiences. En vue de demontrer la sequence des evenements
lors de la lithotripsie, les figures
suivantes proviennent d’une seance

FIG. 2. Modele experimental fait d’une
cuvette dont la base est recouverte
d’une membrane permeable aux ondes
de choc. Le calcul a ete place au fond
d’un sac dont la dimension se compare
a celle de la vesicule biliaire normale.

FIG. 3. Elargissement du cone d’ombre (longues fleches),
temoin du debut de la fragmentation du calcul. Le curseur
(petites fleches) indique l’endroit ou les ondes de choc
convergent.
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effectuee sur un calcul mixte, a
facettes, mesurant 1.6 cm dans son
plus grand diametre et pesant 1.41
g. Une fois l’image echographique
jugee satisfaisante en debut de pro
cedure, les caracteristiques echogra
phiques n’ont pas ete modifiees.

Resultats
Avant le debut de la lithotripsie,
le calcul est bien demontre par
echographie (fig. 4). Les parois du
petit sac de polythene que nous
appellerons “vesicule biliaire” sont
bien visibles; le calcul situe au fond
de la “vesicule biliaire” est bien
demontre ainsi que le cone d’ombre
sus-jacent. Quelques minutes apres
le debut de la lithotripsie, 1’elargissement du cone d’ombre est demon
tre, ce qui temoigne du debut de la
fragmentation du calcul. En effet,
les fragments se deposent au pourtour du calcul creant cet elargissement du cone. Le calcul est toujours visible a la base du cone
d’ombre (fig. 4). Par la suite, a
l’echographie, la “vesicule biliaire”
devient de moins en moins echogenique. En effet, elle semble se
remplir de materiel qui la rend plus

FIG. 4. Echographie du calcul biliaire demontrant le calcul
(petites fleches) et le cone d’ombre sus-jacent (longues
fleches). Le calcul se trouve au fond de la “vesicule biliaire”
(fleches larges).

LITHOTRIPSIE

opaque sur l’image. Ce phenomene
correspond au developpement dans
la “vesicule biliaire” d’un nuage de
poussiere bilieuse verdatre (fig. 5).
Plus tard, on note que le cone
d’ombre s’amenuise (fig. 6) dans
une “vesicule biliaire” qui devient
de plus en plus opaque, c’est-a-dire,
dans laquelle le nuage de poussiere
est devenu plus dense. Le retrecissement du cone d’ombre confirme la
disintegration progressive du calcul. Dans les dernieres minutes
precedant la fin de l’intervention, on
procede a un balayage echographique de la “vesicule biliaire” a la
recherche de cones d’ombre resi-

duels (fig. 7). Ces endroits ou Ton
note de petits cones d’ombre sont
par la suite soumis a l’effet des
ondes de choc en vue de desintegrer
les fragments le plus possible. On
note simultanement, au niveau du
modele experimental, que ces frag
ments de 4 a 6 mm de diametre
devenus legers par la fragmentation
vont et viennent dans la zone de
turbulence creee par les ondes de
choc. On note parallelement, a l’echographie, l’apparition et la disparition alternative des petits cones
d’ombre correspondant a ces frag
ments (fig. 7).
L’indication echographique de la

fin de la procedure nous apparait
demontree de deux faqons. La pre
miere consiste en la visualisation
d’une vesicule biliaire completement
opacifiee par les fragments en sus
pension avec absence de cone d’om
bre (fig. 8). Cette image indique que
la quantite de matieres en suspen
sion rend l’echographie inapte a
visualiser les calculs residuels, s’il
en demeure. Cependant, comme
nous l’avons note, cette image, lorsqu’elle est combinee a l’effet de
balayage des ondes de choc, devient
tres suggestive que les fragments
restants sont de petite taille.
L’autre image echographique ap-

FIG. 5. “Vesicule biliaire” est plus echogenique (fleches) due
a une suspension calculeuse qui la remplie peu a peu.

FIG. 6. Le cone d’ombre s’amenuise (fleches) dans “vesicule
biliaire” de plus en plus echogenique.

FIG. 7. Balayage de la vesicule biliaire a la recherche d’un
petit cone d’ombre (fleches). Ces cones d’ombre apparaissent
et disparaissent, etant projetes sous l’effet des ondes de choc.

FIG. 8. Aspect final de la “vesicule biliaire” et de son contenu
(fleches) a la fin de la lithotripsie. Elle est completement
impermeable aux ultrasons sans evidence de cone d’ombre.
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paraissant demontrer la fin de la
procedure se voit le plus souvent
dans le cas de calculs de plus grand
diametre, c’est-a-dire au-dela de 1
cm. En effet, la quantite de debris
non en suspension demeurant au
fond de la “vesicule biliaire” est
plus grande et ceux-ci s’etalent a
l’endroit le plus declive, ce qui
cause l’elargissement du cone d’ombre (fig. 9). Cependant sous le cone
d’ombre, il n’y a pas de calcul
identifiable. Lorsque les ondes de
choc sont dirigees a ce niveau, on
peut noter a l’echographie la poussiere et les petits fragments qui
s’elevent dans le cone d’ombre
temoignant de leur petite taille.

Discussion
La lithotripsie des calculs biliaires
est presentement le sujet de beaucoup d’interet. Plusieurs etudes ont

demontre la possibilite de desintegrer les calculs par cette techni
que.4-8 D’autres articles ont fait etat
de la fragmentation de calculs biliai
res situes non seulement au niveau
de la vesicule biliaire mais aussi
dans le choledoque et en position
intra-hepatique.910 Quinze pourcent
a 20% des patients presentant des
crises de coliques hepatiques seraient candidats a cette procedure si
elle est prouvee efficace.4
A notre connaissance, la literatu
re actuelle n’indique pas de fagon
claire comment suivre la progres
sion de la lithotripsie des calculs
biliaires. Notre etude in vitro nous a
permis de mettre en correlation les
evenements survenant au niveau du
modele experimental et leur trans
position echographique. Nous
avons constate que l’echographie
permet de determiner avec justesse
les phases de la disintegration des
calculs. Etant donne que l’echogra-

phie donne les informations en deux
plans, ils revient a l’operateur de
manipuler l’appareil dans le troisieme plan (profondeur) de fagon a
visualiser tout le contenu de la
vesicule biliaire. Une fois l’image
echographique du calcul ou du
fragment obtenue, les ondes de
choc sont dirigees vers la cible
grace a un curseur qui apparait sur
l’image echographique.
En resume, l’echographie s’est
revelee un moyen efficace de suivre
la procedure de lithotripsie au ni
veau de notre modele experimental.
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Effects of High-Dose Ketoconazole on
Patients Who Have Androgen-Independent
Prostatic Cancer
T. Eichenberger, MD;* J. Trachtenberg, MD, FRCSCt
Forty-four patients who had metastatic cancer of the prostate that had not responded
to conventional hormonal manipulation were treated with high-dose ketoconazole
(600 to 1200 m g/d). All had castrate serum concentrations of testosterone prior to
therapy. All patients had been categorized as having progressive cancer on
assessment by the criteria of the National Prostatic Cancer Project. After treatment
with ketoconazole, 57% were recategorized as having stable disease. The majority
showed marked subjective lessening of pain on this therapy. Objective responses
were noted but were not consistent. Side-effects were common but tolerable. The
mean survival time was 73.3 weeks. Ketoconazole may be a useful palliative adjunct
in the treatment of hormone-refractory prostatic cancer.

Quarante-quatre patients porteurs de cancers metastatiques de la prostate qui
n’avaient pas repondu aux manipulations hormonales habituelles, ont ete traites
avec de fortes doses de ketoconazole (600 a 1200 m g/j). Tous avaient des taux de
testosterone serique nuls avant le traitement. Tous les patients avaient ete classifies
selon les criteres du Projet national sur le cancer de la prostate comme ayant un
cancer en evolutif. Apres traitement au ketoconazole, 57% des patients ont ete
reclassifies comme ayant une maladie stable. La majorite a manifesto une attenuation
subjective marquee de la douleur grace a cette therapie. Des reponses objectives ont
ete observees, mais elles n’etaient pas constantes. Les reactions adverses ont ete
frequentes mais tolerables. Le temps de survie moyen a ete de 73.3 semaines. Le
ketoconazole peut etre un traitement palliatif d'appoint utile dans les cas de cancers
de la prostate hormono-resistants.

rostatic cancer is the second
most common cause of death
due to malignant disease in North
American men and in the majority
the disease is advanced at the time
it is discovered.1’2 Although the

P

disease is considered to be andro
gen-dependent, only about twothirds of patients who receive thera
py designed to lower concentrations
of androgen (castration or the ad
ministration of estrogens) obtain a
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remission of notable duration. In
spite of an initial response, most
patients relapse and die. No single
agent or combination of agents has
so far provided substantial benefit
to patients with advanced prostatic
cancer.3
Ketoconazole, a synthetic imida
zole dioxolane, is widely used to
treat superficial and deep fungal
infections. In man the action of
ketoconazole is poorly understood.
The drug appears to interfere with a
wide variety of cytochrome P450linked enzyme systems. Recent
studies45 have demonstrated that at
high doses ketoconazole can rapidly
and profoundly inhibit both adrenal
and testicular androgen production
by inhibiting 17,20-desmolase, an
enzyme that is P450-dependent.
These changes in steroidogenesis
are reversible by withdrawal of ther
apy.6 Reports of patients with previ
ously untreated advanced prostatic
cancer who are given ketoconazole
describe a rapidly induced and sus
tained clinical remission accompa
nied with a sustained decrease in
serum testosterone and adrenal an
drogen levels.7 In the course of
treating such patients we have also
noted a marked salutary effect of
ketoconazole on patients who had
relapsed while receiving a variety of
forms of hormonal therapy.8 Indeed,
other investigators have noted simi
lar effects and suggested that keto
conazole may have a role to play in
the treatm en t of androgen-
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independent prostatic cancer.9 In
this study we attempted to define
more precisely the role of ketoconazole in the treatment of patients
who have this disease.

Patients and Methods
Forty-four patients who had biop
sy proven metastatic prostatic can
cer were treated at eight centres
across Canada. The average age
was 69.9 ± 9.1 years (mean ±
SEM) (range from 48 to 84 years).
All had failed to respond to hor
monal therapy which had reduced
their serum testosterone concentra
tion to the castrate level. The previ
ous treatments are shown in Table

the National Prostatic Cancer Pro
ject (complete regression, partial
regression, stable or progression).
Each patient’s duration of “benefit”
was calculated as the time from the
initiation of benefit to the first
evidence of recurrent progression.
The time during which the group
benefited from ketoconazole was
subjected to a “survival” analysis
using the Kaplan-Meier method10 to
estimate the percentage of patients
still on therapy at each week of the
trial. The duration of ketoconazole
therapy was calculated as the differ
ence between the date the patient
first started therapy and the date on
which he was last confirmed to be
still on therapy. In many cases this
was the last recorded visit.

I.

All patients gave their informed
consent and were administered ketoconazole in 200-mg tablets at a
recommended dosage of 200 to 400
mg every 8 hours (to maintain a
maximum concentration of 5 to 10
jig/ml). The dose was adjusted by
serum ketoconazole levels and the
occurrence of side-effects. The pa
tients continued on their original
hormonal therapy. No patient re
ceived supplemental glucocor
ticoids. Patients were allowed to
continue taking additional medica
tion needed to control pain or con
current illnesses. They were seen
weekly for the first month and
monthly thereafter. At each visit a
complete history was obtained, and
they underwent physical examina
tion and extensive biochemical
work-up; all adverse experiences
were reported and each patient was
rated on a five-point abbreviated
Karnofsky performance scale (0 to
4), where 4 represents maximum
performance, and a six-point pain
scale (0 to 5), where 0 represents
no pain. At 3-month intervals bone
scanning was repeated.
The patient’s response to therapy
was assessed using the criteria of
350

Results
Patients who entered this clinical
trial were generally debilitated, be
cause the treatment was considered
as salvage therapy. The laboratory
values were quite variable and often
far outside the normal range. Many
patients were too ill either to attend
every required visit or to have labo
ratory work done. Thus, the data
for laboratory values were not nec
essarily complete for every sched
uled patient visit over the course of
the study.
Twenty-seven patients demon
strated persistent (more than 8
weeks or three visits) improvement
in serum prostatic acid phosphatase
and alkaline phosphatase levels dur
ing therapy, with decreases of more

than 75%. No statistically signifi
cant changes, however, were noted
for these two values in the group as
a whole, although the values during
treatment were generally lower than
those before. This lack of signifi
cance may be attributed to the
extremely wide variance in these
levels before treatment. No signifi
cant changes were noted in markers
of hepatic function or in serum
cortisol levels. In one patient the
bone scan became normal and mul
tiple “hot” areas were eliminated
and two patients had marked im
provement in their bone scans.
The performance ratings showed
little change. The majority of the
patients maintained scores in the 1
and 2 range for the first 12 weeks:
76.7%, 75.7%, 81.2%, 84.8%,
79.3% and 71.4% for weeks 0, 1, 2,
4, 8 and 12 respectively. Beyond
week 12 the data became less relia
ble because of the small number of
patients (11 [25%] or fewer from
week 16 onward). Performance
scores in the range of 1 and 2
remained stable.
Pain scores, on the other hand,
demonstrated a strong decrease
with therapy. The percentage of
patients with scores of 1 or less
increased from 18.5% at the begin
ning of the study to 76.2% by week
12 (Fig. 1), with a corresponding
decrease in analgesic consumption.
On entering this trial, all patients
had progressive disease. During
their treatment with ketoconazole,
25 (57%) patients were recatego
rized as having stable disease. Thir
teen patients showed no benefit

T a b le 1. P re vio u s H o rm o n e T re a tm e n t
T r e a tm e n t

B ilate ra l o rc h ie c to m y ± e s tro g e n
E strogen (d ie th y ls tib e s tro l 3 m g /d )
L h rh a n a lo g u e s (L u p ro n 1 m g /d )
O rc h ie c to m y o r L h rh a n a lo g u e s + a n tia n d ro g e n s *

N o . of p a tie n ts

16
10
4
14

L h rh = lu te in iz in g h o rm o n e -re le a s in g h o rm o n e .
‘ F luta m id e 2 5 0 m g tid o r A n a n d ro n 1 0 0 m g tid .
T h e se ru m te s to s te ro n e le v e l o f all p a tie n ts w a s in th e ca s tra te range ( < 0 .8 n m o l/L ) b e fore
th e ra p y.
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from ketoconazole, 1 had complete
regression and 5 partial regression.
The mean time of benefit on thera
py was 27.3 weeks (median 12
weeks). No significant difference in
duration of response could be found
between the 30 patients who had
been treated with conventional
forms of androgen ablation and the
14 patients in whom total androgen
ablation failed. The mean time on
ketoconazole therapy analysed by
the Kaplan-Meier product limit
method was 35.5 weeks (mean 22.0
weeks, range from less than 1 week
to 96 weeks).
Side-effects were frequent in this
already debilitated group. Thirtytwo patients (72.7%) reported at
least one adverse experience and 29
(65.9%) of them reported experi
ences that were possibly drug relat
ed. There were 23 reports (given by
19 patients) of nausea, vomiting
and gastrointestinal upset, of which
22 were considered possibly drug
related; there were 9 reports of
weakness, fatigue and lethargy (7

possibly drug related). In all of
these patients, the serum cortisol
level was within normal limits.
Seven (15.9%) patients were taken
out of the study because of illness
(two patients) or adverse experience
(five patients).
Eighteen patients died of diseaserelated causes. The mean time to
death was 59.1 weeks (median 73.3
weeks, range from 2 to 100 weeks).

Discussion
To our knowledge this study rep
resents the largest series of patients
treated by high-dose ketoconazole
after the failure of hormonal thera
py. The design was that of a single
armed non-controlled trial. Thus, all
conclusions must be viewed with
caution until they can be substanti
ated in controlled studies. None the
less, we believe that certain assump
tions are warranted. The patients
were all severely ill with progres
sing disease at the time of entry

FIG. 1. Changes in pain score of patients treated with high-dose ketoconazole
during initial 12 weeks of therapy. Values represent percentage of patients with
pain scores of 0 or 1. Pain was rated from 0 to 5 (0 = no pain).

into this study, yet a large percent
age of patients demonstrated a
marked lessening of pain and stabi
lization of their disease. Although
the latter is often difficult to sub
stantiate because of the variable
rate at which the disease pro
gresses, these patients did seem to
benefit, since their condition ap
peared to stabilize, if only for a
short time. The objective responses
that were seen in some of the
patients seem to add further sup
port to the belief that ketoconazole
provides more than just a placebo
effect.
Ketoconazole not only interferes
with testosterone production but
also greatly decreases adrenal an
drogen production.58 The patients
who responded in this study, how
ever, were similarly divided between
those who received only conven
tional testicular androgen ablation
and those who had been subjected
to total androgen ablation. These
data suggest that ketoconazole’s
mechanism of action may be di
vorced from androgen activity. Not
only has the product been shown to
affect androgen synthesis but it also
directly impairs the growth of
human prostatic cancer cells in vi
tro.11 In these studies the androgenindependent human prostatic cancer
cell lines PC-3 and DU-145, when
incubated with ketoconazole,
showed decreased growth from 70%
to 96% at the clinical concentra
tions of 1.0 to 10.0 /ug/ml. Other
agents thought to be of use in this
clinical situation, such as aminoglutethimide, did not demonstrate
similar cytotoxicity. We believe that
this direct cytotoxicity of ketocona
zole may be active in the responses
of these patients. Indeed, the even
tual cessation of benefit could be
predicted by the incomplete inhibi
tion of growth even at the highest
ketoconazole concentration (which
was only intermittently achieved).
The duration of benefit was difficult

►
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to quantify, probably because the
patients were extremely ill and en
tered the trial only as a last chance
at salvage. None the less, the dura
tion of survival is comparable if not
superior to that reported from other
similar trials.12 Historical controls
are usually misleading, but ketoconazole may impart a small survival
advantage. We also believe that the
decrease in pain is significant and
markedly improved the quality of
life for many of the patients. Al
though side-effects were common,
they were rarely severe enough to
limit treatment and were milder
than those experienced by patients
in a similar stage of disease when
treated with estramustine phos
phate or conventional cytotoxic reg
imens (Koenyves I: Personal com
munication, 1987). We believe that
further trials should be undertaken
to determine more precisely the role
of ketoconazole in patients with
advanced prostatic cancer. Experi
mental in-vitro data further suggest
that the cell destruction of certain
classic cytotoxic agents can be in
creased appreciably with the con
comitant administration of ketoco
nazole.13 If this can be substantiat
ed, then ketoconazole may not only
play a role as a palliative agent, but
also as an important adjunct in the
treatment of patients with faradvanced prostatic cancer.
We thank Drs. Orovan, Stogryn, Keat
ing, Sales, Lommersee, Hussey and Bry
son who contributed patients to this
study and Dr. A. Raoult and Mrs. S.
Lund of Janssen Pharmaceutica Canada
for their encouragement for this proj
ect. Janssen Pharmaceutica Canada do
nated ketoconazole and provided finan
cial support.
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Destructive Arthropathy of the Hip
Following Pelvic Irradiation: Report of
Four Cases
T.W. Phillips, BASc, MD, FRCSC;* D.R. Rao, MB, BS, MS(Orth)t
The replacement of orthovoltage by megavoltage radiotherapy has facilitated
selective ablation of cancerous tissue, resulting in less toxicity to bone. However,
damage to bone still occurs and may be more common than generally appreciated. In
four women, all treated for adenocarcinoma of the reproductive tract, radiotherapy
was believed to contribute to acetabular failure and secondary arthritis 2 to 31 years
after treatment. In one case the condition was bilateral.
Because arthritis of the hip is now common in women, there is a risk that unusual
and remote factors may not be recognized or fully appreciated. In these cases
prosthetic joint replacement is likely to fail. Special techniques, including bone
grafting, peripheral support rings, well-fixed and optimally placed sockets and
gradual rehabilitation, are mandatory.

En radiotherapie, le remplacement de i’orthovoltage par le megavoltage a facilite
l'ablation selective des tissus cancereux, reduisant ainsi la toxicite osseuse.
Neanmoins, des dommages osseux surviennent encore, et ils sont possiblement plus
frequents qu’on ne le pense generalement. On croit que, chez quatre femmes qui
avaient ete traitees pour des adenocarcinomes des organes reproducteurs, la
radiotherapie a contribue a un affaissement acetabulaire et a une arthrite secondaire
apparue de 2 a 31 ans apres le traitement. Dans un cas, l’atteinte etait bilaterale.
Parce que l’arthrite de la hanche est devenue commune chez la femme, il y a
risque que des facteurs inhabituels ou lointains ne soient pas reconnus ou apprecies
a leur juste valeur. Dans ces cas, les arthroplasties sont susceptibles d’etre vouees a
l’echec. Des techniques speciales telles que greffes osseuses, anneaux de soutien
peripherique, cavites articulaires solidement fixees en position optimale et readapta
tion graduelle sont obligatoires.

steoradionecrosis is a wellrecognized entity, affecting
most areas of the skeleton. The
femoral neck has been one of the

O

most common locations for second
ary fracture.1 Acetabular failure and
protrusio have been described in
eight patients.2-4 In only one recent
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report2 have the pitfalls of recon
structive arthroplasty been dis
cussed.
In this paper we describe four
patients in whom the condition at
first appeared to be standard arthri
tis of the hip. However, radiologically the arthropathy appeared
more destructive than usual. It was
discovered that all patients had un
dergone radiotherapy. All had also
had recurrent problems from radia
tion cystitis, urethritis or proctitis.

Case Reports
Case 1
In 1977, at the age of 68 years,
this woman underwent a total hys
terectomy and bilateral salpingooophorectomy for adenocarcinoma
of the uterus. Postoperatively, she
received external pelvic irradiation
(50 Gy in 20 fractions over 5
weeks) using 33 mev x-rays, 50% of
the total dose from the anterior
field and 25% from each of the
lateral fields. A scout film obtained
at the cancer clinic before radiother
apy showed that both hips were
normal (Fig. 1).
In 1983 this woman was seen
complaining of a painful right hip.
A fracture of the medial wall and
secondary arthritis were found (Fig.
2). A right hip replacement arthro
plasty was performed. The medial
acetabular wall was found to be
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fractured, eroded and chalk-like,
and was poorly vascularized. A fem
oral head autograft was used to
augment the medial wall. A cement
less Moore-type femoral stem with a
Bateman bipolar head was implant
ed. Seven months later the right
side was asymptomatic but she had
severe pain in the left hip due to a
fracture of the medial acetabulum
with protrusio acetabuli (Fig. 3).
This hip was also reconstructed
using a cementless bipolar prosthe
sis with medial bone grafting. She
did well until June 1985 when she
again began to suffer pain in the
left hip. X-ray films showed protru
sion of the prosthetic head into the
pelvis with a lack of consolidation
of the medial acetabular fracture
(Fig. 4). The bipolar head was re
moved and the medial wall further
grafted, this time with an iliac crest
autograft from outside the radiation
field. An Eichler peripheral support
ring was positioned over the graft
and fixed to the rim of the acetabu
lum with cancellous bone screws. A
polyethylene prosthetic socket was
cemented inside this. In March

1986, a complete transverse frac
ture of the pelvis was noted on
follow-up x-ray films (Fig. 5). This
was also revised with medial bone
grafting and a cemented socket in
side a peripheral support ring. Two
years after this she was doing well
(Fig. 6), but in late 1988 her condi
tion deteriorated with recurrence of
right hip pain and progressive loos
ening of the prosthesis.
Case 2

In 1981, this 71-year-old woman
underwent a total hysterectomy and
bilateral salpingo-oophorectomy for
adenocarcinoma of the uterus. Postoperatively, she received 50 Gy in
20 fractions over 4 weeks on 6 mev
Therac — four fields with equal
weighting. In January 1984, she
presented with a very painful right
hip. X-ray films showed a fracture
of the acetabulum and arthritis

FIG. 2. Case 1. Medial acetabular frac
ture, protrusio and early degenerative
changes of right hip. Left hip appears
normal.

FIG. 1. Case 1. Taken before radio
therapy, x-ray with marking grid
shows acetabular walls inside radiation
field. Iliac bone-graft donor sites are
outside field.
354

(Fig. 7). Roentgenograms obtained
2 months earlier had revealed a
fracture of the medial wall of the
acetabulum but a normal joint
space. A right hip replacement was
performed using a cementless bipo-

FIG. 3. Case 1. Medial acetabular frac
ture on left side similar to right 7
months before. Right bipolar replace
ment doing well.
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FIG. 4. Case 1. Left bipolar head has
migrated into pelvis 2 years after sur
gery.

FIG. 5. Case 1. Nine months after
revision of left arthroplasty with exten
sive medial grafting, peripheral sup
port ring and cemented components.
Acetabulum on right side shows com
plete transverse fracture of medial wall
(arrow).

FIG. 6. Case 1. After revision on both
sides, 2 years on right side and 3 years
on left.

PELVIC ARTHROPATHY AFTER RADIOTHERAPY

lar prosthesis and grafting with
autogenous femoral head exactly as
in case 1. Examination of the re
trieved acetabular fragments re
vealed several areas of grey-brown
discolouration and pitting in the
articular cartilage, and a weakened,
chalk-like bone structure. On mi
croscopic examination there were
irregular areas of thickened trabec
ulae, loss of osteocytes and evi
dence of bone necrosis. At recent
4-year follow-up the patient walks
well, shops and continues living

FIG. 7. Case 2. Preoperative x-ray film
showing fracture of medial acetabular
wall (arrow). Joint space was present 2
months before when fracture was first
detected.

independently in her apartment.
X-ray films show no migration or
protrusio of the acetabular cup, and
the acetabular fracture has united.
Case 3

In 1976, at 39 years of age, this
woman underwent a total hysterec
tomy and bilateral salpingooophorectomy for adenocarcinoma
of the uterus. Preoperatively, she
received intracavitary radium, 45
mg intrauterine and 20 mg intravaginal, for 72 hours for an
estimated total dose of 50 Gy to the
uterus. An estimated 15 Gy was
delivered to each hip joint. Four
years earlier, she had also received
radiotherapy for stage III Hodgkin’s
disease. The subdiaphragmatic por
tion of this was in the form of 35
Gy in 20 fractions over 4 weeks
using cobalt-60 and an inverted Y
field with central pelvic shielding
but with both hip joints in the field.
The total cumulative dose of all
previous exposures to the acetabu
lum had been estimated by the
cancer clinic as 50 Gy.
She presented in 1985 with an
exceedingly painful and destructive

FIG. 8. Case 3. Preoperative x-ray film showing marked erosion of acetabulum and
superior migration of femoral head.

arthropathy of her right hip (Fig.
8). A cementless porous-surfaced
femoral stem with a Bateman bipo
lar head was implanted, after graft
ing the superior acetabular deficien
cy with bone from the resected
femoral head and medializing the
acetabular socket. Intraoperatively,
the acetabulum and femoral head
were found to be dystrophic and
fragmented with areas of avascularity and necrosis. Three weeks later
the head of the prosthesis broke
through the acetabulum. A cement
ed polyethylene acetabular compo
nent was inserted and reinforced by
tricortical bone graft harvested
from the ipsilateral iliac crest. The
graft was fixed solidly over the
polyethylene socket with cancellous
bone screws. At 3-year follow-up
the patient was doing well, was
walking extensively, had no pain
and had a good hip as shown
radiologically (Fig. 9).
Case 4

In 1955, at the age of 51 years,
this woman received irradiation for
adenocarcinoma of the cervix. The
therapy included 80 hours of radi
um (50 mg intrauterine and 20 mg
intravaginal) followed by 60 hours
of radium (40 mg vaginally) for a
total of 4000 mg-h to both uterine
cavity and vagina. This was fol
lowed by external pelvic radiothera
py with cobalt-60 to a dose of 27.4
Gy in 15 fractions over 3.5 weeks
with anteroposterior and posteroanterior split fields with central shield
ing. In 1954 she had also received
external radiotherapy to establish
an artificial menopause because of
irregular vaginal bleeding. Radia
tion was in the form of 14 Gy using
200 kV x-rays. In 1984 a barium
enema examination revealed stric
tures of the lower colon but the hip
joints appeared normal. The total
dose to the hips has been estimated
as 51.4 Gy.
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She presented in 1986, at the age
of 82 years, with a painful left hip,
and x-ray films showed protrusio
and arthritis (Fig. 10). The pro
trusio was unusual in that its
course was rapid and there was no
reactive periosteal bone inside the
pelvis. The medial wall of the ace
tabulum was almost nonexistent,
with only a pale dystrophic mem
brane at the base; it was reinforced
with an ipsilateral iliac crest graft.
An Eichler peripheral support ring
was fixed to the acetabular rim and
a polyethylene socket cemented in
side it. At follow-up 2 years later
this woman had an excellent result
— she had no pain, walked well
with a cane and radiologically had a
good hip (Fig. 11).

occur with the megavoltage tech
niques in use today. Cases of ace
tabular failure reported elsewhere
have had similar doses and types of
radiation at 35 to 70 Gy.2-4
The chronologic, radiologic,
gross and microscopic changes in
our four cases provide convincing

evidence that radiation was an im
portant factor contributing to the
destructive arthropathy. None of
the patients in the present series
had chemotherapy, steroids or pre
vious surgery on the hip. There was
an inverse correlation between age
at the time of radiotherapy, and the

Discussion
It is essential to review the gyne
cologic history of women who have
a rapid course of hip pain and
disability to determine if therapeutic
radiation has ever been given. If
this is so, a radiation oncologist
should be consulted to determine if
the acetabulum was included in the
field and what dosage of radiation it
received. Symptoms of urethritis,
cystitis and proctitis suggest that
substantial amounts of radiation
have been delivered to the pelvis.5
In the hips of all our patients the
destructive arthropathy appeared to
have been triggered by severe pro
trusio or fracture through the
weakened bone of the medial ace
tabular wall. The variability of the
interval from the time of radiothera
py to acetabular fracture suggests
that all unilateral cases may eventu
ally become bilateral.
The dosage of radiation required
to cause damage to bone has been
stated as 30 Gy for the threshold of
cell change and 50 Gy for cell
death.6 Although less frequent,
atrophic changes and fractures do
356

FIG. 9. Case 3. Three years postoperatively, position of prosthesis and fixation of
cup, with incorporation of graft, are good.

FIG. 10. Case 4. Preoperative x-ray film shows fragmentation of medial acetabular
wall, protrusio and degenerative changes of joint.
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interval before arthropathy. The de
gree of osteoporosis at the time of
radiotherapy, as assessed radiologically, had a bearing on the time
interval from irradiation to fracture.
All patients had osteoporotic hips at
the time of presentation with frac
ture. That men treated with similar
doses of radiation to the pelvis for
prostatic cancer rarely developed
secondary fractures7 probably re
lates to the lower incidence of os
teoporosis in men.
The microscopic characteristics
of irradiation-induced bone necrosis
have varied. In the late stages when
there is mechanical bone failure and
fragmentation, signs are obscured
by a nonspecific mixture of necrosis
and secondary inflammation.
Whether frank necrosis occurs is
debatable. Goodman and Sherman,1
from analysis of femoral head mate
rial obtained after radiation-induced
neck fractures, found that total ne

crosis did not occur. They believed
that the osteocyte was damaged and
unable to perform its metabolic
functions in bone maintenance, but
microscopically could look normal.
Radiation-induced fractures can
heal with time and protection from
loading.1 However, the prolonged
morbidity this would entail in ace
tabular fractures necessitates an op
erative approach. Reconstruction in
these cases in which the bone stock
is poor is difficult and demands
techniques often used in revision
hip surgery, such as the use of
protrusio rings and extensive bone
grafting. Ideally, autograft har
vested from the ipsilateral iliac crest
outside the original radiation field
should be used. The need for subse
quent surgery on many of these
hips makes the use of cementless
components attractive, but the
probability of failure of such com
ponents in these cases is high as

demonstrated by our case 1. The
use of acrylic bone cement and
peripheral support rings is preferred
in these cases to maximize the area
and magnitude of immediate fixa
tion.
Based on the improvement in
four of our five hips over a 5-year
period, it is our opinion that radia
tion necrosis of the acetabulum is
not an absolute contraindication to
prosthetic joint replacement. How
ever, it is necessary to recognize
the condition and be aware of the
potential problems.
We thank Drs. Alan Y.C. Cheung and
Peter Corbett of the London Regional
Cancer Clinic for providing details of
the radiotherapy and proofreading the
manuscript.

References
1. Goodman AH, S herman MS: Postirradia
tion fractures of the femoral neck. J Bone
Joint Surg [Am] 1963; 45: 723-730

FIG. 11. Case 4. Two-year postoperative film shows cemented socket solidly
anchored on peripheral support ring and medial bone graft that has consolidated
well.

2. D eleeuw HW, P ottencer LA: Osteone
crosis of the acetabulum following radia
tion therapy. A report of two cases. J
Bone Joint Surg [Am] 1988; 70: 293299
3. H all FM, Mauch PM, Levene MB, et al:
Protrusio acetabuli following pelvic irra
diation. AJR 1979; 132: 291-293
4. Hasselbacher P, S chumacher HR: Bilat
eral protrusio acetabuli following pelvic
irradiation. J Rheumatol 1977; 4: 189196
5. O rton CG, W olf-R osenblum S: Dose
dependence of complication rates in cer
vix cancer radiotherapy. Int J Radiat
Oncol Biol Phys 1986; 12: 37-44
6. B ragg DG, S hidnia H, C hu FCH, et al:
The clinical and radiographic aspects of
radiation osteitis. Radiology 1970; 97:
103-111
7. R ay GR, Cassady JR, B acshaw MA: De
finitive radiation therapy of carcinoma of
the prostate. A report on 15 years of
experience. Radiology 1973; 106: 407418

CIS, VOL. 32, NO. 5, SE P TE M B E R 1989

357

ORIGINAL ARTICLES

Diagnosis of Acute Appendicitis in
Pregnancy
Christine Richards, MD; Salim Daya, MB, MSc*
Although the clinical diagnosis of appendicitis in pregnancy seems to be
complicated by the physiologic changes of pregnancy, evidence from controlled
studies is lacking. The aims of this study were to determine whether there are any
features of appendicitis in pregnant women that would help to establish the
diagnosis and whether any difference exists between the presentation of appendicitis
in pregnant and nonpregnant women. Twenty-eight pregnant women with a clinical
diagnosis of appendicitis were compared with an equal number of nonpregnant
patients matched for age and randomly selected from a group of patients who had
appendicitis. No differences were observed in the presenting symptoms, physical
signs and laboratory tests. The false-positive rates were identical. The results
indicated that the diagnosis of appendicitis is no more difficult in the pregnant state
than in the nonpregnant state.

Bien que le diagnostic clinique de l’appendicite en cours de grossesse semble etre
complique par les changements physiologiques de la grossesse, il y a absence de
preuves a cet effet, issues d’etudes controlees. Les objectifs de cette etude etaient de
determiner s’il existe des caracteristiques de l’appendicite chez la femme enceinte
pouvant aider a etablir le diagnostic, et s’il y a des differences dans le tableau
clinique des femmes enceintes atteintes d’appendicite, par rapport a celles qui ne
sont pas enceintes. Vingt-huit femmes enceintes ayant un diagnostic clinique
d’appendicite ont ete companies a un nombre egal de patientes non enceintes
appariees pour Page et choisies au hasard parmi un groupe de patientes souffrant
d’appendicite. Aucune difference n’a ete observee dans les symptomes, les signes
physiques ou les epreuves de laboratoire. Les taux de faux positifs etaient
identiques. Ces resultats indiquent que le diagnostic d’appendicite n’est pas plus
difficile a etablir chez la femme enceinte que chez celle qui ne Test pas.

cute appendicitis is the most
common nonobstetric condi
tion requiring operative intervention
during pregnancy.1-5 It is not a
frequent complication, occurring
only once in every 1500 deliveries.6
Thus, in most obstetrical units it is

A

encountered approximately twice a
year.
The clinical presentation varies,
often making the diagnosis difficult,
especially later in pregnancy. The
progressive displacement and rota
tion of the tip of the appendix has
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been one factor responsible for this
difficulty. Also, the physiologic
changes of pregnancy may con
found the interpretation of laborato
ry tests. The resulting delay in
diagnosis and operation is a major
factor contributing to the higher
maternal mortality associated with
this disorder. It is generally believed
that if appendicitis is suspected in a
pregnant woman, immediate surgi
cal intervention is indicated. But
often the surgeon is reluctant to
perform exploratory laparotomy
since there is a risk of precipitating
spontaneous abortion or premature
labour. Consequently, better diag
nostic criteria are required to enable
the diagnosis to be made with more
confidence. The purpose of this
study was to compare the presenta
tion of appendicitis in pregnant
women with that in nonpregnant
women to determine whether there
is a specific pattern of presentation
in pregnancy that would aid in its
diagnosis.

Patients and Methods
A chart review was carried out of
28 pregnant patients admitted with
abdominal pain to Chedoke-McMaster Hospital or St. Joseph’s Hospital
in Hamilton, Ont. between Jan. 1,
1981 and Sept. 30, 1986 and who
underwent appendectomy because
of a preoperative diagnosis of ap
pendicitis. The charts from a con
trol group of 28 nonpregnant
women in the same age range and

APPENDICITIS IN PREGNANCY

with a diagnosis of appendicitis ad
mitted during this period were ran
domly selected for comparison. In
formation on presenting symptoms
(vomiting, nausea, diarrhea and
anorexia), physical signs (rebound
tenderness, abdominal guarding,
Rovsing’s sign, psoas irritation and
pyrexia) and results of laboratory

tests (leukocyte count in blood and
urine) were extracted from the hos
pital charts. Histologic findings
were also obtained for each patient
and the two groups compared. The
time from presentation in the hospi
tal to surgery was also recorded and
compared.
The two groups were compared

Table 1. Clinical Presentation in Pregnant and Nonpregnant Patients Presenting With Abdominal
Pain*
Variable
Age, yr
Time from presentation to operation, h
Temperature, °C
Leukocyte count, x 109/L
Blood
Urine
Vomiting
Nausea
Diarrhea
Anorexia
Rebound tenderness
Positive Rovsing's sign
Psoas irritation
Abdominal guarding
Histologically proven appendicitis

Pregnant

Nonpregnant

25.4 ± 0.8
25.1 ± 4 .3
37.1 ± 0.1

26.2 ± 1.9
10.2 ± 1.7
37.3 ± 0.1

14.9 ± 0.6
1.7 ± 0.5
50
71
21
39
68
46
14
64
82

16.0 ± 0 .9
3.0 ± 1.2
46
93
21
39
64
18
11
75
82

'Values are either mean ± SEM or %.

Table II. Clinical Presentation in Pregnant and Nonpregnant Patients With Histologically
Confirmed Appendicitis*
Variable
Age, yr
Time from presentation to operation, h
Temperature, °C
Leukocyte count, x 109/L
Blood
Urine
Vomiting
Nausea
Diarrhea
Anorexia
Rebound tenderness
Positive Rovsing’s sign
Psoas irritation
Abdominal guarding

Pregnant

Nonpregnant

25.3 ± 0.9
11.4 ± 1 .9
37.1 ± 0.1

25.9 ± 2.0
10.7 ± 1.9
37.3 ± 0 .1

15.3 ± 0 .7
1.6 ± 0 .5
57
78
24
36
65
61
12
61

16.6 ± 0 .9
2.1 ± 0 .7
52
100
23
67
65
57
40
83

'Values are either mean ± SEM or %.

Table III. Prevalence of Appendicitis in Each Trimester
Trimester of pregnancy
Appendicitis

1st

2nd

3rd

Totals

Positive
Negative

6
0

13
2

4
3

23
5

Totals

6

15

7

28

x 2 with 2 df = 4.50, p = 0.106.
x 2 due to linearity with 1 df = 4.19, p = 0.041.

using x2> Fisher’s exact and Wilcoxon rank sum tests where appro
priate and significance was tested at
the 5% level.

Results
The average age of the women in
the pregnant group was 26.2 years,
compared with 25.4 years for those
in the nonpregnant group. There
were no differences between the
two groups with respect to symp
toms and physical signs (Table I) or
in the duration from presentation in
the hospital to surgery. The most
consistent symptom present in
these patients was abdominal pain.
Two-thirds of the pregnant patients
presented with nausea and had ab
dominal guarding, rebound tender
ness and demonstrated a positive
Rovsing’s sign. Anorexia and diar
rhea were infrequent and the elicita
tion of psoas irritation was not a
reliable sign. Both groups had simi
lar proportions of patients with
white blood cells in the urine and
elevated blood leukocyte counts.
However, the difference between
the mean levels (pregnant women
14.9 X 109/L , nonpregnant women
16.0 X 109/L ) was not statistically
significant. When the two groups
were compared after selecting only
those who had histologically proven
appendicitis (Table II), again, no
significant differences were found
with respect to symptoms, signs or
laboratory test results. Perforation
of the appendix was observed with
the same frequency (11%) in each
group. The overall false-positive
rate (i.e., histologically normal ap
pendix) was identical in the two
groups (18%). However, there was a
significant (p = 0.041) trend toward
more false-positive cases in the
third trimester (Table III). Also,
50% of the true-positive cases in the
third trimester were complicated by
appendiceal perforation.
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Discussion
The false-positive rate (18%) in
this study is similar to that (21%)
reported in a review of 545 preg
nant patients with a preoperative
diagnosis of appendicitis.7 This sug
gests that, in general, the diagnosis
of appendicitis in pregnancy is no
more difficult than in the nonpreg
nant state. However, significantly
more normal appendices were re
moved in the third trimester than in
the other two. It is known that as
pregnancy advances, the abdominal
pain associated with appendicitis be
comes less characteristic, and the
localizing signs may be in the right
upper quadrant or in the right
flank. This is further complicated
by the uterus pushing the abdomi
nal wall away from the appendix.
Thus, better diagnostic tests are
required so that unnecessary opera
tive intervention and the risk of
precipitating premature labour are
avoided.
The value of leukocytosis in sup
porting the diagnosis has been
thought to be limited since a physi
ologic leukocytosis (up to 12.5 X
109/L ) occurs in pregnancy. The
mean leukocyte count in pregnant
women with histologically proven
appendicitis in this study was 15.3
X 109/ L and 80% of women in the
study had a count greater than 12.5
X 109/L . Using this cut-off level,
the sensitivity of this diagnostic test
was 82%, indicating that very few
patients with histologic appendicitis
would be misdiagnosed. However,
the specificity was only 20%, indi
cating that a very high proportion
of false-positive diagnoses would
occur.
Other diagnostic measures have
been reported. For example, lapa
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roscopy was used to confirm the
diagnosis in one woman.8 Laparos
copy may be useful in the first
trimester when the uterus is still in
the pelvis, but it becomes technical
ly more difficult to perform as preg
nancy progresses. Furthermore,
none of the patients in our study
had a false-positive diagnosis in the
first trimester, indicating that the
diagnosis can usually be made preoperatively on clinical and laborato
ry assessment alone, without the
need for laparoscopy. Culdocentesis
confirmed the need for surgery in
one patient in whom purulent mate
rial was aspirated from the pelvic
cul-de-sac.7 Such a procedure is not
without risk in view of the presence
of the soft, very vascular and en
larged uterus in the pelvis. Also, its
accuracy depends upon the pres
ence of pus in the cul-de-sac, result
ing from perforation of the appen
dix. Such a situation was present in
only 11% of the patients in this
study, further limiting its useful
ness.
Ultrasonography has been de
scribed as a quick, noninvasive and
reliable tool for diagnosing appen
dicitis.9-11 With graded compression
a high degree of diagnostic accura
cy was achieved, leading to appro
priate clinical management.11 Also,
in patients having disease other
than appendicitis, the correct diag
nosis was made. Such a technique
may potentially be of use in preg
nancy to complement the clinical
evaluation, thereby avoiding any
delay in operative intervention.
However, its sensitivity in the pres
ence of perforation is low, so its
value in the presence of this compli
cation is limited.
The mortality and serious mor
bidity associated with appendicitis
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in pregnancy are the result of fail
ure to recognize or suspect the
condition when it presents with
atypical features.12 The key to man
agement lies in earlier diagnosis and
prompt operative intervention. Pa
tients who present in pregnancy
with abdominal pain and have a
leukocyte count greater than 12.5
X 109/ L should be suspected of
having appendicitis, especially if
they also complain of nausea and
have abdominal guarding.
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Neoadjuvant Treatment in Conservative
Surgery of Peripheral Sarcomas
W.J. Temple, MD, FRCS, FACS;* J.A. Russell, MRCP;* K. Arthur, FRCR;*
N.S. Schachar, MD, FRCSC;t T.S. Crabtree, MD, FRCPC;t M.A. Anderson, MD, FRCPCt
Twenty-five patients with soft-tissue and bony sarcomas of the head and neck and
limbs were treated by local neoadjuvant therapy. It consisted of 90 mg of Adriamycin
infused intra-arterially over 3 days into a vessel feeding the involved area and 30 Gy
of radiotherapy given over 10 days; this was followed by a complete resection of the
sarcoma 4 to 6 weeks later. All the tumours were associated with a high risk of local
recurrence; eight were locally recurrent and the remainder were stage II to stage IV
tumours. Serious local complications were seen in 4% of the patients. This rate
compares well with other higher dose neoadjuvant regimens (35 Gy over 10 days),
which are associated with a 35% local complication rate. Follow-up at a mean of 30
months demonstrated no local recurrence. All limbs were spared. Long-term
morbidity was negligible. No effect on systemic control is suggested; only 63% of
the patients were free of systemic disease. This report substantiates other similar
experiences supporting neoadjuvant therapy followed by resection as the treatment
of choice for local control of sarcomas.

Vingt-cinq patients souffrant de sarcomes des tissus mous et des os de la tete, du
cou et des membres ont re?u une therapie neoadjuvante locale. Celle-ci consistait en
90 mg d’Adriamycine perfusee sur une periode de 3 jours par voie intra-arterielle
dans un vaisseau qui alimentait la region atteinte, et de 30 Gy de radiotherapie
administree sur 10 jours; on procedait a une resection complete du sarcome 4 a 6
semaines plus tard. Toutes les tumeurs etaient liees a un risque eleve de recidive
locale; dans huit cas, il s’agissait de recidives locales, alors que les autres etaient des
tumeurs de stades II a IV. Des complications locales serieuses ont ete vues chez 4%
des malades. Ce taux se compare avantageusement avec des doses plus elevees de
therapie neoadjuvante (35 Gy sur 10 jours), lesquelles etaient reliees a un taux de
complication locale de 35%. Les examens de controle effectuees apres 30 mois en
moyenne, n’ont devoile aucune recidive. Tous les membres ont pu etre sauvegardes.
La morbidity a long terme a ete negligeable. Aucun controle systemique n’est
suggere; seulement 63% des patients etaient exempts d’atteinte systemique. Cette
etude corrobore des experiences similaires qui ont demontre que la therapie
neoadjuvante suivie d’une resection constitue le traitement de premier choix quand
il s’agit du controle local des sarcomes.
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ocal control of soft-tissue and
bony sarcomas continues to
challenge the oncologist. In recent
years, the effective use of radiother
apy with limb-salvage surgery has
successfully reduced both local re
currence and limb loss. However,
the local recurrence rate remains
approximately 15% to 20%.1-6 In
the last 5 years, neoadjuvant thera
py of intra-arterially infused
Adriamycin and medium-dose radio
therapy before surgery has provided
further improvement, both in
shrinking many large lesions and
thereby reducing the extent of sur
gery, and in providing long-term
local control in the range of 95%.7
In this report we document our
experience with this regimen in sar
comas of the limbs and head and
neck.

L

Methods
A prospective study was initiated
in 1984 into which all patients with
newly diagnosed or recurrent limb
or head and neck sarcoma needing
further treatment were entered. The
only exclusions were patients with
metastases whose sarcoma could
not be resected for cure, patients
with superficial and small lesions in
which a wide excision would suffice
and patients who refused the proto
col. Before entering the study, all
patients underwent a complete his
tory-taking and physical examina
tion, pulmonary tomography and

CJS, VOL. 32, NO. 5, SEPTEMBER 1989

361

TEMPLE, ET AL.

computed tomography of the lesion
to document the extent of disease.
All lesions were reviewed by a team
of three pathologists.
The protocol was started with 72
hours of continuous intra-arterial
Adriamycin infusion totalling 90
mg (30 mg/d). The catheter was
placed in a large proximal vessel
feeding the area and was never
placed beyond the common femoral
or axillary artery. Intravenous che
motherapy was used for a head and
neck lesion and a shoulder lesion
with multiple feeding vessels when
single-artery catheterization would
not entirely infuse the lesion. Cath
eter access was usually through the
femoral artery. The patient was
kept on bed rest for the 3 days, and
therapeutic anticoagulation was
provided with heparin, keeping the
partial thromboplastin time well
over 80 seconds. After completion
of the Adriamycin infusion, radio
therapy was given at a rate of 3.0
Gy/d for 10 days. In the hand or
foot, it was divided into 1.65 Gy
twice daily for 10 days in an at
tempt to improve normal tissue tol
erance at these difficult sites. The
field extended 10 cm on either side
of the lesion and encompassed a
maximum of two-thirds of the limb
circumference. Four to 6 weeks
later, the patient underwent surgi
cal removal of the tumour.
The planned excision included 2
cm of the skin and scar around the
previous biopsy and a 2-cm margin
in all directions around the residual
tumour. When the tumour was ad
jacent to a vessel or nerve, a mar
ginal excision was accepted as long
as biopsy of the margin showed
that there were no malignant cells
present. The defect was closed pri
marily when possible. When a bone
was resected, an allograft was
placed. When there was massive
soft-tissue resection including skin,
a myocutaneous axial or free flap
was used for cover. All patients
362

were followed up in the sarcoma
clinic on a 4- to 6-month basis by
physical examination and routine
chest x-ray films to document re
currence of disease.

Findings
Twenty-five patients were entered
into this study. One patient had a
lesion of the face above the zygoma
and the remainder had lesions of
the limb or limb girdles (Table I).
Fifteen patients had a biopsy before
neoadjuvant treatment. The remain
ing patients presented with “total
excisions” of the lesions which
were considered inadequate on re
view of the submitted surgical or
pathology report. Eight patients
had locally recurrent lesions with a
history of one to five previous fail
ures of surgery. Three patients had
pulmonary metastases which were
deemed resectable as a second stage
of treatment. Two patients had os
teosarcoma of the bone, one in the
upper humerus and one in the distal
femur.
The sarcomas were of varied his
tologic type (Table II). All were
staged according to the American
Joint Committee for Cancer Staging
and End-Results Reporting (Table
III). Involvement of surrounding
structures such as muscle, nerve,
artery or bone was clinically impor
tant in all but one patient. Mean
follow-up for the entire group is
now 2.5 years, ranging from 1 to 5
years.
The morbidity of treatment in
cluded various problems with the
infusion. Nausea was minimal; only
one patient requested and was given
Gravol intramuscularly. Two pa
tients had thrombosis of the infused
artery and required treatment to
reconstitute the lumen. This was a
direct result of the partial thrombo
plastin times being less than 60
seconds. This is no longer a prob
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lem because the partial thrombo
plastin time is now kept over 80
seconds. One patient had a catheter
dislodge from the axillary artery
into the vertebral artery, producing
temporary confusion and occipital
blindness for 12 hours. Another
patient had pectoral muscle inflamT a b le
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mation secondary to streaming of
the infusion from the main axillary
artery catheter; the condition re
solved over 2 months.
There were no important compli
cations of radiotherapy. Only one
patient had delayed healing in spite
of a myocutaneous flap placed to
cover the defect resulting from
groin, pubic bone and testicular
resection. No patient had a radia
tion-induced bone fracture and only
one patient had moderate fibrosis of
the treated area that resolved within
1 year. In the two patients who had

FIG. 1. Large grade 2 liposarcoma
(stage IIB) of thigh, measuring 25 X
15 cm was clinically palpable in but
tock.

bone resection and replacement,
there were no fractures of the allo
graft; the patient with a replaced
femur has been followed up for over
2 years.
Dramatic shrinkage of the lesions
was seen in over 50% of the pa
tients (Table IV) (Figs. 1 to 5).
Shrinkage often began immediately
after the Adriamycin infusion before
radiotherapy and continued up to
the time of surgery. In two patients,
there was a complete histologic
response. Patients often experi
enced a marked decrease in pain
during the therapy, and it preceded
a clinically measured reduction in
size. The only patient with a tu
mour that grew during treatment
had a soft-tissue osteosarcoma.
Local control was seen in all
treated sites of disease. One patient
with a facial sarcoma had regional
failure outside the treatment field.
This was subsequently controlled
with a cranial facial resection. The
patient is alive and free of local and
systemic disease at 2-year follow
up.
During follow-up, unresectable
systemic disease developed in nine
patients. The disease stage and tu

FIG. 2. Computed tomogram demonstrated lesion of left thigh compressing sciatic
nerve.

mour type are shown in Tables V
and VI. The overall survival rate of
the 25 patients at 30 months was
76% with a disease-free survival of
64% (Fig. 6).
All but one of the patients who
underwent nonosseous limb surgery
returned to normal activity within
weeks of operation. One patient
who had thrombosis of an arterial
replacement graft was partially dis
abled with ischemic pain for 3
years. The patient with an allograft
replacement of the distal segment
of a femur is fully mobile using an
external brace.

Discussion
Our results of neoadjuvant thera
py with intra-arterial Adriamycin
and preoperative radiotherapy are
equal to those of other reports
using a similar regimen and superi
or to treatments consisting of sur
gery and pre- or postoperative radi
otherapy.2_5'7_9 In other series, local
recurrence of high-grade sarcoma
after treatment has been noted clini
cally in 95% of those whose tu
mours recur within 2 years of initial
treatment. Since our mean follow
up is now more than 2.5 years, we
believe that the absence of local
recurrence in our patients is strong
ly supportive of this approach.10
Although in this group of sarco
ma patients the tumours were at
varied sites, and of varied patholog
ic features and stages, all patients
were at high risk for local recur
rence with standard therapy. There
fore, this diversity does not take
away from the results of this study.
The value of this approach is also
emphasized by the dramatic shrink
age of even large lesions before
surgery, an effect that is very un
usual with radiotherapy alone. In
many cases, preservation of major
nerves, arteries and veins, which
normally would have been resected
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to obtain a clear margin, became
possible.
This experience is also important
in that most tumours were large
and many of the patients had recur
rent tumours after multiple previ
ous surgical procedures. It is inter
esting that systemic disease devel
oped in only four of the nine pa
tients on whom we reoperated for
local recurrence. This emphasizes
the fact that one should be as
aggressive in obtaining local control
of recurrent disease as one is for a
patient presenting with a primary
sarcoma. It is also encouraging that
even after previous surgery, limb
salvage is still possible using this
approach.
Anticoagulation with heparin pre
sented difficulties. Since patients
had an intra-arterial catheter and
were fully heparinized, they were
kept in an intensive care setting. As

some of these tumours would
shrink and presumably release large
amounts of procoagulants from
dying cells, the partial thromboplas
tin time would sometimes rapidly
and unexpectedly become subtherapeutic.11 After two experiences
with intra-arterial thrombosis, the
problem was prevented by maintain
ing the partial thromboplastin time
over 80 seconds. We noticed some
unusual streaming effects of the
Adriamycin, not only to areas of the
skin in a few patients, but in one
patient to a muscle. This was asso
ciated with pain or tenderness in
the area involved. When streaming
effects were noted during infusion,
the catheters were retracted a few
centimetres.
Other local complications includ
ed failure of a myocutaneous flap
placed to cover a groin lesion; the
wound healed by secondary inten

tion. One patient had excessive
post-treatment fibrosis which re
solved slowly. No patient had radia
tion-induced fractures. This con
trasts markedly to Eilber’s experi
ence7'8 in which 17% had a second
operation to treat failure of healing
and 11% had a radiation-induced
fracture. The lower morbidity of
our protocol may be a result of

FIG. 4. Lesion was resected with mi
croscopically clear margin without sac
rifice of sciatic nerve.

FIG. 5. At 5 years’ follow-up, patient
remains free of local and systemic
disease.

FIG. 3. By end of radiotherapy and 2 weeks after initiation of treatment, lesion had
shrunk to 10 X 8 cm. Change is shown by comparing amount of soft tissue lateral
to greater trochanter on initial simulation film with lead wire on skin (left) and
follow-up simulation film (right).
364
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FIG. 6. Recurrence-free survival of 25
patients treated by neoadjuvant chemo
therapy and radiotherapy.
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using a radiotherapy dose of only
3.0 Gy/d compared with 3.5 G y/d
as reported by Eilber.

1289-1293
2. S hiu MH, Castro EB. H ajdu SI, et al:
Surgical treatment of 297 soft tissue

3.

Conclusions
We believe that neoadjuvant ther
apy as described in this paper
should be considered for all sarco
mas that cannot be treated by sur
gery alone. The preoperative treat
ment appears to add substantially to
the microscopic sterilization of sar
comas in the periphery of the le
sion, but does not seem to have any
measurable effect on overall control
of systemic disease. When design
ing adjuvant trials to control sys
temic disease, this protocol should
be considered to minimize local re
currence. Although the debate over
whether local control contributes to
overall survival continues,1213 this
factor cannot be ignored in the
analysis of future adjuvant therapy
trials.
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Medial Epicondylitis Caused by Injury to
the Medial Antebrachial Cutaneous Nerve:
a Case Report
Robin R. Richards, MD, FRCSC; William D. Regan, MD, FRCSC
A 35-year-old man who had chronic elbow pain due to medial epicondylitis received a
steroid injection into the medial epicondyle. This was followed immediately by
increased pain and symptoms of dysesthesia in the distribution of the medial
antebrachial cutaneous nerve. On surgical exploration 9 months later, the nerve was
found to lie directly over the medial epicondyle and appeared to have sustained an
injection injury. This report draws attention to the fact that because the posterior
division of the medial antebrachial cutaneous nerve may lie directly over the medial
epicondyle, it may be at risk of direct injury if injections are given into the
epicondyle.

Un homme de 35 ans qui souffrait d’une douleur chronique au coude due a une
epicondylite moyenne a re?u une injection de steroide dans l’epitrochlee. Ceci fut
suivi d’une exacerbation immediate de la douleur et de symptomes de dysesthesie
dans l’aire de distribution du nerf brachial cutane interne. A la chirurgie
exploratrice pratiquee 9 mois plus tard, on decouvrit que le nerf chevauchait
l’epicondyle moyen et semblait avoir subi une lesion par piqure. Cet article veut
attirer l’attention sur le fait que puisque la division posterieure du nerf brachial
cutane interne peut chevaucher l’epicondyle moyen, celui-ci peut etre blesse lors
d’une injection dans l’epicondyle.

picondylitis is a common cause
of elbow pain. Previous publi
cations have not specifically dis
cussed the treatment of medial epi
condylitis (tenderness over the me
dial epicondyle), although it has
been considered in articles dealing
with lateral epicondylitis, constitut
ing 10% to 20% of such series.1-3
According to Hirschl,4 the patho
logic cause of medial epicondylitis

E

is “angiofibroblastic hyperplasia” ,
occurring at the insertion of the
origins of the common flexorpronator muscles. Other causes of
the clinical syndrome of medial epi
condylitis have not been proposed.
We describe a patient with medial
elbow pain refractory to conserva
tive management. Exploration of
the elbow revealed that the posteri
or division of the medial antebrachi
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al cutaneous nerve was inflamed
and enlarged, probably because of a
steroid injection injury. Although
this cause of medial epicondylitis
has never been reported, the prima
ry reason for presenting this case is
to draw attention to the danger of
injury to the medial antebrachial
cutaneous nerve if injections are
administered in the area of the
medial epicondyle.

Case Report

A 35-year-old right-handed man
was referred for the management of
chronic pain in the region of the
right medial elbow. The pain had
begun 15 years earlier as the result
of a fall directly onto the medial
aspect of the elbow during a base
ball game. After the fall, the area of
the medial epicondyle was tender
for 3 to 4 weeks. The patient
continued to play baseball but com
plained of recurrent swelling and
pain while throwing. Over the years
he had been treated with nonsteroi
dal anti-inflammatory agents, ice
and ultrasonography.
In an attempt to alleviate the
pain, the patient was given a steroid
injection directly into the medial
epicondyle. The injection was fol
lowed immediately by a burning
pain over the medial epicondyle; the
pain continued for 1 month. A

MEDIAL EPICONDYLITIS

dysesthetic pain radiating over the
posteromedial forearm distal to the
elbow then developed. For the 9
months before presentation, he ex
perienced constant pain and sensi
tivity to direct palpation of the
medial epicondyle associated with
dysesthesia over the posteromedial
forearm.
On examination, there was in
creased warmth over the medial
epicondyle and marked tenderness
on palpation. The range of elbow
motion was normal. Resisted fore
arm pronation produced epicondylar
discomfort. There was no Tinel’s
sign and no neurologic deficit apart
from hypoesthesia in the distribu
tion of the posterior division of the
medial antebrachial cutaneous
nerve. X-ray views of the elbow,
including oblique views, appeared
normal. Results of nerve conduction
studies of the ulnar nerve across
the cubital tunnel were normal, as
were those of electromyography of
the ulnar innervated musculature of
the hand.
The patient was admitted to hos
pital and the elbow was explored
through a posteromedial incision,
centred over the medial epicondyle.
An enlarged and inflamed posterior
division of the medial antebrachial
cutaneous nerve was found lying
directly over the medial epicondyle
(Fig. 1). The location of the nerve
corresponded to the area of preop
erative tenderness. The underlying
medial epicondyle appeared in
flamed. A neurolysis of the posteri
or branch of the medial antebrachial
cutaneous nerve was performed,
and a portion of the medial epicon
dyle was resected. Postoperatively,
the medial epicondyle was support
ed in a posterior slab for 2 weeks.
Two months postoperatively the pa
tient had a full range of elbow
motion with complete resolution of
pain over the medial epicondyle.
One year later sensation continued
to be decreased in the distribution

of the posterior division of the
medial antebrachial cutaneous
nerve. The patient was able to re
turn to sports activity.

Discussion
The medial antebrachial cutane
ous nerve originates from the
eighth cervical root and emerges
from the medial cord of the brachial
plexus to pierce the deep fascia in
the mid-brachium.5' 7 The nerve,
now in a subcutaneous location,
divides into an anterior branch,
coursing anterior to the medial epi
condyle and a posterior branch. The
posterior branch has been noted by
Dellon and MacKinnon5 to vary in
location, crossing from the anterior
mid-brachium to the posterior fore
arm from 6 cm proximal to 6 cm
distal to the medial epicondyle. The
posterior division of the medial an
tebrachial cutaneous nerve provides
sensation to the posteromedial fore
arm. Its subcutaneous location
makes it prone to injury.
Our patient had pain directly over

the medial epicondyle with posterior
and volar radiation. Initially, his
symptoms were characteristic of
medial epicondylitis. However, after
the cortisone injection, the quality
of the pain changed. An injection
injury to the posterior division of
the medial antebrachial cutaneous
nerve likely occurred at that time.8
This is supported by the following
findings: (a) the nerve lay directly
over the medial epicondyle, (b)
symptoms of numbness developed
in the distribution of the nerve after
the injection and (c) the nerve ap
peared inflamed at the time of ex
ploration.
Leffert9 and Dellon and MacKin
non5 have advised careful dissection
of the cubital tunnel region to avoid
injury to the posterior branch of the
medial antebrachial cutaneous
nerve. The latter authors reported
injury to the posterior branch in 23
of 25 patients who had recurrent
ulnar nerve entrapment and were
referred for re-exploration. The sur
geon must be aware of the nerve’s
course when exposing the medial
epicondyle. Since the physician has

FIG. 1. Posterior division of medial antebrachial cutaneous nerve crossing directly
over medial epicondyle. Nerve was enlarged and inflamed. Underlying medial
epicondyle was inflamed. Medial epicondylectomy and external neurolysis of nerve
were carried out.
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infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use o f MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

®Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.
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Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the in cid e n ce of subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.

CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillinsorotherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly a ll a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a history of gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous colitis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration o f the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling’s solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100yug/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g c o n c o m ita n t a d m in is tra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.
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Use in Pregnancy

The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
to pregnant patients is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
Nursing Mothers

Cefoxitin is excreted in human milk.
Children

In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g/kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions

Throm bophlebitis has occurred with intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic

M a cu lo p a p u la r rash, u rtic a ria , p ru ritu s ,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal

Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood

Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function

Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function

Hypotension.
Renal Function

Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m o n o g ra p h on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration

The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating co n d itio n s as m alnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults

The usual a d u lt dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by
severity of in fe ctio n, susce p tibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.

Usual Adult Dosage
Type of
infection

Daily
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

•Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or glom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:

A t p re se n t th e re is in s u ffic ie n t data to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recommendations for adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g adm inistered intram uscularly or in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

RENAL
FUNCTION

CREATININE
CLEARANCE
mL/min

DOSE

FREQUENCY

MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN® in the dry state should be stored
below 30°C. The dry m aterial as well as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.

50-30

1-2 g

every 8-12 h

Moderate
impairment

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

Severe
impairment
Essentially
no function

In patients undergoing hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADMINISTRATION in the complete
monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

01 week of age20-40 mg/kg every 12 h I.V.
1-4 weeks of age
20-40 mg/kg every 8 h I.V.
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Perforated Diverticulitis After Surgery
Andrus J. Voitk, MD, MSc, FRCSC;* Robert A. Mustard, MD, FRCSCt
The authors report on three patients who had a perforated sigmoid diverticulum
after unrelated surgery. If the preceding operation is remote in time from the
perforation, detection is relatively easy, but if the perforation occurs shortly after
major abdominal surgery, its presentation may be totally masked by the
postoperative state. Awareness of this possibility may help alert the clinician to the
presence of perforation of a sigmoid diverticulum in unexplained postoperative
collapse. Although discovery of these three cases suggests that diverticular
perforation is not uncommon after surgery, a causal relationship is not known, and
the authors could not find any previous reports of such a relationship.

fered acute diverticular perforation
after surgery suggested that this
association is not rare, yet we were
unable to find published reports of
it.

Case Reports
Case 1

Les auteurs signalent trois patients qui ont subi une perforation d’un diverticule
sigmoidien apres une intervention chirurgicale totalement independante. Quand
l’operation precede de beaucoup la perforation, la detection est relativement simple
mais, quand la perforation survient tot apres une chirurgie abdominale majeure, le
tableau clinique peut se confondre avec l’etat postoperatoire. En gardant a l’esprit
cette possibility, le clinicien pourra soupconner la presence d’une perforation d’un
diverticule sigmoidien face a un affaissement postoperatoire inexplique. Alors que la
decouverte de ces trois cas indique que les perforations diverticulaires ne sont pas
rares apres la chirurgie, on ne connait pas de rapport de cause a effet et les auteurs
n’ont pu retracer aucun rapport prealable d'un tel lien.

bout 50% of North Americans
over the age of 50 years have
diverticulosis, and diverticulitis will
develop in 20% of these. Although
it is usually self-limiting, diverticuli
tis rarely presents with acute perfo
ration without significant pro
dromes. Diverticular perforation is a
catastrophe, needing prompt recog
nition and treatment to prevent
death. Attempts to identify patients
with such complications postoperatively by quantitative assessment of

A

the acute-phase response have not
been successful. The diagnosis of
these complications remains entirely
clinical, yet the signs and symptoms
of diverticular perforation after
major abdominal surgery may be
totally obscured by the postopera
tive state. One may also speculate
on a possible causal relationship
between surgery and diverticular
perforation, unrecognized to date.
Our experience, reported in this
paper, with three patients who suf
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An obese 67-year-old diabetic
woman presented with an insidious
3-year history of passing feces
through the vagina. There was no
heralding episode of fever or ab
dominal pain. Contrast studies dem
onstrated diverticulosis of the sig
moid colon and a fistula from the
sigmoid to the vagina. The cause
was assumed to be diverticular and
not related to a hysterectomy per
formed 26 years earlier. The fistula
was cannulated vaginally and ex
cised transabdominally. As the sig
moid colon looked healthy, a Zstitch was used to close the fresh
ened edges of the small hole left by
the excised fistula. The vagina was
repaired similarly and omentum
placed between. Cefazolin, 1 g, was
given intravenously 2 hours preoperatively and every 6 hours postoperatively for 24 hours. Her postop
erative course was uncomplicated,
with no fever and early return of
bowel function. She was scheduled
for discharge on postoperative day
6, ambulatory, with bowel move
ments and eating a full diet. That
morning she reported sudden ab
dominal pain. On examination she
appeared pale and sweating, her
pulse was 110 beats/min, her body
temperature 38.7°C and she had

PERFORATED DIVERTICULITIS

abdominal guarding and rebound
tenderness. The leukocyte count
was 12.0 X 109/L . A leak of the
closed fistula was suspected, so oral
feedings were stopped. When she
did not improve after 48 hours of
intravenous fluids and antibiotics, a
laparotomy was done. Fibropurulent peritonitis and a pelvic abscess
were found, with a perforated diver
ticulum in an area of acutely in
flamed sigmoid colon about 20 cm
proximal to the intact site of the
fistula repair. Abscess drainage,
peritoneal toilet and a Hartmann
resection were followed by satisfac
tory recovery.
Case 2
A 67-year-old woman complained
of sudden acute lower abdominal
pain with sweating and numbness
of the right leg, 3 days after a total
replacement of the right hip. Rup
ture of an abdominal aneurysm was
suspected, so she was referred to a
tertiary care hospital. On arrival
there her body temperature was
38.7°C and she was in acute dis
tress with abdominal guarding and
rebound tenderness. The vascular
consultant thought she had perito
nitis, and computed tomography ex
cluded an aneurysm. Free air was
seen on abdominal films, and a
diagnosis of perforated diverticulosis made. At laparotomy, sigmoid
diverticulitis was found with perfo
ration and free purulent material in
the peritoneal cavity. Peritoneal toi
let was carried out and a Hart
mann’s resection performed. Her
recovery was smooth.

hiatal area. The morning after oper
ation she was unexpectedly found
cyanotic and sweating, with a blood
pressure of 8 0 /6 0 mm Hg, a pulse
rate of 68 beats/min and body
temperature of 36.7°C. The abdo
men was not distended but was
tender, and bowel sounds were ab
sent, in keeping with her postopera
tive state. The hemoglobin concen
tration and leukocyte count were
normal, with normal differential and
no shift. No air was seen in the
mediastinum or abdomen on x-ray
films. A roentgenogram after a di
lute barium swallow failed to dem
onstrate a leak at the hiatus; never
theless the working diagnosis re
mained iatrogenic esophageal perfo
ration. Morphine overdose, hypo
thyroidism, hypoadrenalism, diabet
ic acidosis, pulmonary edema, pul
monary embolism, pneumonia, myo
cardial infarction and acute blood
loss were all excluded by appropri
ate examinations, tests or therapeu
tic maneuvers. She was transferred
to the intensive care unit where
treatment with broad-spectrum anti
biotics, intravenous fluids, steroids
and dopamine was started. Within
48 hours Klebsiella pneumoniae
was cultured from the blood. Fol
lowing initial recovery from shock
there was no further improvement
and after 8 days she was transferred
to a tertiary care hospital. After
another 2 weeks of intensive care,
pelvic abscesses became evident.
Laparotomy was done and abscess
es were drained. A perforated sig
moid diverticulum was found as the
source. A transverse colostomy was
done and eventually she recovered.

Case 3

Discussion
A 63-year-old woman underwent
uncomplicated truncal vagotomy
and Nissen fundoplication for recur
rent ulcers and esophageal reflux.
Adhesions from previous operations
precluded laparotomy beyond the

When an association between an
operation and subsequent complica
tion is known, diagnosis of the
complication is likely. Even when
no association is known, if the

second event is dramatic, the cor
rect diagnosis is made in time.
However, if there is no known asso
ciation and the presentation is
masked by the first operation, the
correct diagnosis may be beyond
reach. Our patients illustrate this
spectrum of diverticular perforation
after surgery. In the first patient,
the possibility of perforation was
anticipated because primary suture
repair is known to carry this risk.
The acute deterioration after initial
satisfactory recovery led to early
diagnosis and reoperation. The only
unexpected finding was the new site
of perforation with healing of the
original repair. In the second pa
tient, the first operation was extra
abdominal, proving that postopera
tive diverticular perforation is a
spontaneous event, needing no di
rect physical contribution from the
preceding operation. The peritonitis
of free diverticular perforation is so
dramatic that the seriousness is
obvious to a physician of any spe
cialty and a referral process quickly
narrows down the possibilities, lead
ing to the appropriate diagnosis.
In the first two patients, suffi
cient time elapsed between the oper
ation and the perforation to detect a
dramatic change easily. The third
patient illustrates the worst circum
stances in which postoperative di
verticular perforation can occur.
The condition was entirely unex
pected, there being no known asso
ciation between the primary surgery
and diverticular perforation. Adhe
sions had prevented examination of
the colon, which may have shown
evidence of active inflammation. For
24 hours after major abdominal
surgery, the patient expects abdom
inal pain and is unable to distin
guish new pain in the same region,
further dampened by analgesia.
Pain, tenderness, guarding and lack
of bowel sounds are all normal
findings at this stage after abdomi
nal surgery. Although our patient’s
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collapse was dramatic, cyanosis and
hypotension herald a wide range of
conditions, of which diverticular
perforation is not foremost. The
initial absence of fever, tachycardia
and leukocytosis did not point to
sepsis, although it was considered
in the differential diagnosis and
antibiotics were prescribed after
blood cultures were taken. Growth
of K. pneumoniae confirmed this
diagnosis, even though the origin
remained unknown. Despite inabili

ty to demonstrate the leak, the
working diagnosis remained unrec
ognized iatrogenic esophageal per
foration. Administration of antibiot
ics delayed the appearance of pelvic
abscesses, which eventually led to
the correct diagnosis.
Present knowledge suggests that
the temporal relationship described
in this paper is not causal and can
be explained only by chance associ
ation due to the relative prevalence
of both surgery and spontaneous

diverticular perforation in the popu
lation. However, if such anecdotal
reports become common, then a
causal relationship may be suspect
ed, possibly explained by increased
collagenase activity after surgery,
with attendant collagen breakdown
in thin-walled diverticula. Whether
fortuitous or not, it will serve the
clinician well to be aware of this
rare event after surgery, because its
presence may be totally unrecogniz
able unless suspected. ■

ration of text and illustrations, which
requires constant flipping back and
forth.
Although the book’s title promises a
discussion of “essential” radiology in
head injury, with the widespread avail
ability of computed tomography, plain
films have become much less essential.
Indeed, the introductory chapter lists a
number of indications for computed
tomography after trauma, both subse
quent to or instead of plain films.
Generally speaking, these lists could be
even broader and in many areas plain
skull films have become an anachro
nism. However, computed tomography
is not universally available and, al
though the clinical utility of plain films
is frequently questionable, useful infor
mation is sometimes obtained. This
book is a reasonably good text on
plain-film examinations in head injuries,
and in this respect fulfils its purpose.
The introduction is followed by chap
ters on projections and anatomy, cal
cifications, linear fractures, depressed
fractures, fractures in children, skullbase fractures, facial fractures and nor
mal variants and postoperative appear
ances. The text of each chapter is brief
but generally adequate. The illustra
tions are generally well produced and
most complement the text reasonably
well. Some are excellent and depict
beautifully both common and unusual
features of the traumatized head. There
are a few computed tomograms, some

of which are not particularly well de
scribed. The chapter on facial injuries is
well done and here plain films remain
the procedure of choice.
Although there are no major flaws in
the book, there are a few unnecessary
errors. Computed tomography should
perhaps be more widely used and could
be better interpreted. The illustrations
of normal anatomy have too many la
bels, making them hard to read. An
illustration of facial fractures fails to
mention a portion of a dental plate
displaced into the nasopharynx, per
haps by the endotracheal tube insertion.
This would be a vital feature of these
films in terms of immediate patient
management.
Overall, this is a reasonably good
introductory text on the radiologic as
pects of head injury using plain films.
There is nothing new here compared
with many much older texts, but the
information is gathered together in one
book which is easy to read and well
illustrated. It is certainly of historical
value and would be of some value to
senior medical students or junior house
officers, keeping in mind that the clini
cal efficacy of plain skull films is fre
quently questionable, and that plainfilm findings can even be misleading.
Certainly computed tomography is the
essential radiologic procedure in head
injury, and in most instances probably

BOOK REVIEWS
continued from page 330

chapter 2, only references 1 to 4 are
quoted in the text. If the remainder are
meant to be general references, they
should have been so identified.
The educational and practical value
of this book is not diminished by these
shortcomings. Confidence based on ex
tensive experience permeates the text,
and this should reassure readers who
are members of a team that cares for
such patients. Indeed, as the author
stated, “it is teamwork which saves
patients with cardiothoracic trauma”.
Ray C-J. Chiu, MD, PhD. FRCSC
Professor o f Surgery.
McGill University,
The Montreal General Hospital.
1650 Cedar Ave.,
Montreal. PQ
H3G 1A4

ESSENTIAL RADIOLOGY IN HEAD
INJURY. A Diagnostic Atlas of Skull
Trauma. D.W.H. Mok and L. Kreel.
215 pp. Illust. Heinemann Profession
al Publishing Ltd, Oxford; Butterworths, Stoneham, Mass., 1988.
$90.00 (US). ISBN 0-433-00041-4.
The stated intent of this book is to
provide a practical atlas for dealing with
the radiologic aspects of head injuries.
It is a small but well-organized book,
except for the now-commonplace sepa
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Isolated Posterior Cruciate Ligament
Injury in a Child: Literature Review and a
Case Report
C. Frank, MD, FRCSC;* R. Strother, MDt
The authors describe the sixth reported case of a child with a truly isolated
posterior cruciate ligament (PCL) injury and the first in which the deficiency was
not repaired immediately. Review of this case emphasizes a number of points: the
need for awareness of PCL injuries in children; the inability of x-ray films to detect
cartilaginous avulsions in such circumstances; and the fact that missed PCL
avulsions can cause locking and may also result in abnormal ligament length in the
growing child, preventing reattachment. Finally, it is noteworthy that despite
ongoing PCL laxity in this child, functional results were excellent at 3.5-year
follow-up, supporting at least short-term conservative management of such injuries
in children.
Les auteurs decrivent le sixieme cas signale de dechirure isolee vraie du ligament
croise posterieur (LCP) chez un enfant et le premier chez qui cette lesion ne fut pas
reparee immediatement. L’etude de ce cas met en lumiere plusieurs points: la
necessite de rechercher une dechirure du LCP chez l’enfant; l’inutilite de la
radiographie pour deceler les avulsions cartilagineuses dans de telles circonstances;
et le fait que l’incapacite de reconnaltre des avulsions de LCP peut entrainer un
blocage et aussi resulter, chez l’enfant en croissance, en un ligament de longueur
anormale pouvant empecher le rattachement. Finalement, il faut souligner que
malgre une hyperlaxite du LCP chez cet enfant, les resultats fonctionnels sont
excellents apres 3.5 ans, ce qui suggere de s'en tenir a un traitement conservateur,
du moins a court terme, dans ce genre de blessure chez l’enfant.

nee ligament injuries in skeletally immature children are
rare,1 fewer than 100 cases having
been reported.1' 18 Of these, about
40 have involved the posterior cru
ciate ligament (PCL) in patients
under the age of 18 years. l 2 A ~
6,9.11,12.14-17 Only five were definitely
isolated PCL injuries. Three of
those were avulsions from the
femur in boys under the age of 8
years and all three were repaired.1'17

K

The fourth and fifth were in a
14-year-old boy and a 16-year-old
girl with tibial avulsion; they also
were repaired.216 Four of these five
children had residual stiffness and
instability.
In this report we describe a sixth
case of an isolated PCL injury, in a
7-year-old boy. The condition was
diagnosed late and has, with the
exception of an arthroscopic proce
dure, been treated conservatively
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with good functional results over
3.5 years of follow-up.
Case Report

A 7-year-old boy suffered an inju
ry to his right knee while skiing.
The exact mechanism was not re
called. X-ray films taken at the time
of injury were reported as normal.
No diagnosis was made and no
specific treatment was instituted.
Approximately 1 year later, the
boy noted the sudden onset of lock
ing of his knee. On repeat physical
examination a posterior sag was
evident, with positive passive and
active posterior drawer tests. All
other tests gave normal results. The
clinical diagnosis of posterior cruci
ate ligament (PCL) insufficiency
was established. Repeat x-ray films
now showed a small bony fragment
in the intercondylar notch, but no
other abnormalities.
Arthroscopy revealed a rounded
femoral osteochondral fragment at
tached to an avulsed, shortened
PCL. There was no other abnormal
ity in the knee. Since this fragment
was responsible for the locking of
this patient’s knee and since it
could not be approximated to its
original insertion site, it was
trimmed. After quadriceps therapy,
the boy returned to a fully active
life-style and has remained that way
for the past 2.5 years (3.5 years
post-injury). He plays soccer, partic
ipates in karate and is asymptomat
ic. He had one episode of pain
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during a karate kick but this re
solved quickly without swelling.
Present examination of his knee
reveals a significant posterior sag
but no other abnormality. X-ray
films remain normal.

Discussion
This case illustrates a number of
important points concerning PCL
injuries in children. First, as noted
elsewhere,1 there must be an aware
ness of PCL injuries for patients of
all ages. While rare, isolated PCL
injuries can occur in children. Sec
ond, avulsion of the femoral attach
ment of the PCL could not be seen
on the original x-ray films in our
patient, probably because the inser
tion site had not yet ossified. Subse
quent x-ray films showed the ossify
ing fragment. While it is possible
that fragment displacement was a
late event, it seems more likely that,
as reported by Sanders and col
leagues17 and Frankl and Wasilewski10 it was simply not visible on
original plain x-ray films. Arthro
scopic examination of our patient’s
knee at the time of the original
injury would have been the only
means of confirming the site of the
PCL lesion and should likely be
considered in all suspicious lesions
in children, as in adults. Third, over
the year th at the avulsed PCL was
missed, the ligament either short
ened, as noted in a case described
by Meyers,14 or failed to grow in
proportion to the joint, causing it
to be too short to reattach. Rather
than attaching the rounded-off frag
ment to an abnormal location on
the femur,14 we trimmed it. This
cured the symptom of locking
which clearly had been due to the
impingement of this avulsed inser
tion; this is an interesting and previ
ously unsuspected potential cause
of locking.
The last important point in this
case revolves around the treatment
374

controversy, which is based on con
flicts or deficiencies in the litera
ture. Even acutely repaired avul
sions121617 of ligaments in children
have not had perfect subjective and
objective results at 2-year follow
up. A PCL reconstruction, the only
other surgical option, is without
documented precedent in a child.
The most successful PCL recon
structions in adults use bony tun
nels,5 which would not be appropri
ate in children. Other options for
PCL reconstruction111219 20 similarly
cannot guarantee a safe and reliable
method for treating a child’s knee.
The 3.5-year follow-up of this
patient suggests that, as with the
adult,2'6-915 the pediatric PCL-deficient knee is subjectively very satis
factory in the short term, despite
being objectively lax. This does not
mean, however, that our patient will
not experience symptoms in the
future.5-614 If his knee does not
deteriorate, however, as seen in the
short-term follow-up of other series
of adult PCL deficiencies,9'15'21 then
long-term conservative management
of pediatric PCL deficiencies may
suffice. From our experience with
short-term follow-up, conservative
management of PCL deficiencies in
children, for at least a few years,
may be justified.
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Lymphoma Pancreatitis: a Real Entity
C.A. Kotwall, MD, MSc, FRCSC; J.R. Brow, MD, FRCPC; R.G. Keith, MD, FRCS, FRCSC
Pancreatitis induced by malignant disease is uncommon. A case of lymphoma
presenting as acute pancreatitis and subsequent pancreatic abscess is reported; this
led to the patient’s death, 6 weeks after the initial attack of pancreatitis. Five other
reports are reviewed. The pancreatitis always preceded the diagnosis of lymphoma
and the preoperative diagnosis was always difficult.
Lymphoma pancreatitis should, therefore, be considered in the etiology of acute
pancreatitis, especially if the more likely causes have been ruled out.

Les pancreatites provoquees par les cancers sont peu frequentes. On decrit un cas de
lymphome qui prit les apparences d’une pancreatite aigue, puis, subsequemment,
d’un abces pancreatique; le patient deceda 6 semaines apres Faeces de pancreatite
initial. Cinq autres cas sont passes en revue. Chaque fois, la pancreatite preceda le
diagnostic de lymphome et celui-ci fut toujours difficile a etablir en preoperatoire.
La pancreatite d’origine lymphomateuse devrait done etre envisagee dans
l’etiologie de la pancreatite aigue, surtout si les causes les plus probables ont deja
ete eliminees.

mong the various causes of
pancreatitis, that which is tu
mour induced is unusual. Pancreati
tis associated with primary adeno
carcinoma of the pancreas is well
known,1 but that induced by lym
phoma is rare. We report a case of
abdominal lymphoma presenting as
severe acute pancreatitis and pan
creatic abscess.

A

Case Report
A 31-year-old man had a 3-day
history of epigastric pain radiating
to the back. He had previously felt
well and was only an occasional
social drinker. On abdominal exami

nation, he had marked localized
tenderness in the epigastrium and
left upper quadrant. The leukocyte
count, hemoglobin and serum calci
um levels and results of liver func
tion tests were normal; the serum
amylase value was 340 U /L (nor
mal 25 to 115 U/L). Ultrasonogra
phy revealed enlargement of the
neck, body and tail of the pancreas.
The pain resolved with conservative
management and he was dis
charged.
He was readmitted 1 week later
with recurrent severe epigastric
stabbing pain and nausea. He had
acute epigastric tenderness but no
peritoneal signs. The serum amy
lase level on admission was 222
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U/L. He became progressively ic
teric with a serum bilirubin level of
115 jim ol/L (normal < 17
jumol/L), a serum aspartate amino
transferase level of 175 U /L (nor
mal 25 to 41 U/L) and a serum
alkaline phosphatase level of 608
U /L (normal 25 to 96 U/L). Com
puted tomography revealed consid
erable thickening of the pancreas,
consistent with acute pancreatitis.
The patient’s pain subsided, but
because of progressive jaundice and
abdominal distension he was trans
ferred to our hospital.
He appeared ill and had gross
ascites, right upper quadrant ten
derness and diffuse guarding. Ab
dominal paracentesis was performed
and 1350 ml of thick fluid was
obtained, culture of which grew
Staphylococcus aureus and Strepto
coccus faecalis. Computed tomogra
phy revealed a 9-cm phlegmonous
mass in the head of the pancreas, a
fluid collection in the lesser sac,
and free intraperitoneal fluid (Fig.
1). Nine days after admission he
became febrile (leukocyte count of
20 X 109/L ) and antibiotics were
prescribed. The serum bilirubin
level was 236 txmo\/L, serum as
partate aminotransferase 133 U /L,
alkaline phosphatase 535 U /L and
serum lactic dehydrogenase 3160
U /L (normal < 150 U/L). The
sepsis did not resolve and, because
of progressive respiratory and renal
insufficiency, surgery was per
formed 13 days after transfer, the
preoperative diagnosis being pan
creatic abscess.
At laparotomy, the patient’s pan
creas was grossly enlarged and in-
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durated; the process involved most
ly the head but also included the
body and tail of the pancreas. There
was an infected lesser sac pseudo
cyst with surrounding retroperito
neal inflammation and friability of
all blood vessels. Th. greater omen
tum was preinfarctive. Liver and
gallbladder appeared normal. The
lesser sac was drained of fluid and
necrotic debris; the retroduodenal
space and right paracolic gutter
were explored, but no collection
was found. Greater omentectomy
was performed. There was an ex
traordinary amount of retroperito
neal bleeding that required packing.
Intraoperatively, the patient re
quired 16 units of packed cells and
considerable inotropic support. He
was returned to the intensive care
unit in irreversible shock and died
the following day, 6 weeks after the
illness began. Pathological exami
nation of the greater omentum dis
closed poorly differentiated lympho
cytic lymphoma extensively infil
trating adipose tissue. The patient’s
family would not give permission
for an autopsy.

disease metastatic to the pancreas.
In six of these seven patients, acute
pancreatitis preceded the diagnosis
of carcinoma.
Malignant lymphoma can also in
volve the pancreas. In the series of
Erlich and colleagues6 of 323 pa
tients with lymphoma, in all of
whom autopsy was done, the pan
creas was the most common gas
trointestinal organ to be invaded by
tumour. This occurred in 86 pa
tients (26.6%); however, there was
no mention of acute pancreatitis
secondary to the lymphoma. Pres
ently, the incidence of “lymphoma
pancreatitis” is unknown.
Five reports in the literature doc
ument a total of six patients with
lymphoma pancreatitis.7-11 Five of
them had non-Hodgkin’s lympho
ma, and one had Hodgkin’s lym
phoma and pancreatitis. In all six
patients plus our patient, acute pan

creatitis was the presenting mani
festation and occurred an average
of 5 weeks before the definitive
diagnosis of lymphoma was made.
Two of the patients presented with
acute pancreatitis and pancreatic
abscess. Obtaining tissue for histo
logic confirmation of a pancreas
suspected of harbouring lymphoma
is important, because two of the
five patients with known follow-up
who received chemotherapy and ra
diotherapy survived 1 year from the
time of diagnosis. At present, how
ever, we can offer no criteria for the
diagnosis of lymphoma pancreatitis,
aside from any suspicious findings
at the time of laparotomy.
The pathophysiology of tumour
pancreatitis is still speculative. Pro
posed mechanisms include ductal
obstruction,5 ductal obstruction and
rupture with direct parenchymal tu
mour invasion34 and ischemia sec-

Discussion
There is no doubt that epithelial
cancers, both primary and metastat
ic to the pancreas, can induce acute
pancreatitis. In the Mayo Clinic se
ries1 of 255 consecutive patients
with pancreatic and ampullary ade
nocarcinoma, acute pancreatitis was
present and preceded the diagnosis
of carcinoma in 26 (10.2%). Meta
static tumours invading the pancre
as and causing acute pancreatitis
are much less common. There are
isolated reports in the literature
with primary sites in the stomach,2
lung (squamous cell and small cell
cancer)3-5 and tonsil.2 In McLatchie
and Imrie’s prospective study2 of
360 patients with acute pancreati
tis, 7 (1.9%) were found to have
376

FIG. 1. Computed tomogram at level of head of pancreas, showing 9-cm
phlegmonous mass in head (2), fluid collection in anterior lesser sac (1) and free
intraperitoneal fluid (3).
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an introductory text in computed to
mography would be more useful.

David Johnston from Leeds). The book
was published in German in 1986, then
in English in 1988; the translation has

needs, keeping in mind that at $240.00
US, the book is overpriced.
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been well done.
The most striking aspect of this book
is the extreme variation in the quality o f
the contributions. The editors have not
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SURGERY OF THE STOMACH. Indi
cations, Methods, Complications. Edit
ed by H.D. Becker, Ch. Herfarth, W.
Lierse and H.W. Schreiber. 374 pp.
Illust. Springer-Verlag New York,
Inc., Secaucus, NJ, 1988. $240.00
(US). ISBN 0-387-17116-9.
This multiauthored text deals primarily
with operative techniques for treating
gastric and duodenal diseases and is
aimed at the practising gastric surgeon.
Although most o f the contributors are
from West Germany, some are from
France, the US and the UK (notably

insisted on a minimum standard for
each o f the 29 chapters and the book
suffers as a result.
The chapters on anatomy, Billroth I
and II resections, resection o f the
cardia, gastric reconstruction, highly
selective vagotomy and remedial opera
tions on the stomach are excellent and
well illustrated. The authors have illus
trated stapling and suturing techniques
for many procedures, and this adds to
the value o f the book. There are, how 
ever, a number o f chapters in which the
topic is covered only briefly and superfi
cially. These detract from the book, and
in many instances could have been
omitted. Thus, the coverage of topics in
the book is very spotty. Anyone co n 
templating purchase should examine
the book to see if it meets his or her
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PE R SPE C TIV E S
IN
V A SC U LA R
SURGERY. Edited by Jerry Goldstone.
162 pp. Illust. Quality Medical Pub
lishing, Inc., St. Louis, 1988. Price
not stated. ISSN 0894-8046.
This book, the first issue o f a semi
annual publication produced by Vascu
lar Surgery Outlook, is intended as a
new concept in vascular surgery publi
cation, filling the gap between scientifi
cally oriented journals and textbooks.
continued on page 386
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Femoral Appendicitis: An Unusual Case
E.M. Guirguis, MD, CCFP; G.A. Taylor, MD, FRCSC; C.D.J. Chadwick, MD, FRCSC
The presentation of acute appendicitis in a strangulated femoral hernia is rare. The
authors describe what they believe is the first reported case of necrotizing fasciitis
as a consequence of a gangrenous appendix in this situation. An 80-year-old woman
presented with crepitant cellulitis of her right thigh with fever and leukocytosis,
leading to a preoperative diagnosis of necrotizing fasciitis. Intraoperatively, an
unsuspected gangrenous appendix was found in an incarcerated femoral hernia. A
knowledge of the existence of this rare and serious condition will avoid delay in its
recognition and management.
II est rare de decouvrir une appendicite aigue dans un cas de hernie femorale
etranglee. Les auteurs decrivent ce qu’ils croient etre le premier cas de fasciite
necrosante en resultat d’appendice gangreneux a survenir dans une telle situation.
Une femme de 80 ans presentait une cellulite crepitante a la cuisse gauche, avec
pyrexie et leucocytose, le tout compatible avec un diagnostic preoperatoire de
fasciite necrosante. A l’operation, on decouvrit un appendice gangreneux enclave
dans une hernie femorale. On pourra eviter des delais de diagnostic et de traitement
en gardant a l’esprit l’existence de cette affection rare mais serieuse.

lthough rare, the finding of
acute appendicitis in an incar
cerated femoral hernia has been
reported previously.1' 10 The signs
and symptoms usually relate to the
gastrointestinal tract and the skin
overlying the hernia.16-8 We en
countered a patient with gangre
nous appendicitis in an incarcerated
femoral hernia, presenting with nec
rotizing fasciitis of the right thigh,
without gastrointestinal or abdomi
nal signs and symptoms. To our
knowledge, such a presentation has
not previously been reported.

A

Case R eport

An 80-year-old diabetic woman
presented with a 5-day history of

increasing pain, swelling and red
ness of the right medial thigh, with
intermittent fever.
Her medical history included atri
al fibrillation, hypertension and
non-insulin-dependent diabetes. She
was taking digoxin, furosemide,
glyburide and acetaminophen.
On examination, her temperature
was 37.8°C, blood pressure
110/70 mm Hg, pulse rate 128
beats/min (irregularly irregular)
and respiratory rate 20/min. She
appeared ill and distressed and com
plained of pain in the right thigh.
An area of cellulitis over the middle
portion of the medial thigh mea
sured approximately 12 cm in diam
eter. The affected area was notably
crepitant on palpation. The abdomi
nal examination revealed normal

bowel sounds and a soft, nontender
abdomen, with no palpable or
ganomegaly or masses.
The patient’s hemoglobin level
was 155 g /L and the leukocyte
count was 11.0 X 109/ L (normal
differential). Her blood glucose level
was 35.1 mmol/L. X-ray films of
the right thigh showed soft-tissue
edema and extensive gas within the
soft tissues (Fig. 1). Three-view
films of her abdomen appeared nor
mal.
A clinical diagnosis of necrotizing
fasciitis of the right thigh was
made, and the patient was taken to
the operating room for drainage
and debridement. Using a longitudi
nal incision over the erythematous
area, we initially encountered ede-
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FIG. 1. Preoperative x-ray film of right
thigh with soft-tissue penetration
shows extensive soft-tissue gas in
upper medial thigh extending down
great saphenous vein.

FEMORAL APPENDICITIS

matous inflammatory tissue but no
sign of suppuration or tissue necro
sis; however, on dissecting upward
toward the inguinal ligament, we
found a large, foul-smelling cavity
containing pus and necrotic tissue.
It was then apparent that the septic
process originated in the femoral
canal. Exploration of the femoral
canal through an oblique inguinal
incision revealed an incarcerated
femoral hernia containing a gangre
nous perforated appendix. A culture
swab, taken from the right thigh
intraoperatively, grew diphtheroids,
Bacteroides oralis, and group B
(8-hemolytic streptococci.

Comment
In their review of the literature,
Jackson and Bell11 categorized gan
grenous and necrotic soft-tissue in
fections. Necrotizing fasciitis is
characterized by an acute inflamma
tory process, involving the subcuta
neous tissue and the deep fascia,
and toxemia. Two different sets of
organisms have been isolated from
patients with necrotizing fasciitis.
One set (isolated from 81.2% of
subjects) consists of aerobes and
anaerobes: the aerobes include a
variety of streptococci and en
terobacteria and the anaerobes in
clude Bacteroides sp and peptostreptococci. The other set of organ
isms (18.8%) consists of group A
streptococci (Streptococcus pyo
genes), either alone or with a few
staphylococci (Staphylococcus au
reus or Staphylococcus epidermi-

dis).n M Culture of material from
this patient’s thigh resulted in isola
tion of the organisms more fre
quently associated with necrotizing
fasciitis.
Necrotizing fasciitis is most fre
quently found in debilitated patients
such as those suffering from alco
holism, severe diabetes, malnutri
tion, advanced age, ulcerative coli
tis, Crohn’s disease,
an im
munocompromised state and severe
arteriosclerosis of large or medium
sized vessels. Our patient’s age and
diabetic state were likely contribut
ing factors in the development of
her necrotizing fasciitis.
Although the finding of acute
appendicitis in a femoral hernia has
been well documented,1-10 the pre
sentation of necrotizing fasciitis due
to the condition has not previously
been reported. Although the fre
quency of acute appendicitis in fem
oral hernias is unknown,1 an esti
mated 0.13% of cases of acute
appendicitis occur in various exter
nal hernial sacs.4 9
Gangrenous appendicitis in a
strangulated femoral hernia is
thought to be caused by constric
tion of the lumen of the appendix
by the neck of the hernial sac,5
leading to inflammation and subse
quent gangrene of the appendix.1 In
this case the infection spread into
the right medial thigh, resulting in
the development of a fulminant nec
rotizing fasciitis. This complication
was the major presenting feature
and overshadowed the signs and
symptoms of the underlying abdom
inal condition.

In approaching patients with
crepitant cellulitis of the thigh, a
knowledge of the existence of this
extremely rare but serious condition
will avoid delay in its recognition
and management.
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BCefizoxsterile ceftizoxime sodium

THERAPEUTIC CLASSIFICATION
Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of ceftizoxime results from in
hibition of cell-wall synthesis in aerobic and anaerobic gram-positive and gram
negative organisms. In vitro, ceftizoxime shows a strong affinity for penicillin
binding proteins la, lbs and 3 of E. coli.
INDICATIONS AND CLINICAL USES
CefizoxTM (sterile ceftizoxime sodium) may be indicated in the treatment of the
infections listed below when caused by susceptible strains of the designated
microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus sp. (includ
ing S. pneumoniae but excluding enterococci); Klebsiella sp.; Proteus mirabilis;
Escherichia coli; Haemophilus influenzae (including ampicillin-resistant strains);
Staphylococcus aureus (including penicillinase-producing but excluding
methicillin-resistant strains); Serratia sp.; and Enterobacter sp.
URINARY TRACT INFECTIONS caused by Escherichia coli; Staphylococcus epider
midis; Pseudomonas aeruginosa; Proteus mirabilis; Klebsiella sp.; Serratia
marcescens; and Enterobacter sp.
Due to the nature of the underlying conditions which usually predispose patients to
Pseudomonas infections of the urinary tract, a good clinical response accompanied
by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli; Staphylococcus
epidermidis; Streptococcus sp. (excluding enterococci); Klebsiella sp.; Bacteroides
sp. (including . fragilis); Peptococcus sp.; and Peptostreptococcus sp.
8

SEPTICEMIA caused by Streptococcus sp. (excluding enterococci but including S.
pneumoniae); Staphylococcus aureus (excluding methicillin-resistant strains);
Escherichia coli; Bacteroides sp. (including 8 . fragilis); Klebsiella sp.; and Serratia
marcescens.
SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus (excluding
methicillin-resistant strains); Staphylococcus epidermidis; Escherichia coli;
Klebsiella sp., (including K. pneumoniae); Streptococcus sp. (excluding enterococci
but including Group A B-hemolytic Streptococcus pyogenes); Proteus mirabilis;
Serratia sp.; Enterobacter sp.; Bacteroides sp. (including 8. fragilis); Peptococcus
sp., and Peptostreptococcus sp.
BONE AND JOINT INFECTIONS caused by Staphylococcus aureus (excluding
methicillin-resistant strains); Proteus mirabilis; Peptococcus sp.; and Pepto
streptococcus sp.
Specimens for bacteriologic culture should be obtained prior to therapy in order to
identify the causative organisms and to determine their susceptibilities to cefti
zoxime. Therapy with CefizoxTM may be initiated before results of the susceptibility
studies are known. However, modification of the treatment may be required once
these results become available.
CONTRAINDICATIONS
CefizoxTM (sterile ceftizoxime sodium), is contraindicated in persons who have
shown hypersensitivity to ceftizoxime or other members of the cephalosporin group
of antibiotics.
WARNINGS
Before therapy with CefizoxTM (sterile ceftizoxime sodium) is instituted, careful
inquiry should be made to determine whether the patient has had previous hyper
sensitivity reactions to cephalosporins, penicillins, or other drugs. CefizoxTM
should be given cautiously to penicillin-sensitive patients. Antibiotics, including
CefizoxTMi should be administered with caution to any patient who has demon
strated some form of allergy, particularly to drugs. If an allergic reaction to Cefi
zoxTM occurs, its administration should be discontinued. Serious acute hyper
sensitivity reactions may require epinephrine and other emergency measures.
Pseudomembranous colitis has been reported with the use of CefizoxTM (and other
antibiotics). Therefore, it is important to consider this diagnosis in patients adminis
tered CefizoxTM who develop diarrhea.
Treatment with broad-spectrum antibiotics alters normal flora of the colon and may
permit overgrowth of Clostridia. Studies indicate a toxin produced by Clostridium
d ifficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe
cases should be managed with fluid, electrolyte and protein supplementation as
indicated. When the colitis is not relieved by drug discontinuance or when it is
severe, consideration may be given to the administration of oral vancomycin or
other suitable therapy. Other possible causes of colitis should also be considered.

Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The
use of CefizoxTM in pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus. The pharmacokinetics
of CefizoxTM jn pregnant patients has not been investigated. Reproduction studies
performed in rats and rabbits have revealed no evidence of impaired fertility or harm
to the fetus caused by ceftizoxime. Animal reproduction studies, however, are not
always predictive of human response.
Labour and Delivery: The safety and efficacy of CefizoxTM Use during labour and
delivery has not been investigated.
Nursing Mothers: Ceftizoxime is excreted in human milk in low concentrations
(less than 4% of serum concentrations at 1 hour after dosing). The clinical signifi
cance of this is unknown; therefore caution should be exercised if CefizoxTM jS to
be administered to a nursing woman.
Infants and Children: The safety of CefizoxTM in infants less than 6 months of age
has not been established. In children six months of age and older, treatment with
CefizoxTM has been associated w ith transient elevated levels of eosinophils,
SGOT, SGPT and CPK (creatine phosphokinase). The CPK elevation may be related
to intramuscular administration.
Elderly Patients: The elimination o f ceftizoxime may be reduced due to an agedependent reduction in renal function.
ADVERSE REACTIONS
CefizoxTM (sterile ceftizoxime sodium) is generally well tolerated.
Adverse
Incidence
Incidence
Reaction
<1%
>1% but <5%
Hypersensitivity:

Rash
Pruritus
Fever

Liver:

Transient elevation of SGOT,
SGPT and alkaline phosphatase

Blood:

Neutropenia
Leukopenia
Thrombocytopenia

Renal:

Transient elevation
of BUN and creatinine

Local:
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Injection site: burning, cellulitis,
phlebitis (with IV administration),
pain, induration, tenderness,
parasthesia

Genitourinary:

Vaginitis

Gastro
intestinal:

Diarrhea, Nausea, Vomiting, Pseudomembranous colitis

No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE
No case of acute overdosage has been reported to date; consequently there is no
specific information available on symptoms or treatment. In cases of suspected
overdosage, supportive therapy should be instituted according to symptoms. Serum
ceftizoxime levels can be reduced by hemodialysis.
DOSAGE AND ADMINISTRATION
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly
or intravenously after reconstitution.
Dosage and route of administration should be determined by the condition of the
patient, severity of the infection and susceptibility of the causative organism(s). The
intravenous route may be preferable for patients with bacterial septicemia, or other
severe or life threatening infections.
The usual course of treatment should be 7-14 days, and should normally continue at
least 48 hours after evidence of bacterial eradication has been obtained. For
B-hemolytic streptococcal infections, a minimum of 10 days of treatment is
recommended.
DOSAGE
Adults: The recommended daily dosage of CefizoxTM is 1 to 12 grams admin
istered in equally divided doses every 8 or 12 hours (see Table 1 below).
TABLE 1
Type of Infection

PRECAUTIONS
General: Transient elevations of BUN and serum creatinine have been observed in
clinical studies. However, there is no other evidence that CefizoxTM (sterile cefti
zoxime sodium) has produced alterations in renal function. Renal status should be
periodically evaluated, especially in seriously ill patients.
Prolonged use of CefizoxTM may result in the overgrowth of nonsusceptible
organisms including species originally sensitive to the drug. Careful observation of
the patient is essential. If superinfection occurs during therapy, appropriate
measures should be taken.
CefizoxTM should be administered with caution to individuals with a history of
gastrointestinal disease, particularly colitis.
Impaired Renal Function: Since ceftizoxime is excreted primarily in the urine,
patients with impaired renal function (i.e., creatinine clearance <1.32 mL/s or
<79 mL/min) should be placed on a special dosage schedule recommended under
DOSAGE AND ADMINISTRATION. Normal dosages in these individuals are likely to
produce excessive serum concentrations of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and
aminoglycosides has caused nephrotoxicity. The effect of administering CefizoxTM
concomitantly with aminoglycosides is not known.

Transient eosinophilia
Thrombocytosis
Positive direct Coombs’ test

Uncomplicated
Urinary Tract

Daily Dose
(Grams)

Frequency and Route

1

500 mg q12h, IV or IM

Other Sites

2-3

1 g q8h or q12h, IV or IM

Severe or
Refractory

3-6

1 g q8h, IV or IM, to
2gq8h orq12h, IV orIM*

Life-Threatening

9-12

3 o r4 g q8h IV

*When administering 2 g intramuscularly, the dose should be divided and injected
into different large muscle masses.
Because of the serious nature of urinary tract infections due to Pseudomonas
aeruginosa and because many strains are only moderately susceptible to CefizoxTM,
higher dosage may be appropriate when urinary tract infections are caused by
these organisms. Other therapy should be instituted if the response is not prompt.

Adults with Impaired Renal Function: In patients in w hom the creatinin e cle a ra nce
is 1.32 m L/s (79 mL/min) or less, the dosage of CefizoxTM m ust be reduced. Fo llo w 
ing an in itia l loading do se of 500 mg to 1.0 g IM or IV, the m ain ten an ce d osing
sched ule presented in Table 2 sh o u ld be follow ed in pa tie n ts with reduced renal
function.

RECONSTITUTION

STANDARD VIALS (1 GRAM and2GR^S )
For Intramuscular Injection: Reconstute w it h
teriostatic W ater for Injection.

Reconstitution Table f c S t a n d a r d Vials - I.M. Injection

TABLE 2
Renal
Function

Creatinine
C learan ce
mL/s
mL/min

Less Severe
Infections

Life-Threatening
Infections

50-79

500 mg
q8h

750 mg to 1.5 g
q8h

M oderate to
0.08-0.82
severe im pairm ent

5-49

250 or 500 mg
q12h

500 mg to 1.0 g
q12h

H e m od ia ly sis
patients*

0-4

500 mg q48h or
250 mg q24h

500 mg to l.O g
q48h or 500 mg
q24h

M ild
Impairment

0.83-1.32

0-0.07

*ln pa tie n ts undergoing he m od ia lysis no ad d itio n a l supplem ental d o sing is
required. DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT
RECEIVES THE DOSE AT THE END OF THE DIALYSIS. W hen started 24 hours after
a d m inistra tion of 1 g o f CefizoxTM, hem odialysis h a s been show n to reduce serum
levels by 50% .
W hen o n ly the serum creatinine level is available, cre a tinin e clearance m ay be
c a lcu la te d from the fo llow ing form ulae (for pa tie n ts 18 years and over only). The
serum cre a tinin e level should represent renal fun ctio n at the steady state.
Males:
Cre atin ine C learan ce

Vial
Size

D iluent to be
A d d e d to Vial

A p p ro x im a te
A v a ila b le
V o lu m e

A pproxim ate
Average
Concentration

ig
2g

3.0 m L
6.0 m L

3 .7 m L
7 .4 m L

270m g/m L
270 mg/mL

Shake w ell until d isso lv e d .
For Intravenous Injection: Reconstitus o n l y w it h S te rile W ater for Injection.
Reconstitution Table fv S t a n d a r d Vials - I.V. Injection
Vial
Size

D iluent to be
A d d ed to Vial

A p p r o x im a t e
A v a i la b le
V o lu m e

A pproxim ate
A verage
Co ncentratio n

1g
2g

10 m L
20 m L

1 0 .7 m L
2 1 .4 m L

95 mg/m L
95 mg/m L

Shake w ell until d isso lv e d .
For Intravenous Infusion: Reconstitute a s f o r intravenous inje ctio n. Further
dilute the reconstituted so lu tio n to 50 t o 1 0 0 m L with one of the “ S o lu tio n s for
Intravenous Infusion” (see below).

W eight (k g )x (140-age)

(mL/min)

TABLE 4: Solutions for Intravenous Infusion

72 x serum creatinine (mg/100 mL)

Cre atin ine Clearance

W eight (kg) x 140 - age)

(ml_/s)

49 x serum creatinine ( /xmol/L)

Females: 0.85 of the above values
Infants and Children: The follow ing dosage sched ule is recom m ended:
TABLE 3
Age G roup
Infants (6 mo-2 yrs.),
and
Children (2-12 yrs.)

S t e r ile W ater for Injection or Bac

Sodium C hlorid e Injection
5% or 10% Dextrose Injection
5% Dextrose and 0.9%, 0.45% or 0.2% S o d iu m C h lo r id e Injection
Ringer’s Injection
Lactated R inger’s Injection
10% Invert Sugar in S te rile W ater for Inje ctio n
5% Sodium B icarb o n a te in Sterile Water fo r I n je c tio n
5% D extrose in L a c ta te d Ringer’s In je c tio n O N L Y when re co nstitu te d with
4% Sodium B icarb o n a te Injection.
STABILITY O F SOLUTIONS

Unit Dosage

Freq uency and Route

Storage: A ll re co n stitu te d solutions a n d t h o s e further d iluted sh o u ld be used
within 24 hours if stored at room te m p e ra tu re o r w ithin 48 h o urs if refrigerated.
These storage lim its are fro m the time o f th e in it ia l reconstitu tion .

50m g/kg IVorIM

q6h orq 8h , IV or IM

Incompatibility: CefizoxTM should n o t be a d d e d to blood p ro d ucts, protein
hydrolysates or a m in o a c id s . CefizoxTM s h o u ld not be m ixed to g e th e r with an
am inoglycoside.

The p e d ia tric dosage should not exceed the m axim um adult dosage for serious
infections.

DOSAGE FORMS

ADMINISTRATION

Availability: CefizoxTM jS available a s a s t e r ile pow der in S ta n d a rd V ia ls of
1 gram or 2 gram s, co n ta in in g ceftizoxim e a s s o d iu m salt.

Intramuscular: The reconstituted so lution of CefizoxTM sho uld be injected well
w ithin the body of a relatively large m uscle, such a s the gluteus. W hen a d m iniste r
ing 2 g IM d o se s, the do se should be divided eq ually and then injected into different
large m u sc le masses.

Storage: C e fizo xT M p o w d e r for injection s h o u ld be stored at room tem perature
(15°-30°C).

Intravenous: Injection (bolus): The reconstituted s o lu tio n of CefizoxTM should be
injected slo w ly over 3 to 5 m inutes, directly or through the tubing system by w hich
the patient is receiving another com p atib le intravenous solutio n. During a d m inistra 
tion of the so lu tio n containing CefizoxTM, it is d e sira b le to tem porarily disco n tin u e
a d m in istra tion of the other solution.
Interm ittent or continuous infusion: The further d ilute d reconstituted so lu tio n of

CefizoxTM sho uld be adm inistered over a 20 to 30 m inute period.
NOTE: CefizoxTM so lu tio n s sho uld not be p h y sic a lly m ixed with any other drug.
There is a known inco m p a tib ility w ith am in og lycosid e a n tib io tics. Therefore, they
sho uld not be p hysically m ixed w ith CefizoxTM so lu tio n s nor adm inistered at the
sam e site.
PHARMACEUTICAL INFORMATION
CHEMISTRY

FOOTNOTES
’As indicated in the m anufacturer's prod u ct monograph. Cefizox, S m ith Kline & French Canada L td ., 1988.
2As indicated in the m anufacturer's p ro d u c t monograph cefoxitin, M e r c k S harp & Dohm e Canada, 1985.
3LouM .A. etal.: 14th International Congr. Chemother., Kyoto, Jap an. J u n e 1985, pp 2378-2379.
4Neu H.C., Chin N .X .: The activity and beta-lactamase stab ility of cefo tetan com pared to other beta-lactam antibiotics.
Chemioterapia 1985;4:271-277.

Trade Name: CEFIZO XTM

5Fu K .P , Neu H.C.: Antibacterial a ctiv ity o f ceftizoxime, a B-lactam ase-stable cephalo sporin A n tim icrob Aaents
Chemother. 1980;12:583-590.

Proper Name: Ceftizoxim e Sodium
Chemical Name: Sodium (6R-[6°», 7 6 (Z )]]-7 -[[(2 ,3 -d ih y d ro -2 -im in o -4 -th ia zo ly l)
(m e th o x y im in o )a c e ty l]a m in o ]-8 -o x o -5 -th ia -1 -a za b ilc y c lo [4.2.0] o c t - 2 - e n e - 2 carb o xyla te

6Thornsberry C.: Review of in vitro activ ity of third-generation ce p h a lo sp o rin s and other newer beta-lactam antibio tics
against clinically important bacteria. A m . J. Med 1985;/y (Suppl. 2A): 15-20.
7DrulakM.W., Chow A .W .: Com paritive in vitro activity o f ceftizoxim e cefoperazone and cefoxitin against anaerobic
bacteria. Antim icrob. Agents Chemother. 1981;20:683-685.
8Aldridge K .E . et al.: Com parision of the activities of penicillin 6 and n ew B-lactam antibio tics again st clin ical isolates of
Bacteroides species. Antim icrob. A g e n ts Chemother 1984;26(3):410-413.

Structural Formula:
COON,

9Adapted from Parker D.D .: Abstr. A n n u . Meet. Am, Soc. M icrobiol..A tlanta, GA, M arch 1987, Abstract no. A-107, p. 18.
10Kitzmann R. Cost analysis of the e c o m o m ic effect of replacem ent of cefoxitin with ceftizoxim e. Presented at the 45th
Annual Meeting, Am erican S ociety o f H ospital Pharmacists. San Francisco, California.
’ ’ Guastell C. Cost savings realized fro m interchanging ceftizoxim e fo r cefoxitin A m J H o sd Pharm 1988
Nov;45:2376-2377.
12Wikler M .A. et al.: E fficacy of ceftizoxim e administered twice daily fo r th e treatment of serious in fectio ns in hospitalized
patients. Infect. Med. 1986;(Suppl.):9-12.

Molecular Formula: C 1 3 H i 2 N 5 0 5 S 2 Na
Molecular Weight: 405.38
Description: C eftizo xim e Sodium is a white to pale ye llo w c ry sta llin e powder.
Composition: CefizoxTM v ia ls c o n tain ceftizoxim e so d iu m (expressed in term s
of^ free acid). The sodium content o f each gram o f CefizoxTM is approxim ately

,3Data on file. S m ith Kline & French Can ada Ltd.
14Sanford J . P : Guide to A n tim icrobial Therapy. West Bethesda, M D :An tim icrob ial Therapy Inc. 1988:50.
,5RichardsDM . Heel RC. Ceftizoxime: A review of its antibacterial activity, pharm acokinetic properties and therapeutic
use. Drugs 1985:29:281-329.
K
"O iP iro J. M ay JR . Use o f ce p h a lo sp o rin s with enhanced antianaerobic activity for treatm ent and prevention of
anaerobic and mixed in fectio ns. Clin P h a rm 1988 Apr:7.285-302.
17Bellomo S. Antim icrobial activity of cefizo xim e sodium: Com parision with cefoxitin Hosd Formul 1988:23
(Suppl. D): 18-27.
K

m g (2.6 m E q sod ium ion).
S o lu tio n s o f CefizoxTM range from colou rless to p ale yellow , depending upon the
d iluent and volum e used. The so lu tio n should be d isca rd e d if it b ecom es cloudy.
The pH of fre sh ly reconstituted so lu tio n s usually ran g es from 6.0 to 8.0.

A so lu tio n o f 1 g CefizoxTM jn 13 mL Sterile Water for Injection is isotonic.

SMITH KLINE &FRENCH CANADA LTD.
M ississauga, Ontario L5N 2V7
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Carcinoids of the Kidney: Case Report and
Literature Review
Saad Juma, MD;* J. Curtis Nickel, MD, FRCSC;* Iain Young, MD, FRCPCt
Primary carcinoids of the kidney are very rare, only 10 cases having been reported
in the literature. The authors report a case of primary renal carcinoid in a
50-year-old woman. A radical nephrectomy with lymphadenectomy was successfully
performed and there was no residual or recurrent tumour at 2-year follow-up. A
review of the reported cases revealed a variable, nonspecific presentation. Most
laboratory tests were non-contributory except for urinalysis. When a renal carcinoid
is diagnosed, a search should be made for a possible primary elsewhere. Primary
renal carcinoid does exhibit malignant behaviour. It should be managed by radical
nephrectomy with retroperitoneal lymphadenectomy.

Les carcino'ides renaux primitifs sont tres rares. Seulement 10 cas ont ete decrits
dans la presse medicale. Les auteurs en signalent un cas chez une femme de 50 ans.
Une nephrectomie radicale avec lymphadenectomie fut pratiquee avec succes; il n’y
avait ni tumeur residuelle, ni recidive, a l’examen de controle, 2 ans plus tard.
L’etude des cas signales revele un tableau clinique variable et non specifique. A part
le test d’urine, la plupart des examens de laboratoire ne sont d’aucun apport au
diagnostic. Quand un carcinoide renal est diagnostique, une autre tumeur primitive
devrait etre recherchee. Les carcino'ides renaux primitifs mainfestent un comportement malin. Le traitement consiste a pratiquer une nephrectomie radicale avec
lymphadenectomie retroperitoneale.

rimary renal carcinoids are very
rare tumours that arise from
cells of neuroendocrine origin (Kul
chitsky cells). The presence of these
cells in the kidney, however, has
been a source of controversy since
they are not known to be a compo
nent of the normal kidney. Several
theories have been proposed to ex
plain their presence, including neu
roendocrine cell ectopia or seque
stration,1 neuroendocrine metapla
sia of mesodermal tissue23 and neu-

P

roendocrine differentiation of cells
regardless of their embryonic ori
gin.4
We report a case of primary renal
carcinoid with regional nodal metas
tasis.

by ultrasonography, which was
done to find the cause of her epi
gastric pain and weight loss. She
had undergone appendectomy, hys
terectomy and cholecystectomy and
was allergic to intravenous contrast
dye. Her medical history was other
wise unremarkable, and findings on
physical examination were within
normal limits.
Results of laboratory investiga
tions, which included complete
blood count and measurement of
serum electrolytes, creatinine and
amylase, blood urea nitrogen and
liver function, were normal. Urinaly
sis revealed traces of blood and
protein. The chest x-ray film ap
peared normal. Ultrasonography of
the abdomen revealed a left renal
mass and a computed tomogram
confirmed the presence of a 3 X 5
cm solid bilobed mass with focal
calcification in the lower pole of the
left kidney (Fig. 1). The inferior
vena cava, liver, spleen and other
intra-abdominal viscera appeared
normal.

Case Report
A 50-year-old woman was re
ferred to our unit for further evalu
ation of a left renal mass discovered

From the ’"Department o f Urology and tDepartment o f Pathology, Queen’s University, Kingston,
Ont.
A ccepted for publication Mar. 15, 1989
Reprint requests to: Dr. J. Curtis Nickel, Department o f Urology, Queen’s University, Kingston
General Hospital, Kingston, Ont. K7L 2V7
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FIG. 1. Unenhanced computed tomo
gram shows bilobed mass with calcifi
cation in lower pole of kidney.

CARCINOID OF THE KIDNEY

At laparotomy, a solid mass con
fined to the left kidney was found,
with no evidence of extrarenal ex
tension. Grossly, the remaining in
tra-abdominal structures were nor
mal. A left radical nephrectomy
with lymphadenectomy was done.
Postoperative recovery was uncom
plicated.
Gross examination revealed a
solid yellow tumour measuring 5.5
X 3 X 2 cm, which was confined to
the lower pole of the kidney. There
was no capsular, pelvic or vascular
invasion. On light microscopy, the
tumour was composed of interlac
ing cords of uniform cells contain
ing central oval nuclei (Fig. 2). The
Fontana stain was negative, but the
Grimelius stain showed numerous
argyrophilic granules. Immunoperoxidase stains for neuron-specific
enolase were positive and electron
microscopy demonstrated abundant
neurosecretory granules (Fig. 3).
These findings are characteristic
of a carcinoid. Three of 11 peri
aortic lymph nodes contained metastases. Immunoperoxidase tech
niques identified no insulin, glu
cagon, somatostatin or calcitonin
within tumour cells.
In view of these findings, further
investigations were done, includ
ing bone scanning, upper gastro
intestinal endoscopy, colonoscopy,
barium enema examination and ur
inary 5-hydroxyindoleacetic acid

(5-HIAA). All results were normal.
Follow-up 2 years postoperatively
showed no residual or recurrent
tumour.

FIG. 2. Tumour is composed of cords
of uniform cells with ovoid nuclei
(hematoxylin-phloxine-saffron stain,
original magnification X 400).

FIG. 3. Electron photomicrograph
demonstrates abundant neurosecretory
granules in cytoplasm of tumour cells
(original magnification X 8000).

Discussion
Twelve cases of renal carcinoid
have been reported;1-10 however, we
noticed two instances of duplicate
case reporting.37-9 Of the remaining
cases, only eight were adequately
documented.1-10 The average age at
the time of presentation was 46.8
years and no sex tendency was
observed. The tumour was unilater
al in all cases with no predilection
for either kidney. No familial ten
dency was noted.
Clinical presentation was variable
and nonspecific. The most common
presenting symptoms and signs
were abdominal pain (30%) and
gross hematuria (20%). Patients
were asymptomatic in 20% of the
cases. The most consistent physical
finding was an abdominal or flank
mass, in 60% of the cases.1-36-9
Laboratory tests, including com
plete blood count and measurement
of serum electrolytes, blood urea
nitrogen and creatinine levels and
liver function test results were not
contributory; urinalysis may reveal
hematuria, proteinuria, glycosuria
or pyuria. Urinary excretion of
5-HIAA was measured in three

cases and was normal.47 Ul
trasonography may demonstrate a
renal mass and intravenous pyelog
raphy may show a mass, dilated
pelvis and calyces, or non-visualiza
tion of the affected kidney, with or
without calcification. Computed to
mography in our case and two
previously reported cases10 demon
strated a bilobed renal mass with
focal calcification. Renal angiogra
phy was done in two cases and
demonstrated a hypovascular or
avascular mass.8'10 Chest x-ray films
reported in four cases were normal.
Bone scanning was negative in
three cases45 and showed increased
activity in another two; however,
skeletal survey in both of these
showed no evidence of metastatic
deposits.27 When a renal carcinoid
is diagnosed, a search for a possible
primary elsewhere should include a
small-bowel follow-through and
barium enema.
The pathological findings in
these cases have been more consis
tent. The tumour was solid in six
cases and had a cystic component in
another three. One case was report
ed in a benign cystic teratoma,6 and
another in a horseshoe kidney with
renal dysplasia.9
Microscopically, these tumours
were composed of uniform cells
with central oval nuclei and few
mitotic figures (Fig. 2). Grimelius or
Bodian stains demonstrated argyro
philic granules in eight cases,1-7
and the Fontana stain for argentaffian granules was positive in two
cases and negative in six.1-7 No
special stains were reported in three
cases. Electron microscopy, when
employed, consistently showed neu
rosecretory granules in the cystoplasm (Fig. 3). Immunoperoxidase
studies were used in three cases and
were positive for glucagon in one
case5 and for serotonin, glucagon
and somatostatin in another,3 and
were negative in the third.
The association of renal carcinoid
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with the carcinoid syndrome was
reported in one case in which the
tumour was secreting glucagon.5
This case does not allow for accu
rate conclusions to be drawn, and in
view of the scarcity of available
information, we believe that car
cinoid syndrome in association with
a primary renal carcinoid should be
treated similarly to carcinoid syn
drome associated with a primary
tumour outside the kidney.
Primary renal carcinoid does ex
hibit malignant behaviour; however,
its prognosis remains uncertain. In
the reported cases, the tumour was
confined to the kidney in five ca
ses,1-36 extended through the renal
capsule in one,5 was found at the
resection margin in one,4 and in
regional lymph nodes in four
cases.5 7'8 A positive bone scan was
reported in two cases, but neither
patient had evidence of bone in
volvement on skeletal survey.2'7

Seven patients were alive after an
average follow-up of 3.7 years and
no deaths were reported. Treatment
of primary renal carcinoid should be
radical nephrectomy with retroperi
toneal lymphadenectomy when pos
sible. The lymphadenectomy will
allow proper staging of the tumour,
but the therapeutic value of the
procedure is still unconfirmed.

4.

5.

6.

We thank Dr. Paul Mozarowski for his
help with the ultrastructural study and
acknowledge the editorial assistance of
Dimitra Baxter.
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BOOK REVIEWS
continued from page 377

Recognized vascular surgeons review
controversial subjects in the manage
ment of patients with arterial insuffi
ciency. The articles are followed by a
critical appraisal of the review by the
editor, to which the authors have an
opportunity to respond. This format is
further strengthened by a round-table
discussion with a moderator and panel
ists, a section focusing specifically on
vascular techniques and a discussion of
a case for which a second opinion is
being sought from an established vascu
lar surgeon.
In this first edition the role of lasers
in vascular surgery is discussed, the
management of patients with abdominal
aortic aneurysms and coronary artery
disease assessed, and a fiery defence, by
John Porter, of the reversed saphenous
vein graft in preference to the in-situ
vein bypass presented. The focus on
reconstructive techniques for venous
obstruction and valvar incompetence is
timely and well carried out, and many
vascular surgeons will be interested in
386

Frank Veith’s discussion of the ap
proach to the middle and distal portions
of the deep femoral artery when it is
used as the origin or termination for
secondary bypasses. The article on
asymptomatic carotid stenosis is timely
and well done.
All the discussions are comprehen
sive and include long lists of up-to-date,
appropriate references. The opportunity
for discussion of issues provided in the
editor’s comments is well used. In gen
eral, the articles are objectively ap
praised, although in the discussion re
garding the use of the reversed saphe
nous vein or the in-situ vein for lower
extremity bypass, the authors’ preju
dices show through. This does not
apply to the discussion on the asymp
tomatic carotid bruit; it is finally becom
ing apparent that a tight asymptomatic
carotid stenosis may be a lesion that
still requires carotid endarterectomy.
The articles provide a useful, up-todate reference for community surgeons
wishing to read a balanced account of
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opposing views in controversial areas of
vascular surgery. The book is easy to
read and, in general, the articles make
their point without being verbose. The
print is clear, the headings make the
text easy to follow, and the diagrams
are, on the whole, easy to read, al
though the transverse sections of the
thigh in Veith’s account of exposure of
the middle and distal portion of the
profunda femoris leave a little to be
desired. At $191, some may find this
book overpriced, and I suspect that this
series will have a short life. One can
only go so far with controversy, and
this one volume seems to have dealt
with most issues already, so it will be
interesting to see what else is to come.
John L. Provan, MS, FRCS,
FRCSC, FACS
Ste. 418,
E.K. Jones Building,
160 Wellesley St. E.
Toronto, Ont.
M4Y 1J3

ORIGINAL ARTICLES

Persistent Ectopic Syndrome
J.D. Cairns, BM, FRCSC; D. Xuereb, MD, FRCSC
Persistent ectopic syndrome is a complication of conservative surgery for tubal
pregnancy. This study is directed toward the escalating conservatism in the
treatment of tubal ectopic pregnancy and its possible sequelae. Residual trophoblast
propagation after initial surgery is becoming more frequent. Two cases are reported.
The first woman was admitted with an acute abdomen; salpingectomy was performed
to control hemorrhage from tubal rupture at the site of the previous salpingostomy.
The second woman was treated by fimbrial expression. Because of the recurrence of
pain, the beta human chorionic gonadotropin (BHCG) levels were measured; they
indicated fresh trophoblastic activity. She was treated with methotrexate orally, 10
m g /d for 5 days. The need for BHCG surveillance of conservatively managed tubal
ectopic pregnancy is stressed. The value of using methotrexate when tubal integrity
persists is discussed in the light of its traditional role against trophoblastic
tumours.

over traditional resection o f the
affected tube is improved fertility.
The worst scenario for conservative
surgery would be an unacceptable
incidence o f ectopic pregnancy in
the retained tube or the persistence
of trophoblastic tissue following an
incomplete procedure. This report
is concerned with the second possi
bility — the so-called persistent
ectopic syndrome.

Case R eports
La persistance d’un syndrome ectopique est une complication des chirurgies
conservatrices lors des grossesses tubaires. Cette etude s’adresse a la montee du
conservatisme dans le traitement des grossesses tubaires ectopiques et a ses
sequelles possibles. Apres la chirurgie initiale, une propagation trophoblastique
residuelle devient plus frequente. On en signale deux cas. La premiere femme fut
hospitalisee en abdomen aigu; une salpingectomie fut pratiquee en vue de juguler
une hemorragie causee par la rupture de la trompe au point de salpingostomie. La
deuxieme femme fut traitee par extraction de la frange. A cause d’une recidive de la
douleur, on mesura les taux de beta-gonadotrophines chorioniques humaines
(BHCG); ils indiquaient une activite trophoblastique recente. La patiente fut traitee a
l’aide de methotrexate par voie orale a raison de 10 m g /j pendant 5 jours. On
souligne la necessity de surveiller les taux de BHCG dans les cas de grossesses
tubaires ectopiques traitees de fa?on conservatrice. On commente l’interet d’utiliser
du methotrexate quand il y a persistance de l’integrite tubaire, a la lueur de son role
traditionnelle contre les tumeurs trophoblastiques.

n 1884, Lawson Tait1 first de
scribed salpingectomy for ectopic
pregnancy. Treatment initially was
directed at controlling intraperitoneal hemorrhage, but conservative
surgical treatment before tubal rup
ture has become more common.23
The incidence o f ectopic preg

I

nancy increased threefold in the
years 1970 to 1980,4 and, concur
rently, the diagnosis of unruptured
ectopic pregnancy was facilitated
by the use of serum /3-human chori
onic gonadotropin (BHCG) and pel
vic ultrasonography. The most solid
argument for conservative surgery
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Case 1
A 29-year-old woman (G2 P I),
first seen at 7 weeks’ gestation
because o f vaginal spotting and
abdominal pain, stated that her first
child had been delivered by cesarean
section and she had used an intra
uterine device between pregnancies.
A qualitative BHCG was positive for
pregnancy and the uterine cavity
was empty on pelvic ultrasonogra
phy, but a right adnexal mass was
described, measuring 4 x 3 cm.
Lapafoscopy revealed a fusiform
swelling in the isthmus o f the right
fallopan tu b e . The ectopic pregnan
cy w« eva cu a ted by a right salpin
gostomy- F o u r weeks after the pro
cedure t h e woman came to the
emerFn c y
department with an
acute a b d o m e n . Symptoms and
signs w e r e
characteristic of intrapedoneal hemorrhage. There
was ) rn a rk e d reduction in the
hemo/lobin level. At laparotomy,
the k flio r rh a g e was estimated at
one lbT- T h e bleeding was at the
site a t h e previous salpingostomy.
Examination o f the resected tube
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showed a persistent trophoblast.
Recovery was complete and the pa
tient later conceived and was deliv
ered at term of a live infant.

Case 2
A 27-year-old woman (G1 PO)
presented with uncertain menstrual
dates, early symptoms of pregnancy
and abdominal pain. She had been
using an intrauterine device for
contraception. Laboratory findings
showed a BHCG positive for preg
nancy (279 U/L) and an empty
uterine cavity on ultrasonography.
Laparoscopy showed an ectopic
pregnancy in the right ampulla with
blood exiting from the tubal osti
um. At laparotomy, the distal onethird of the tube was “milked” to
extrude the pregnancy. The patient
was seen 4 weeks postoperatively,
when she presented with abdominal
pain. Her hemoglobin level was 142
g /L and BHCG 3520 U/L. Pelvic
ultrasonography again showed an
empty uterine cavity. Experience
with the first case suggested persis
tent trophoblastic activity at the
previous ectopic site. In this in
stance, however, there had been no
hemorrhage. Methotrexate orally
was prescribed (10 m g/d for 5
days). Serial determinations of
BHCG were recorded for 7 weeks.
Levels declined from 3080 U /L to
366 U /L over the initial 12 days. A
week later the level was 75 U /L
and the next week 34 U/L. Ten
weeks after the conclusion of che
motherapy, the patient had her first
menstrual period. Since then she
has been pregnant on two occa
sions: on the first, she had a miscar
riage at 6 to 8 weeks and on the
second, she had a term pregnancy.

Discussion
Persistent ectopic syndrome is
defined as the persistence of tro
388

phoblast at the operative site. The
incidence of this complication is
unknown, but it will likely increase
as the numbers of ectopic pregnan
cies and conservative procedures
rise.
It is almost certain that micro
scopic amounts of trophoblast re
main following fimbrial expression
and salpingostomy. Fimbrial expres
sion is especially likely to leave
trophoblast behind and is possibly
contraindicated for that reason.
Parmley5 pointed out that the major
propagation in ampullary pregnancy
is between serosa and muscularis.
This type of ectopic pregnancy
should be treated by salpingostomy.
In the isthmus, propagation occurs
in the tubal lumen and lends itself
to salpingostomy or mid-segmental
resection, with anastomosis at a
later date.
Morbidity from persistent ectopic
syndrome is related to intraperitoneal hemorrhage, as exem
plified in case 1. Initially, there was
confusion over the appearance of a
secondary hemorrhage, and this led
to a delay in diagnosis.
Bell and colleagues6 reviewed
nine cases of persistent ectopic syn
drome, including the first reported
by Kelly and associates7 in 1979.
The characteristics common to each
case include a conservative proce
dure for ectopic pregnancy, fol
lowed by an acute abdomen caused
by hemorrhage at the operative site.
It is important, when conservative
measures are offered, that an expla
nation of possible postoperative
problems should include persistent
ectopic syndrome.
Management depends on early
recognition. Johnson and associ
ates8 and Rivlin and colleagues9
insist on follow-up of conservative
procedures by serial measurement
of BHCG levels, the first of which
should be performed 14 days after
the initial surgery. If the level has
dropped markedly, there is no need
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for further surveillance. If, however,
the levels plateau or rise, persistent
trophoblastic activity is indicated.
If, as in our case 1, there is intraperitoneal bleeding, early salpin
gectomy is necessary. If there is no
bleeding, laparoscopy should be
performed to assess the affected
tube, and depending on these find
ings, chemotherapy or salpingecto
my should be recommended. The
use of methotrexate has been
adopted as one option in the man
agement of trophoblastic tumours.
More recently, this agent has been
used in some ectopic pregnancies
associated with unusual surgical
risks, such as cervical pregnancy,10
cornual pregnancy,11 abdominal
pregnancy and pregnancy associat
ed with hyperstimulation syn
drome.12 If methotrexate is effective
in these circumstances, it should
provide an effective option for some
patients who have persistent ectopic
syndrome, diagnosed early and who
do not have intraperitoneal he
morrhage.
Higgins and Schwartz13 and
Cowan and colleagues14 reported
excellent results following the use
of methotrexate for persistent ec
topic syndrome, with no indication
of a toxic reaction. Each group
used a different dosage. The mini
mum effective dose is not known.
Ichinoe and colleagues15 believe
that the dose should be tailored to
the trophoblast activity evidenced
by quantitative BHCG estimates. To
date no failures have been reported
following treatment of residual tro
phoblast with methotrexate.

Conclusions
Persistent ectopic syndrome is a
recognized complication of conser
vative tubal surgery for unruptured
ectopic pregnancy. Although few
cases have been reported, the num
bers will likely increase as the num-
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ber of conservative procedures
being performed rises. The conse
quences of persistent ectopic syn
drome relate to the severity of intraperitoneal hemorrhage. Conser
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levels. If persistent ectopic syn
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be given to chemotherapy using
methotrexate.
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When nausea and vomiting
impede recovery, Stemetil acts where
the process begins in the mind.
—

Stemetil blocks impulses from
the chemoreceptor trigger zone and
depresses the vomiting center. /Is an
antiemetic, Stemetil is indicated for all
the causes o f nausea and vomiting,
especially surgery, chemotherapy,
radiotherapy and their accom
panying anxiety situations.
Prescribe Stemetil and make sure your hospital/ A
wards are stocked with the forms you need. Available
/
in tablets, suppositories, liquid and IV/IM injection.
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CLASSIFIED ADVERTISING

As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1
month before issue date. Regular classified rates (for each insertion): $45.00 for the first 40 words or less, additional words 60<p each
(additional $17.00 for frame). Special Display under 100 words, 2Vi in. X 2 in., $110.00. $6.00 charge (first insertion only) for CJS box
numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery. PO Box 8650, Ottawa, Ontario K1G 0G8.
CARDIAC SURGERY: ON - Unique opportu
nity for several licensed physicians/surgeons
to assist in operating room for expanding
cardiac surgery program. Surgical experience
preferred, but willing to train suitable appli
cants. Fee for service remuneration. Must
have, or be eligible for, licence with the
Ontario College of Physicians and Surgeons,
and have CMPA insurance. Interested appli
cants please submit a detailed resume to:
Victoria Hospital, Division of Cardiovascu
lar and Thoracic Surgery, 3 70 South
Street, Ste. C102, London, ON, Canada
N6A 4G5. For further information please
call: (51 9) 6 7 2 -3 3 0 0 .
-S 89-31
UNIVERSITY CHAIRMAN, DIVISION OF
UROLOGY: ON - The Department of Sur
gery, University of Toronto, is seeking appli
cants for the position of University Chairman
of the Division of Urology. The incumbent is
responsible for the clinical care, teaching and
research programs in eight fully affiliated
teaching hospitals in the University of Toron
to. The applicant should have demonstrated
leadership ability as well as an established
reputation in academic urology, including
teaching and research. The position of Chief

of Urology at the Toronto Hospital (including
the Toronto General and Toronto Western
Divisions) will also be vacant as of July 1,
1990 and may be offered to the University
Chairman of Urology. In accordance with Ca
nadian immigration requirements, this adver
tisement is directed primarily to Canadian
citizens or permanent residents. Applicants
should send a letter and accompanying curric
ulum vitae to: Dr. B. Langer, R.S. McLaugh
lin Professor and Chairman, Department of
Surgery, University of Toronto, The Ban
ting Institute, 1 00 College St., Toronto,
O N M 5G 1L5.
-S89-34
GENERAL SURGEON: MB - Required to
join a progressive group of twelve general
practitioners, one obstetrician/gynecologist,
and one orthopedic and plastic surgeon.
Guaranteed income provided for first 12
months, and thereafter, if mutually agreeable,
partnership would be offered. Early partner
ship by agreement is available. The clinic
occupies three floors of a modern, downtown
medical facility in a university city of 40 000,
and services a large trading area. A 220-bed
hospital with a 12-bed, intensive care unit, a
201-bed geriatric and rehabilitation hospital, a

Cardiovascular Thoracic Surgery
The Department of Surgery of The University of Calgary
and the Foothills Hospital invites applications for a
full-time appointment as Division Chief, Cardiovas
cular Thoracic Surgery at the Foothills Hospital.
The incumbent will be responsible for the develop
ment and promotion of research initiatives within the
Division. Other responsibilities include administra
tive duties related to the functions of an academic
division, promotion of excellence in education and
the promotion of quality assurance in patient care.
Academic rank and salary commensurate with
experience and qualifications. The starting date is
negotiable.
In accordance with Canadian immigration require
ments, priority will be given to Canadian citizens and
permanent residents of Canada. The University of
Calgary has an Employment Equity Program and
encourages applications from all qualified candi
dates, including women, aboriginal people, visible
minorities, and people with disabilities.
Please submit a curriculum vitae and the names of
three references by September 30, 1989, to:
Dr. R. Y. McMurtry
Department of Surgery
The University of Calgary
1403 - 29 Street N.W.
Calgary, Alberta T2N 2T9
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large regional laboratory, and an ultrasound
department, is located in the city. Interested
persons are asked to contact: Mrs. D.J.
Mistal, Western Medical Clinic, 144 6th
St., Brandon, MB, R7A 3N2, Tel: (204)
7 2 7-6451.
-S89-14
UNIVERSITY HEAD OF THORACIC SUR
GERY: ON - The University of Toronto,
Department of Surgery is seeking a new Head
of its Division of Thoracic Surgery. The in
cumbent will be responsible for coordinating
the clinical teaching and research activities of
the University Division of Thoracic Surgery.
This includes tw o teaching divisions of tho
racic surgery and individual thoracic surgeons
in other affiliated teaching hospitals within the
University of Toronto system. This incumbent
will be expected to have an established repu
tation in clinical thoracic surgery, as well as in
teaching and research. University rank and
salary are negotiable. Priority will be given to
Canadian residents, but permission has been
received to interview Canadians and nonCanadians at the same time. Please forward
replies to: Dr. B. Langer, Chairman, Depart
ment of Surgery, 100 College St., Room
311, Toronto, ON M5G 1 L5.
-S89-30

Royal Alexandra
Hospital
Committed to Caring
Edmonton’s Royal Alexandra Hospital, one o f Canada’s leading service and teaching
hospitals, is a 932 bed city and regional health care facility. The Hospital is
committed to excellence in health care through its Active Treatment, Women’s and
Children’s Centres.
Join the Royal Alexandra team as we move in to the future with an exciting new
direction and redevelopment o f our facility.

CANADA
CHIEF
DEPARTMENT OF SURGERY
Applications are invited for a “ Surgeon-in-Chief", Department of Surgery,
Royal Alexandra Hospital, a 932 - bed, acute care facility, affiliated with the
University of Alberta. A hosptial/university-based salary is available to
complement private practice opportunities. Fifty-two (52) Surgeons practise
within the Department, which has eight Divisions. There are 330 adult
in-patient beds and 60 pediatric beds within the facility. In excess of 30,000
surgical procedures are performed each year on an in-patient or ambulatory
basis. Patient care, education and research opportunities are exciting.
Edmonton, Alberta, Canada - an attractive, dynamic place to work, is the
heart of Alberta - land of opportunity.
The capital city, affords the best in education, health care, recreation,
entertainment, shopping and all other amenities. Alberta’s low tax rate and
inexpensive housing make it less costly to live in Edmonton than in any other
major Canadian city.
Centrally located on the North Saskatchewan River, Edmonton is within easy
reach of recreational areas in the Canadian Rockies. Edmonton is the place
for people, industry, commerce, agriculture and a high quality of life.
Correspondence to:
Dr. Tom Noseworthy
Associate Vice President, Medical Planning
Royal Alexandra Hospital
Room 1412, 10240 Kingsway
Edmonton, AB T5H 3V9
Phone: (403) 477 - 4107
FAX: (403) 477 - 4048
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Academic Appointment in
General Surgery
The Cold Lake Regional Hospital is a modern, multi
level progressive facility with the potential bed capacity
of 150. We seek an additional

Psychiatrist
Surgeon
GP / Anesthetist
GP / Obstetrician / Gynecologist
The Tri-town area in which the hospital is located is,
approximately 300 kilometers East of Edmonton. Pri
mary care and specialty referral care is offered to a
growing population.
The successful candidates must be eligible for licensure
in Alberta. In accordance with Canadian immigration
requirements, priority will be given to Canadian citizens
and permanent residents of Canada.
Please forward your confidential resume, including refer
ences, to:
The Search Committee
Cold Lake Regional Hospital

Postal Service “A ”
COLD LAKE, Alberta
TOA 0V0
Tel: (403) 639-3322, Ext. 280.
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Cold Lake Regional Hospital
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The University of Calgary Faculty of Medicine Department of
Surgery invites applications for a full-time faculty position in
General Surgery at the Assistant or Associate Professor level.
The successful candidate will be expected to develop an in
dependent research program in clinical gastrointestinal sur
gery, in association with other members of the Division and
the Gastrointestinal Research Group. Conditions of the ap
pointment include successful application for support to the
Alberta Heritage Foundation for Medical Research and/or
the Medical Research Council of Canada.
Applicants will require an MD and a Fellowship in General
Surgery from the Royal College of Physicians and Surgeons
of Canada, or equivalent. Successful candidates will have
75% of their time protected for research. The appointed sur
geon will be offered privileges in one of the affiliated teach
ing hospitals.
In accordance with Canadian immigration requirements, pri
ority will be given to Canadian citizens and permanent resi
dents of Canada. The University of Calgary has an
Employment Equity Program and encourages applications
from all qualified candidates, including women, aboriginal
people, visible minorities, and people with disabilities.
Interested candidates should submit a curriculum vitae, the
names of three referees, and a letter stating their goals and
research interests by September 30, 1989 to:
Dr. W. Temple
Chief of General Surgery
Foothills Hospital
1403 - 29 Street N.W.
Calgary, Alberta T2N 2T9
-S-89-32
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NEW FROM MILES

THE POWER OF
THE FREEDOM OF TABLETS.

AND FREEDOM
I WIDE RANGE OF INDICATIONS — lower respiratory tract — urinary tract
— skin/soft tissue

— bone and joint

■ BROAD SPECTRUM
Highly active* in vitro against a broad range of gram -p o sitiv e and gram-negative
pathogens, “...the most potent anti-pseudomonas agent...”1
Editorial, The Lancet.

m HIGH TISSUE PENETRATION
Serum, tissue and fluid levels well above inhibitory levels.2

■ EXCELLENT PATIENT COMPLIANCE
Convenient B.I.D. dosage. Well tolerated — low incidence of side effects.3

NEW

TABLETS

*ln vitro activity does not necessarily
imply a correlation with in vivo results.

POTENT
YETPO.

f a
MILES

For prescribing information see page 318

polyglyconate monofilament absorbable suture

The multi-faceted
absorbable suture
appearing in
Plastic and
General surgery
theatres
everywhere. For a
personal
presentation call
your D + G
Representative
today.

Cyanamid Canada Inc.
88 McNabb Street
Markham, Ontario L3R 6E6
(416) 470-3600
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